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SUMMARY 
BACKGROUND 
The autoinflammatory diseases are disorders characterized by recurrent 
inflammatory episodes in charge of different organs. There is no apparent 
involvement of autoantibodies nor of antigen-specific T lymphocytes, but 
dysregulation of the innate immune response.  
The Blau syndrome (BS) is a rare autosomal dominant autoinflammatory disease 
clinically characterized by symmetrical arthritis, granulomatous dermatitis and 
recurrent uveitis. The disease is caused by single mutations in CARD15/NOD2, 
encoding the NOD2 protein that is known to regulate the defense against 
pathogens by activating the NF-κB signalling pathway. 
In this thesis, functional analysis was carried out aimed at characterizing p.E383K 
mutation found in one Italian family affected by Blau syndrome. After the in vitro 
study of mutant NOD2, we investigated the activity of NF-κB and the production 
of pro-inflammatory cytokines both ex vivo and in vitro. 
In the second part of this thesis, we assessed in detail both the signalling pathways 
known to be involved in inflammation and a wide range of inflammatory 
mediators (pro-inflammatory cytokines and chemokines) in a cohort of patients 
affected by different hereditary autoinflammatory diseases such as FMF and 
TRAPS or complex diseases like Behçet and Adult Onset Still's disease. The aim 
of this studies was to increase the molecular knowledge of these disorders in order 
to identify possible predictive or diagnostic biomarkers for each disease and to 
develop future preventive and therapeutic strategies. 
 
MATERIALS AND METHODS 
For ex vivo functional analysis on Blau syndrome, peripheral blood monocyte 
cells (PBMC) were collected from 2 Italian patients carrying p.E383K mutation. 
For the evaluation of NF-κB, PBMC were lysed and analyzed by Reverse Phase 
Protein Array (RPPA); while for the production of mediators of inflammation 
(IL1β, IL6, IL8, TNFα, IFNγ, IL12, IL17, IL22, IL23), PBMC were cultured for 7 
hours in presence or absence of lipopolysaccharide LPS [100ng/ml] and 
muramildipeptide MDP [10μg/ml] and cytokines were quantified by ELISA and 
antibody microarray techniques. 
For the functional analysis in vitro on Blau syndrome, the starting point was the 
creation of 3 constructs containing cDNA of human NOD2 wild-type and mutated 
p.E383K and p.R334W. These plasmids were stably transfected into HEK293 
cells, cultured for 7 and 24 hours in the presence or absence of MDP [10μg/ml]. 
The activity of NF-κB was firstly determined indirectly by evaluating the 
expression of IKBα and phosphorylated form in p.E383K cellular lysates by 
Western blotting. RPPA also assessed NF- κB activity by analysis of the 
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expression pathway components compared to NOD2 wild-type. IL8 was assayed 
in the supernatants through antibody microarray technique. 
In the second part of the study, serum and PBMC were collected from 40 patients 
with autoinflammatory diseases and 27 healthy controls. The PBMC were lysed 
and prepared for RPPA analysis of the major components of the NF-κB, 
PI3K/Akt, MAPK, JAK/STAT/c-Src and inflammasome (NALP1) signalling 
pathways. From the serum, mediators of inflammation (IL1β, IL6, IL8, TNFα, 
IFNγ, IL12, IL17, IL22, IL23) were assessed by antibody microarrays. 
 
RESULTS 
Confocal microscopy revealed that p.E383K NOD2 resides in cytoplasm of 
transfected HEK293 cells, as well as wild-type and p.R334W NOD2. The 
expression of p.E383K NOD2, assessed by Western blotting , do not present any 
variations after MDP stimulation. As regards the analysis of the NF-κB pathway, 
in vitro studies show an inactivation of this pathway in HEK293 cells presenting 
p.E383K NOD2, while the pathway components are upregulated ex vivo in 
comparison with healthy controls. Both in vitro RPPA and indirect Western 
blotting analysis of total lysates from p.E383K NOD2 transfected cells present 
lower expression of phospho IkBα than IKBα in presence or absence of MDP 
stimulation. No increase expression for other components of the pathway, such as 
phospho NF-κB and IKKα/β, was then detected, even in nuclear extracts. 
Concerning cytokines in Blau syndrome, both in vitro and ex vivo studies have not 
identified a significant increase secretion of most of the pro-inflammatory 
cytokines analyzed. The dosage of IL8 in vitro presents low level of the 
chemokine in cells expressing p.E383K NOD2. The ex vivo results of 
supernatants at basal level reflect the serum results for the same cytokines 
analyzed. Furthermore, IL17, IL22 and IL23 release is higher in patients than in 
controls, while IL12 is reduced in patients. The presence of the stimulus (LPS, 
MDP or both) does not lead to significant increases in the levels of IL1β, IL6, 
IL8, TNFα and IFNγ in patients compared to controls.  
The search for biomarkers in autoinflammatory diseases patients shows an up-
regulation of several pro-inflammatory components of the studied pathway, when 
compared to healthy subjects. In Behçet disease, NF-κB, PI3K/Akt, Erk1/2 
MAPK pathways are statistically up-regulated, whereas in patients with Adult 
Onset Still's disease all analyzed pathways appear to be activated more than in 
controls. In TRAPS patients, many of the components of NF-κB, PI3K/Akt, 
Erk1/2 and SAPK MAPK, and JAK/STAT pathways are up-regulated, while for 
FMF patients inflammasome and Erk1/2 and SAPK MAPK pathways result 
activated. In Blau syndrome components of the NF-κB, p38 MAPK and PI3K/Akt 
pathways are up-regulated. Cytokine analysis in different autoinflammatory 
diseases suggests a higher release of IL8, IL22, IL23 and IL17 in all the analyzed 
diseases. Furthermore, all other cytokines significantly raised in patients affected 
by Adult Onset Still's disease. The release of TNFα and IFNγ in TRAPS patients 
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is increased. In FMF patients, IL1β, IL6, IL8 and IFNγ levels result higher than in 
controls. 
 
CONCLUSION 
This is the first time that the mutation p.E383K in CARD15/NOD2 associated 
with Blau syndrome has been functionally evaluated. The contrasting results 
presented by our in vitro and ex vivo data on NF-κB pathway may indicate that the 
activation do not depend only on NOD2 in carriers of p.E383K mutation. Further 
experiments need to be done to clarify these results, using also different in vitro 
models. Regarding the ex vivo and in vitro studies on cytokines levels, it seems 
that there is not a primary mediation of IL1β and other pro-inflammatory 
cytokines in Blau syndrome patients carrying p.E383K, with the exception of 
IL17/22/23 whose role has to be deeply investigated. 
This work therefore offers an insight into the molecular pathophysiology of these 
autoinflammatory disease. Analyses with statistical models of the signalling 
molecules presenting significant raised levels will be required to generate specific 
diagnostic algorithms and to identify valuable biomarkers to be used as targets for 
specific therapeutic intervention. The cytokine profiles observed may help to 
distinguish different autoinflammatory diseases in terms of numbers of cytokines 
raised. Moreover, Th17-related cytokines (IL17/22/23), significantly raised across 
all diseases, suggest an important role for Th17 cells in autoinflammatory 
diseases. Targeting Th17 cells and their related cytokines may be an effective 
therapeutic approach for autoinflammatory diseases in future 
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SOMMARIO 
SCOPO DEL LAVORO 
Le malattie autoinfiammatorie sono patologie caratterizzate da episodi 
infiammatori recidivanti a carico di differenti organi. In esse non vi è apparente 
coinvolgimento di autoanticorpi nè di linfociti T antigene specifici, ma 
disregolazione della risposta immunitaria innata. 
La Sindrome di Blau (BS) è una rara malattia autoinfiammatoria autosomica 
dominante caratterizzata dal punto di vista clinico da artrite simmetrica, dermatite 
granulomatosa e uveite ricorrente. La malattia è causata da singole mutazioni nel 
gene CARD15/NOD2, codificante la proteina NOD2 che è nota regolare il 
pathway di difesa da patogeni attivando la via del segnale NF-κB.  
In questo studio è stata effettuata dapprima una serie di analisi funzionali volte a 
caratterizzare la mutazione p.E383K ritrovata in un'unica famiglia italiana affetta 
da sindrome di Blau. Dopo lo studio in vitro della proteina NOD2 mutata, si è 
voluta approfondire l’attività di NF-κB e la secrezione di citochine pro-
infiammatorie sia ex vivo che in vitro. 
Nella seconda parte della tesi, si sono volute studiare nel dettaglio sia le vie del 
segnale note essere implicate nell'infiammazione, sia un ampio range di mediatori 
dell'infiammazione (citochine pro-infiammatorie e chemochine) in una coorte di 
soggetti affetti da differenti malattie autoinfiammatorie sia ereditarie quali FMF e 
TRAPS, sia complesse quali Behçet e morbo di Still nell'adulto. Lo scopo era 
approfondire le conoscenze molecolari di tali patologie per identificare possibili 
biomarcatori predittivi o diagnostici per ciascuna malattia e sviluppare in futuro 
strategie terapeutiche mirate e preventive. 
 
MATERIALI E METODI 
Per l'analisi funzionale in vitro sulla sindrome di Blau, punto di partenza è stato la 
produzione di 3 costrutti contenenti cDNA umano di NOD2 wild-type e mutato 
p.E383K e p.R334W. Questi costrutti sono stati trasfettati stabilmente in cellule 
HEK293, poste poi in coltura per 7 e 24 ore in presenza o assenza di 
muramildipeptide MDP [10μg/ml]. L’attività di NF-κB è stata determinata 
dapprima indirettamente valutando l’espressione di IKBα e forma fosforilata nelle 
cellule mutagenizzate p.E383K mediante Western blotting dei lisati cellulari. In 
seguito mediante Reverse Phase Protein Array (RPPA) è stata valutata 
l'espressione dei componenti del pathway rispetto a NOD2 wild-type. É stata 
inoltre dosata l'IL8 nei surnatanti delle colture mediante tecnica antibody 
microarray. 
Per l'analisi funzionale ex vivo relativa alla sindrome di Blau, sono stati analizzati 
2 soggetti italiani affetti e portatori della mutazione p.E383K, da cui sono state 
estratte le cellule monocitarie del sangue periferico (PBMC). Per la valutazione 
dell'attività NF-κB, i PBMC sono stati lisati e analizzati mediante RPPA. Per la 
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produzione di citochine (IL1β, IL6, IL8, TNFα, IFNγ, IL12, IL17, IL22, IL23) i 
PBMC sono stati invece posti in coltura per 7 ore in presenza o assenza di agenti 
di stimolo quali lipopolisaccaride LPS [100ng/ml] e di muramildipeptide MDP 
[10μg/ml] e le citochine sono state dosate mediante tecnica ELISA e antibody 
microarray. 
Nella seconda parte dello studio, sono stati presi in esame 40 pazienti affetti da 
malattie autoinfiammatorie (Behçet, Still nell'adulto, FMF, TRAPS e Blau in 
particolare) e 27 controlli sani, dai quali sono stati raccolti siero e PBMC. 
Quest'ultimi sono stati lisati e preparati per l'analisi RPPA dei maggiori 
componenti delle vie del segnale NF-κB, PI3K/Akt, MAPK, JAK/STAT/c-Src e 
inflammasoma (NALP1). Dal siero sono state dosate IL1β, IL6, IL8, TNFα, IFNγ, 
IL12, IL17, IL22, IL23 mediante antibody microarray. 
 
RISULTATI  
La microscopia confocale ha evidenziato una pronunciata presenza di p.E383K 
NOD2 nel citoplasma delle cellule HEK293 trasfettate, così come per NOD2 
wild-type e mutato p.R334W. L'espressione di p.E383K NOD2, valutata mediante 
Western blotting, non presenta variazioni in seguito a stimolazione con MDP per 
7 o 24 ore. Per quanto concerne l'analisi del pathway NF-κB, lo studio in vitro 
presenta una mancata attivazione nelle cellule HEK293 presentanti p.E383K 
NOD2, mentre il pathway risulta upregolato ex vivo rispetto ai controlli sani. In 
vitro infatti si nota un'inferiore espressione di IKBa fosforilato rispetto a IKBa in 
presenza o assenza di stimolazione MDP, sia nell'analisi indiretta con Western 
blotting sia mediante RPPA dei lisati totali delle HEK293 trasfettate con p.E383K 
NOD2. Non è stato rilevato poi alcun incremento di espressione per altri 
componenti del pathway, quali la forma fosforilata di NF-κB, IKKα/β, anche 
nell'estratto nucleare. Sia lo studio in vitro che quello ex vivo non hanno 
identificato un incremento significativo, sia a livello basale che in seguito a 
stimolazione, di secrezione della maggior parte delle citochine pro-infiammatorie 
analizzate. Il dosaggio di IL8 in vitro presenta bassi livelli citochinici nelle cellule 
esprimenti p.E383K NOD2. I risultati basali ex vivo da surnatante rispecchiano 
quanto osservato da siero per le medesime citochine analizzate. Inoltre si è notato 
un rilascio di IL17, IL22 e IL23 maggiore nei pazienti, unitamente ad un minor 
rilascio di IL12, rispetto ai controlli. La presenza di stimolo (LPS; MDP o 
entrambi) non ha portato a incrementi significativi dei livelli di IL1β, IL6, IL8, 
TNFα e IFNγ nei pazienti rispetto ai controlli. 
La ricerca di biomarcatori nei pazienti affetti da malattie autoinfiammatorie ha 
evidenziato una up-regolazione di molti componenti pro-infiammatori dei pathwy 
studiati, quando comparati a soggetti sani. Nella malattia di Behçet, le vie 
metaboliche NF-κB, PI3K/Akt, Erk1/2 MAPK sono risultate statisticamente up-
regolate, mentre nei pazienti affetti da Still dell'adulto tutti i pathway analizzati 
risultano essere maggiormente attivati rispetto ai controlli. Nei pazienti TRAPS, 
presentano livelli aumentati molti dei componenti dei pathway NF-κB, PI3K/Akt, 
 7 
Erk1/2 e SAPK MAPK, e JAK/STAT, mentre per i pazienti FMF si nota 
l'attivazione del pathway legato all'inflammasoma e di quello Erk1/2 e SAPK 
MAPK. Nella sindome di Blau sono invece risultati upregolati componenti dei 
pathway NF-κB, PI3K/Akt e p38 MAPK. 
Dall'analisi citochinica nelle differenti malattie autoinfiammatorie si evince un 
maggior rilascio di IL18, IL22, IL23 e IL17 in tutte le patologie analizzate. Inoltre 
si è notato un incremento significativo dei livelli di TNFα e IFNγ nei pazienti 
TRAPS, di IL1β, IL6 e IFNγ nei pazienti FMF e di tutte le citochine in analisi nei 
pazienti affetti da Still dell'adulto. 
 
DISCUSSIONE 
Questa è la prima volta che viene studiata a livello funzionale la mutazione 
p.E383K nel gene CARD15/NOD2 associato alla sindrome di Blau. Per quanto 
riguarda il pathway NF-κB, i risultati contrastanti ottenuti in vitro ed ex vivo, 
possono indicare come l'attivazione non sia regolata solamente da NOD2 per i 
portatori della mutazione p.E383K. Ulteriori esperimenti saranno necessari per 
chiarire questi risultati, utilizzando anche differenti modelli cellulari in vitro. I 
risultati ex vivo e in vitro relativi al dosaggio citochinico non sembrano 
evidenziare un coinvolgimento primario di IL1β e delle altre citochine 
proinfiammatorie nella patogenesi della sindrome di Blau,ad eccezione di 
IL17/22/23, il cui ruolo dovrà essere studiato più approfonditamente. 
Questo lavoro di tesi offre inoltre una panoramica della patofisiologia molecolare 
di differenti malattie autoinfiammatorie. Un'analisi approfondita dei componenti 
dei pathway individuati con elevati livelli di espressione rispetto ai controlli sani 
sarà necessaria per identificare validi biomarcatori da poter utilizzare come target 
terapeutici. I profili citochinici ottenuti possono essere d'aiuto nel discriminare le 
differenti patologie sulla base di quali citochine presentino dosaggi maggiori 
rispetto ai controlli. Inoltre, IL17 IL22 e IL23 presentano livelli 
significativamente più elevati in tutte le malattie analizzate, suggerendo un 
importante ruolo nelle autoinfiammatorie per le cellule Th17 secernenti tali 
citochine. Utilizzare le cellule Th17 e le citochine ad esse associate come target 
terapeutico potrebbe essere in futuro un nuovo approccio nella cura delle malattie 
autoinfiammatorie. 
 
  
 8 
 
General Introduction 
9 
GENERAL INTRODUCTION 
1 General overview on autoinflammatory diseases 
The autoinflammatory diseases are characterized by seemingly unprovoked, 
recurrent episodes of fever, serositis, arthritis, and cutaneous inflammation, but 
the usual hallmarks of autoimmunity, namely high-titer autoantibodies and 
antigen-specific T cells, are usually absent [1]. The term autoinflammatory was 
coined to draw the distinction between this category of illnesses and the more 
classically recognized autoimmune diseases, such as systemic lupus 
erythematosus and rheumatoid arthritis, in which the hallmarks of adaptive 
immunity are more evident [2]. The formal recognition and genetic understanding 
of autoinflammatory diseases have defined some mechanisms of self-direct 
inflammation independent to the adaptive immunity. Such a definition would 
encompass autoinflammatory mechanisms across a continuum model of 
immunology (a spectrum from autoimmune to autoinflammation) [3].  
Although this concept originally applied to monogenic hereditary recurrent fevers, 
it has expanded over time to include polygenic (complex) autoinflammatory 
diseases. Dinarello proposed the division in classic diseases, probable and 
municipalities on the basis of sensitivity to inhibition of IL1 [4]. With the 
recognition that these inflammatory diseases without hallmarks of adaptive 
immunity were in fact disorders of the innate immune system, Masters and 
colleagues proposed a new schema based upon underlying molecular mechanisms 
[1]. Since the association between the autoinflammatory diseases and the innate 
immune system has strengthened, the "autoinflammatory disease" definition 
should be reassessed to include all clinical disorders marked by abnormally 
increased inflammation, mediated predominantly by the innate immune system, 
with a significant host predisposition [5]. Although these mechanistic 
classifications present some limits, such as the absence of naturalness and both 
clinic and inflammatory relevance, they are the most commonly used to 
discriminate the different forms of autoinflammatory diseases. Very recently, 
Grateau and colleagues proposed another, more clinically-oriented, definition of 
autoinflammatory diseases as diseases with clinical signs of inflammation, 
associated with elevated levels of acute-phase reactants, which are attributable to 
dysfunction of the innate immune system, genetically-determined or triggered by 
an endogenous factor. From this foundation, a clinically-based multidimensional 
classification of autoinflammatory diseases was described [6] 
A few clinical common features have been identified between all the inherited 
autoinflammatory diseases, such as the recurrent nature of inflammatory episodes, 
the presence of fever, and the frequent involvement of skin, serous membranes, 
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eyes, joints, lymph nodes, gastrointestinal tract, and nervous system. Each of 
these syndromes may have a more or less severe inflammatory manifestations [7]. 
Understanding of the pathogenesis of autoinflammatory diseases has grown 
rapidly in the past decade owing to advances in genome research and technology. 
An updated classification scheme is based on the garnered molecular insights, 
supplanting the uncompleted clinical classification: IL1β activation disorders, NF-
κB activation syndromes, protein misfolding disorders, complement regulatory 
diseases, disturbance in cytokine signalling, and macrophage activation 
syndromes [1]. 
 
 
Disease Gene 
(Protein) 
Inheritance Clinical features Ref 
Familial autoinflammatory disorders    
Familial 
Mediterranean Fever 
(FMF) 
MEFV (pyrin) Autosomal 
recessive 
Periodic fevers (lasting 3–7 
days), serositis, arthritis 
8,9 
Tumor Necrosis 
Factor-associated 
periodic syndrome 
(TRAPS) 
TNFRSF1A  
(TNF receptor 
1) 
Autosomal 
dominant 
Periodic fevers(lasting 1-6 
weeks), serositis, rash, 
episcleritis 
2 
Mevalonate kinase 
deficiency (MKD) 
MVK 
(mevalonate 
kinase) 
Autosomal 
recessive 
Periodic fevers (lasting 3-7 
days), non-destructive 
arthritis, lymphoadenopathy, 
vasculitic skin lesion 
10,11 
Cryopyrin-associated 
periodic syndromes 
(CAPS):  
FCAS, MWS and 
NOMID 
NLRP3 
(NLRP3) 
Autosomal 
dominant 
Cold-induced inflammation, 
fevers, sterile meningitis, 
bone lesions 
12,13 
NALP12 associated 
Periodic syndrome 
NLRP12 
(NLRP12) 
Autosomal 
dominant 
similar to CAPS 14 
Blau syndrome (BS) CARD15/NOD2 
(NOD2) 
Autosomal 
dominant 
Granulomatous dermatitis, 
uveitis, arthritis 
15, 
16 
Complex disorders 
    
Schnitzler syndro0me Sporadic - urticaria, intermittent 
fever,arthritis 
17 
Still disease Complex - fever with unknown etiology, 
rash, arthritis, and 
involvement of several organ 
systems 
18 
Behçet disease Complex -  oral and genital 
ulcerations, folliculitis, 
erythema nodosum and 
uveitis. 
19 
Tab. 1: Molecular and clinical features of autoinflammatory disorders presented in this thesis 
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1.1 Hereditary recurrent fevers 
In the last decade, the genetic cause of several familial autoinflammatory 
syndromes have been identified, as presented in Tab. 1. The genes that are 
responsible for these syndromes have been found to encode key sensors and 
transducers of inflammatory signal transduction pathways [3]. Some of the genes 
involved, such as TNFRSF1A were previously well known, whereas the discovery 
of mutations in NLRP3, NLRP12, CARD15/NOD2 highlighted their importance in 
inflammatory signalling pathways. 
To date, twelve are the better known hereditary monogenic disorders: familial 
Mediterranean fever (FMF); tumor necrosis factor receptor-associated periodic 
syndrome (TRAPS); mevalonate kinase deficiency (MKD); cryopyrin-associated 
periodic syndrome (CAPS), a group which includes familial cold urticaria 
syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic infantile 
neurological cutaneous articular (CINCA); Guadeloupe Variant Periodic Fever 
syndrome (FCAS2); granulomatous diseses which include Blau syndrome (BS) 
and early-onset sarcoidosis (EOS); and, finally, the hereditary pyogenic disorders 
including PAPA (pyogenic arthritis, pyoderma gangrenosum, and acne) 
syndrome, Majeed syndrome (MS), and deficiency of the IL1 receptor antagonist 
(DIRA). These diseases are generally characterized by early onset but adult onset 
has also been described, in particular for FMF and TRAPS [20]. Type AA 
amyloidosis is the most serious complication of most diseases, due to excessive 
production of serum amyloid-A (SAA), synthesized in the liver following 
stimulation by certain proinflammatory cytokines, such as IL1β, and also IL6 and 
tumor necrosis factor-α (TNF-α). 
 
1.1.1 Familial Mediterranean Fever - FMF 
 
Fig. 1: Schematic representation of recessively inherited FMF-associated mutations in the MEFV 
gene [21]. 
 
FMF is inherited as a recessive disease and is characterized by short episodes of 
fever and inflammation involving the joints and serosal surfaces. Mutations in the 
MEFV gene, which encodes the protein pyrin, were found in 1997 to underlie 
most cases of this disease [8]. The mutations are present at very high frequency in 
several populations, in particular in the Mediterranean basin and Middle East [22]. 
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As numerous patients with FMF clinical criteria but without genetic mutatios 
were reported, genetic heterogeneity was proposed [23]. Gershoni and colleagues 
suggested also that complex alleles can lead to a more severe form of the disease 
[24]. 
Mutations are found throughout the MEFV gene (http://fmf.igh.cnrs.fr/infevers), 
but the most severe are clustered in exon 10 (Fig. 1). Pyrin is an adaptor protein 
expressed in neutrophils and monocytes that contains an N-terminal eponymous 
pyrin domain and a domain at the C-terminal end termed the B30.2 or PRY–
SPRY domain. Pyrin can assemble with ASC and pro-caspase 1 in human cells to 
facilitate the cleavage of pro-caspase 1. This mutation affects several cell 
signalling pathways affecting upregulation of caspase-1 and IL1β and inhibition 
or down regulation of apoptosis and NF-κB [25]. FMF is usually responsive to 
colchicine that is effective in preventing the attacks and the development of AA 
amyloidosis. However, glucocorticoid may decrease the attacks of FMF when it is 
used early and in high doses [26]. 
 
1.1.2 Mevalonate Kinase Deficiency - MKD 
 
 
Fig. 2: Schematic representation of mutations in MVK that have been identified in patients 
presenting with MKD, in blue [21]. 
 
Mevalonate Kinase Deficiency is a recessive inherited disease, presenting an 
increased IgD titres, recurrent fever, macula-papular rashes and athralgia lasting 
for 3-7 day. This condition is caused by mutations in the mevalonate kinase 
(MVK) gene, responsible for severe mevalonic aciduria [11]. Although various 
ethnic and racial backgrounds can be affected by MKD, most patients have a 
European descent. MKD-associated mutations are broadly distributed throughout 
the protein sequence (Fig. 2). Mevalonate kinase is an enzyme important in 
cholesterol and non-sterol isoprene biosynthesis as it converts mevalonic acid to 
5-phosphomevalonic acids. Recent investigation into the signalling pathways that 
may be affected by alteration in the MK pathway has implicated the small GTPase 
Rac1, PI3K and protein kinase B as key molecules that could give rise to activated 
caspase-1 (and IL1 and inflammation) due to isoprenoid deficiency [27]. 
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Treatments of this disease can include anakinra (IL1 receptor antagonist), 
colchicine, non-steroidal anti-inflammatory drugs, and glucocorticoids. 
Incomplete response to etanercept has been reported [26]. 
 
1.1.3 TNF receptor-associated Periodic Syndrome (TRAPS) 
 
Fig. 3: Schematic representation of mutations in the TNFR1 protein that are associated with 
TRAPS [21]. 
 
TNF receptor-associated periodic syndrome (TRAPS) is an autosomal dominant 
autoinflammatory disease associated with mutations in TNFRSF1A gene encoding 
TNFR1 protein [2]. 
Patients experience recurrent fevers, abdominal pain, rash, and internal 
inflammatory manifestations such as serositis, fasciitis and episcleritis, but only 
10% develop amyloidosis [28].  
The majority of identified mutations in TNFR1 associated with TRAPS are 
missense mutations affecting the extracellular region of the receptor 
(http://fmf.igh.cnrs.fr/infevers/) (Fig. 3). 
Mutations affecting cysteine residues that partecipate in disulphide bonds have 
been associated with the most severe and penetrant disease phenotype with an 
increased risk of amyloidosis [29]. 
It is still unclear the presence of hyper-inflammatory state in TRAPS patients, but 
there are some hypothesis. The earliest proposes a defective shedding of the 
mutated receptor, raised from the observation of lower serum levels of soluble 
TNFR1 in TRAPS patients that only slightly increased during the febrile attacks. 
This TNFR1 shedding defect may lead to insufficient soluble TNFR1 to neutralize 
TNFα, thus resulting in the continuous inflammatory stimulus that is notable in 
TRAPS [30]. Since this defect is not present in all patients, this hypothesis alone 
is not sufficient. A second hypothesis is related to protein misfolding. Intracellular 
aggregation of TNFR1 as misfolded protein might constitutively induce ligand 
independent signalling and/or induction of ER (Endoplasmic Reticulum) stress 
responses that may play an important role in TRAPS. Ligand independent 
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signalling might lead to an imbalance between cell activation and apoptosis, 
leading to reduced NF-κB signalling. Todd and other investigators demonstrated 
that TRAPS-associated mutations in the ectodomains result in the receptor 
displaying defective behavior, but the signalling properties of the cytoplasmic DD 
domain are not defective in the mutants [31]. The last hypothesis concern the rule 
of the NF-κB signalling. Several functional studies have noted the role of NF-κB 
in the transmission of the signal induced by the binding TNF-receptor. Looking at 
both high and low penetrance mutations associated with TRAPS, it was observed 
an increase in the activity of the various subunits of NF-κΒ and of the 
proinflammatory response [32]. 
Treatments of the inflammatory episodes of TRAPS should be glucocorticoids 
and non-steroidal anti-inflammatory drugs (NSAIDs), in addition to TNFRSF1B: 
Fc fusion protein (etanercept). Other drugs such as IL1 blocking agent (anakinra) 
have been successfully used [26]. 
 
1.1.4 Cryopyrin-associated periodic syndrome (CAPS)
 
Fig. 4: Schematic representation of dominantly inherited NLRP3 mutations in patients with CAPS 
[21]. 
 
Cryopyrin-associated periodic syndrome (CAPS) are a group of autosomal 
dominant autoinflammatory diseases caused by autosomal dominant or de novo 
mutations of NLRP3 gene that encodes cryopyrin [12]. NLRP3 belongs to the 
family of NLR (nucleotide binding domain and leucine-rich repeat containing 
proteins) that is implicated in inflammation and apoptosis [33]. C-terminal 
leucine-rich repeats (LRR) had been implicated in sensing bacterial components, 
suggesting a role in the innate immune response. The identification of NLRP3 
mutations in CAPS coincided with the realization that the NALP3 protein is a key 
component of the inflammasome, a multiprotein complex that can activate 
caspase-1 [34]. Hyper-activation of the inflammasome results in increased 
caspase-1 generation leading to hyper-secretion of IL1. Another proinflammatory 
event, activation of IL6, is mediated via NF-κB. 
The clinical picture of CAPS includes: 
a) Familial cold autoinflammatory syndrome (FCAS), 
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b) Muckle-Wells syndrome (MWS), 
c) Neonatal-onset multisystem inflammatory disease (NOMID) or chronic 
infantile neurologic cutaneous articular (CINCA) syndrome. 
These conditions are no longer considered as three sub-phenotypes with 
increasing severity of the heterogeneous presentation of this monogenic disease. 
Instead, they seem to display a continuum of symptoms [13]. 
Anti IL1 therapy should be the eligible one, preferring rilonacept and 
canakinumab to anakinra [26]. 
 
1.1.5 NALP12 associated periodic syndrome 
 
Fig. 5: Schematic representation of NLRP12 mutations in patients with NALP12 associated 
periodic syndrome [http://fmf.igh.cnrs.fr/ISSAID/infevers/]. 
 
NALP12 associated periodic syndrome is an autosomal dominant disease caused 
by mutations in the NLRP12 gene encoding for the protein NLRP12, which plays 
a crucial role in immune system mechanisms against pathogenic agents. As in the 
case of CAPS, the disease can be induced by generalized exposure to cold and is 
characterized by recurrent fever episodes lasting for 5–10 days accompanied by 
skin rash, headache, lymphadenopathy, mouth ulcers, and abdominal pain [14]. 
Treatment choice is based on the use of antihistamines, NSAIDs, and 
corticosteroids in less serious cases or the administration of anakinra in more 
serious ones [26]. 
 
1.2 Complex autoinflammatory syndromes 
As prevously described, some complex diseases have been classified as 
autoinflammatory disorders, including vasculitic syndromes such as Behçet 
disease, idiopathic febrile syndrome (Still disease) and Schnitzler disease. 
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1.2.1 Schnitzler disease 
This disease is characteristically associated with monoclonal IgM gammopathy, 
which may involve B-cell lineage [14]. The clinical features (urticaria, 
intermittent fever, arthritis and elevated acute-phase reactants) remind to the 
hereditary fever syndromes, in particular MWS. The biochemical data suggest an 
influence of proinflammatory cytokines and IL1β inhibitor is very beneficial in 
the treatment [35]. 
 
1.2.2 Adult Onset Still's disease (AOSD) 
Adult Onset Still Disease affects people older than 16, either de novo or those 
with a history of systemic JIA (juvenil idiopatic arthritis). Disease severity varies 
significantly among affected subjects and, even, within the same individual. To 
date, the mechanisms underlying AOSD are not completely understood. High 
levels of interleukin IL1β, IL6, IL17, IL8, IL18, and TNF-a have been reported 
[36]. These findings seem highly relevant, as elevated serum IL6 and/or IL18 
levels have been associated with systemic symptoms such as fever, skin rash and 
hepatic dysfunction, and correlated with raised serum C-reactive protein (CRP) 
levels. The similarities between autoinflammatory disorders and AOSD might 
suggest common pathogenic pathways and place AOSD as a non-familial, 
sporadic form. Related to the cytokines levels, IL1 inhibition is currently 
considered the mainstay of treatment for AOSD [37]. 
 
1.2.3 Behçet's disease (BD) 
Behçet's disease is a complex chronic and relapsing inflammatory disorder that 
has been extensively described in young adults from Eastern Asia and 
Mediterranean countries. BD is considered a systemic inflammatory disease, most 
likely involving adaptive immunity and particularly T lymphocytes skewed 
towards the T helper 1 phenotype and producing the pro‐inflammatory mediators 
IL2, IL6, IL8, IL12, IL18, TNFα and IFNγ [19]. Its essential manifestations are 
oral and genital ulcerations, folliculitis, erythema nodosum and uveitis. The 
presence of vasculitis worsens the prognosis, introducing the potential for 
life‐threatening complications such as thrombophlebitis, arterial aneurysms and 
occlusion. The aetiology of BD is unknown. BD shares clinical similarities with 
certain well‐recognised autoinflammatory disorders. Different works have 
demonstrated a higher frequency of MEFV mutations in patients with BD, with 
respect to their ethnicity [38,39]. Recently, the R92Q mutation in the TRAPS 
gene, which is responsible for another defect of innate immunity, was reported to 
have increased in patients with BD [40].  
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2 Blau syndrome 
Blau syndrome (BS, MIM #186580) is a rare autoinflammatory granulomatous 
disorder described for the first time by Edward Blau in 1985 as a dominantly 
inherited, chronic inflammatory syndrome characterized by the clinical triad of 
granulomatous dermatitis, symmetric arthritis and recurrent uveitis [41]. In 1996, 
the BS locus was mapped in the chromosomal region 16q12.1–13, which contain 
one of the susceptibility genes for Crohn’s disease [42]. In 2001, Miceli-Richard 
et al. identified the gene that confers susceptibility for BS, discovering three 
missense mutations (p.R334Q, p.R334W and p.L469F) in the region encoding the 
nucleotide-binding domain (NBD) of the caspase recruitment domain gene 
(CARD15/NOD2) in four French and German BS affected families [15]. The 
familial form of BS can be differentiated from early onset sarcoidosis (EOS), a 
multiorgan sporadic disease characterized by onset in the first 4 years of life, 
joint, skin, eye, lymph node involvement, and recurrent fevers, with possible 
abdominal or central nervous system involvement. In spite of the notable clinical 
similarities, originally BS was considered a distinct entity from EOS. Later, 
genetic analyses demonstrated that many patients with EOS also presented 
mutations in the NOD2/CARD15 gene. For this reason, some authors have 
proposed that BS and EOS are, respectively, familial and sporadic forms of the 
same disease [43,44]. Milman et al. proposed to classify patients with EOS as 
patients with “sporadic BS” due to de novo mutations, restricting the term EOS to 
patients with features of sarcoidosis and without mutations in CARD15/NOD2 
[45]. 
 
2.1 Clinical aspects 
The occurrence of BS is reported primarily among Caucasians although it has 
been also reported in Asians as well as Afro-Americans [43]. For most patients, 
the disease is characterized by early onset, typically at ages before 3–4 years; 
however, symptoms could appear after 10 years of age [45]. The most common 
manifestation of the disease is arthritis, often mistaken for juvenile rheumatoid 
arthritis (JRA) [46]. Joint manifestations usually appear such as symmetric 
polyarthritis, involving wrists, metacarpophalangeal (MCP), 1st 
metatarsophalangeal (MTP) and proximal interphalangeal (PIP) joints of hands 
and feet, ankles and occasionally elbows (Fig. 6a). Progression to deforming 
arthritis may occur, leading to severe handicap caused by flexion contractures of 
fingers and toes (camptodactyly) and decreased motion of large joints. 
BS has been described with various skin manifestations, such as papulonodular 
tender brownish rash and multiple, firm, subcutaneous nodules (Fig. 6b). The 
appearance is variable, often symmetric, located on the trunk and/or extremities 
[47]. The lesions’ histology consistently demonstrates non-caseating granulomas 
 with multinucleated giant cells [
epithelioid cells may be revealed by electron microscopy ,which 
marker for BS [49]. 
The most relevant morbidity of BS is eye involvement [5
manifestations are recurrent anterior uveitis or panuveitis toge
photophobia and blurred vision. Granulomatous uveitis, often bilateral, can evolve 
into a cataract and band keratopathy, often requiring surgery (Fig
Atypical cases of BS have been reported which involve organs othe
joints or eyes, such as liver and kidney [
No studies on the optimal treatment for patients with BS have been made yet, 
to its rarity and the variations in the severity and evolution of its expressions. 
Low-dose glucocorticoids are generally
Biologic anti-cytokine agents
therapeutic approach in refractory cases 
 
Fig. 6: Clinical and histological aspects of Blau syndrome. 
a) Asymptomatic diffuse brownish papulae of some millimeter in diameter, firm subcutaneous 
nodules, varying in size from 5 to 30 mm in diameter, on the extensor surfaces of the legs. b) 
Enlargement of interphalangeal joints. c) Skin biopsy from the right for
granulomas, containing several histiocytes and multinucleated giant cells with strong PAS 
positivity and rare lymphocytes and eosinophils. d) Granulomatous uveitis, evolved into cataract 
and band keratopathy. 
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2.2 Genetic and functional aspects 
The identification of CARD15/NOD2 as the gene responsible for BS marked the 
major turning-point for BS studies [15]. Since 2001, several cohorts have been 
genotyped and different CARD15/NOD2 mutations have been identified in BS 
patients from distinct ethnic origins (Fig. 7b). The most commonly observed 
mutations are missense substitutions affecting the highly evolutionary conserved 
arginine residue at position 334 (R334W or R334Q) [15, 54-56]. These mutated 
alleles make codon 334 a genetic hot spot for mutations. Most of the other 
mutations are found only once or few times. A multiple sequence alignment of 
NOD2 with homologous proteins have shown that the position of BS mutations 
correspond to the position of pathogenic mutations in NLRP3 protein linked to 
CAPS [57]. This suggests a close connection between the two diseases. 
CARD15/NOD2 encodes a multi-domain protein of 1040 amino acids, namely 
nucleotide oligomerization domain 2 (NOD2). NOD2 is a member of the NOD-
like receptor family (NLR) that play an important role in innate immune defense. 
NOD2 expression has been mainly occurred in the cytosol of myelomonocytic, 
dendritic, and Paneth cells [58,59], which are major component of non-caseating 
granulomas. More recently NOD2 has shown to be present in the plasma 
membrane of intestinal epithelial cells [60]. The baseline expression of NOD2 is 
low, but it is known that the protein can upregulate itself, when activated by its 
ligands [61]. 
As shown in Fig. 7a, NOD2 has a typical three-domain structure composed of two 
N-terminal effector region consisting of caspase recruitment domain (CARD), a 
centrally located NACHT that is critical for activation, and nine C-terminal 
leucine-rich repeats (LRRs) that sense the pathogen-associated molecular patterns 
(PAMPs) [62].The N-terminal domain mediated signaling through its homophilic 
interactions with other CARD containing protein. The centrally located NACHT 
domain displays ATPase activity and is necessary for activation and 
oligomerization leading to inflammatory signaling responses [63].  
NOD2 is a general detector of intracellular invasive bacterial infections, sensing 
small peptides such as muramyl dipeptide (MDP), a degradation product from 
both Gram-positive and Gram-negative bacterial peptidoglycan [64]. A crucial 
role for NOD2 in bacterial clearance has been demonstrated in vitro and in vivo 
for infection with a variety of pathogens [65, 66]. NOD2 was shown to mediate 
additional cellular responses to the host defense system in response to viral 
ssRNA [67] and to direct autophagy by recruiting one of the key components for 
autophagosome formation [68]. 
Basically, NOD2 activation leads to the activation of NF-κB that is present in the 
cytoplasm as an inactive form binded with inhibitory proteins known as inhibitor 
of κBs (IκB) (Fig. 8). NOD2 resides in the cytoplasm of resting cells in an 
autoinhibited conformation due to the intramolecular interactions of its LRR and 
CARD domains: the response to bacterial components (MDP) results in an 
 oligomerization via NACHT 
effector domain and inducing the recruitment of the serine
through a CARD-CARD interaction. Follo
activates the IkB-kinase-γ (IKK
of IKK complex, and promotes 
IKKβ (the catalytic subunit 
phosphorylation of the inhibitor
which translocates to the nucleus where it initiates the transcriptional activation of
proinflammatory genes [16
Since BS is due to an increased activity of NF
classified as an autoinflammatory disease. Howev
gain-of-function mutations in NOD2 affects the pathogenesis of Blau syndrome 
and whether a genotype
manifestations and NOD2 mutations. R
that an elevated basal NF-
disease onset since they found that patients with mutated NOD2 and low NF
activity tended to experience complications (i.e. arthritis and uveitis) at a later 
age.  
 
Fig. 7a-b: Genetic aspects of Blau syndrome. 
a) Schematic presentation of CARD15/NOD2 gene and the nucleotide positions of BS
mutations (NM_022162.1). Exons are represented by boxes whereas horizontal lines stand for 
introns. b) Detailed representation of NOD2 displaying amino acid positions of BS
mutations. The numbers under the diagram
domain (data from http://www.uniprot.org/uniprot/Q9HC29
a 
b 
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Fig. 8: Biochemical aspects of Blau syndrome.  
Schematic representation of the NF-κB signalling pathway NOD2 dependent. MDP activates 
cytosolic NOD2 through direct interaction with the leucine-rich repeat region. Binding leads to the 
oligomerization of NOD2 and recruitment of the kinase RIP2 through homotypic CARD–CARD 
interactions. RIP2 then activates the IKK complex. This results in phosphorylation, ubiquitination 
and degradation of IKB, and downstream activation of associated NF-kB 
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3 Microarray techniques 
Multiplex analytical technologies are crucial for the complex task of deciphering 
disease-specific biomarker patterns as they provide the opportunities for an all-
inclusive approach, not previously possible using conventional technologies such 
as the enzyme-linked immunosorbent assay (ELISA). There are currently 
numerous commercially available multiplex immunoassay technologies that offer 
the possibility to detect multiple analytes simultaneously [70]. 
Protein microarray is a high-throughput method used to track the expression of 
proteins, to determine their function on a large scale. Protein microarray is a rapid, 
automated and highly sensitive technique, consuming small quantities of samples 
and reagents. The advantages achieved by high sensitivity, and high throughput 
makes protein microarrays a powerful technique in the proteomic study for 
discovery of new drugs, markers and detection of known proteins [71].The 
method consists to immobilize large numbers of proteins as a spatially organized 
array of spots on a coated glass slide [72]. The concept of immobilizing 
antibodies onto functionalized glass or plastic slide surfaces was first developed in 
the 1980’s and realised as a multiplex alternative to the ubiquitous ELISA by the 
late 1990s [73, 74]. The spots may represent complex mixtures such as cell 
lysates, antibodies, tissue homogenates, recombinant proteins or peptides, body 
fluids or drugs [71, 75-78]. Density of protein spots (called features) on a printed 
array can easily reach 2,000 features per square centimetre. Sample volumes 
deposited onto the surface for any single feature would be in the 50-500 picolitre 
range. Both these characteristics depend upon the exact substrate material and 
system setup used [70]. 
Fig. 9: Slide based multiplex arrays require individual arrays to be separated with a frame and 
gasket device.  
A-D) Antibody microarray technique; E) Detection step for Reverse Phase Protein Array [70] 
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3.1 Antibody Microarray 
An antibody microarray is a specific form of protein microarrays, in which a 
collection of capture antibodies are spotted and fixed on a solid surface such as 
glass, plastic or silicon chip, for the purpose of detecting antigens. The concept 
and methodology was first introduced by Chang in 1983 [79]. His work was 
focused on the employment of antibody microarrays for the detection and 
quantification of cells bearing certain surface antigens, particulate antigens, and 
soluble antigens. 
Nowadays, the antibody microarray technique requires robotic printing of specific 
antibody sets upon an activated slide surface. Once sealed, the arrays was treated 
as ELISA wells, with appropriate blocking, sample exposure and washing. 
Detection of each target analyte was then achieved by adding a cocktail of 
biotinylated detection antibodies to complete the sandwich followed by 
amplification and streptavidin conjugated Cy5 (Fig. 9). High resolution scanning 
enabled signal intensity measurements for each feature, representing a separate 
analyzers detection. Technical replicates and some internal standards were 
included within the array. Different amplification methods can be used, dependent 
upon the testing samples. A standard curve is generated much like in a traditional 
ELISA, creating a dilutional series from recombinant antigen mass standards. The 
sensitivity of antibody microarrays is in the range of ELISA [80].  
There are many advantages in antibody microarray for high throughput analysis, 
including the fact that it does not require direct label of proteins contained in 
samples fluids. It is also a high sensitive and specific assay, that allows highly 
sensitive detection of numerous low abundance biomarkers. Nevertheless, an 
obvious limitation is the requirement of two non-overlapping accessible epitopes 
and two validated antibodies for a target molecules [81,82]. The most common 
application of antibody microarrays is to profile experiments on plasma or serum 
samples to detect a wide range of diverse molecules, such as cytokines and 
chemokines [83]. 
 
3.2 Reverse Phase Protein Array 
This technique was first introduced by Liotta and Petricoin in 2001 [75]. Reverse 
phase protein arrays (RPPA) was technically similar to the antibody microarray. 
Unfractionated samples (cell lysates) were printed directly onto coated glass slides 
and immobilized as the spot feature. The specificity of the analyte-specific 
antibodies was critical to ensure unbiased measurements and was verify by 
Western Blot. Those slides were probed with a range of antibodies specific for 
individual signalling molecules, both phosphorylated and non-phosphorylated. 
Signal detection for RPPA analysis of intracellular proteins is often performed 
using either a directly labeled reporter primary antibody, or primary and reporter 
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conjugated secondary antibody (Fig. 9c). The array is optically scanned at high 
resolution and the obtained data is quantified, usually as digital data [84]. 
There are many advantages in RPPA for high throughput analysis, including the 
small spot size of the individual spots (features) of 150 to 200 µm in diameter 
allowing the incorporation of thousands of spots per microarray. This facilitates 
comparisons between samples, since each sample is exposed to the same 
experimental conditions during analysis. RPPA is also highly sensitive due to its 
miniature format that provides increases in the signal density and requires 
extremely small amounts of sample [85]. There are some obstacles in the 
application of RPPA, related to the requirement of high affinity antibodies and to 
the state of the proteins to analyse. To overcome these obstacles, all antibodies 
should be tested for specificity and sensitivity and all the proteins have to be 
denatured [86,87]. 
An important application of RPPA is to investigate cellular signalling pathways in 
normal and diseased conditions. RPPA can be used to visualize the state of signal 
transduction pathways, providing data on post-translational modifications such as 
phosphorylation, degradation, protein cleavage and ubiquitination [88, 89]. RPPA 
data can be useful to identified novel diagnostic, prognostic and predictive 
biomarkers on a wide range of diseases, in order to clinically stratify different 
patients groups, so as to develop personalized, preventive or therapeutic 
strategies. 
 
3.3 Microarray requirements 
The optimization of assay conditions is one of the major challenge for microarray 
technology. 
 
Printing surface 
The demand for even higher densities as well as the need for decreased sample 
consumption and quantification led to the application of glass slides as solid 
supports with coated surfaces.  
The ideal printing surface should provide high sample binding capacity, good spot 
morphology, minimal autofluorescence or colour background and compatibility 
with available detection methods. There are a variety of commercially available 
activated glass or coated slides, such as nitrocellulose, amino-, aldehyde-silane 
and epoxy-silane glass slides [90]. Microporous surfaces and membranes such as 
nitrocellulose, nylon and polyvinylidine difluoride (PVDF) have high binding 
capacity and nitrocellulose coated glass slides are commonly used surfaces for 
protein arrays [91]. 
In this study nitrocellulose slides were used for RPPA, whereas poly-l-lysine for 
antibody microarray. Advantages for using nitrocellulose slides are the high 
affinity binding property, the commercial availability and the compatibility with 
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different methods of detection. The auto-fluorescence of nitrocellulose is the main 
disadvantage. Glass slides with poly-l-lysine are instead easy to prepare, handle 
and robust. They present very good signal-to-noise ratios and high homogeneity, 
even though a detection limit at 2000 amol/spot [90]. 
 
Printing condition 
Prior to printing samples on the slides there are some parameters that should be 
considered including the type of pin used for depositing the sample onto the 
surface, the capabilities of the printing robot, sample volume, viscosity and the 
numbers of arrays and slide surface to be used. Dependent on the arraying robot 
capabilities and substrate design, a spot array design can be tailored according to 
the number of samples [92]. Temperature, humidity and dust/debris are critical 
conditions during printing, since they can easily affect array quality of printing. 
Increased temperature and decreased humidity may cause evaporation of the 
sample, whereas dust on the substratum causes interference with detection 
methods. 
 
Blocking Buffer 
The blocking buffer is important in decreasing the detection background and 
provide good signal to noise ratios. Furthermore, the use of blocking conditions in 
RPPA that differ from those used for Western blot validation of the primary 
antibodies can alter the data output [92]. 
 
Amplification 
Amplification of microarray signals enhances the signal especially if the target 
analyte has low abundance. There are different methods of amplification that have 
been used, especially in antibody microarray. Tyramide signal amplification 
(TSA) is based on the horseradish peroxidase (HRP)-catalysed deposition of 
reactive biotinylated tyramine at sites of immunoreactivity, which binds to protein 
molecules at the sites of HRP activity. Biotinylated tyramine reacts with 
peroxidase in the presence of hydrogen peroxide and forms a reactive group with 
a short half-life, which is thought to bind covalently to proteins at electron-rich 
amino acid residues. This results in an increased amount of biotin at sites of 
immunoreactivity, which can be detected by streptavidin-based methods, leading 
to a significant improvement on the sensitivity of signals [94,95]. The use of TSA 
is sensitive and specific. Another amplification technique employs the 3DNA 
dendrimers technology from Genisphere (Hatfield, PA, USA) [96]. These 
fluorescently labeled dendrimers are conjugated to Streptavidin, allowing for 
detection of biotinylated targets. The signal amplification is significant, due to the 
40 fluorescent dyes per Streptavidin molecule.  
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Detection methods 
In this study, we have not tested different detection methods. It was already 
confirmed from previous work (data unpublished; MBTI group, Nottingham) that 
infrared should be the most convenient, sensitive and eligible method to detect 
specific proteins. 
There are different methods for detecting the target analyte on microarray slides, 
such as Immunofluorescence, Colorimetric and Near-Infrared (NIR). 
Due to health, safety issues and long detection times the use of radioactive 
detection methods in microarray is very limited.  
Chemiluminescent detection method is based on the similar procedure used for 
western blotting, in which the antigen is identified with primary antibody 
followed by secondary antibody conjugated with either alkaline phosphatase (AP) 
or HRP. Detection is achieved through the cleavage of a chemiluminescent agent 
and the reaction product produces luminescence in proportion to the amount of 
protein. Even if this method is sensitive and rapid, the low feature resolution is an 
important drawback. 
Another technique is based on colorimetric detection. Chromogens are molecules 
that act as substrates for an enzymatic reaction to generate a coloured substance. 
The most common chromogen used in microarray is diaminobenzidine (DAB) 
with HRP labelled antibodies. The brown DAB precipitate is stable and produces 
signals with relatively low background. However, there are several disadvantages, 
such as the mutagenicity of DAB, the limited lifetime of the reaction and the low 
dynamic range of chromogenic imaging [97, 98]. 
Fluorescence in microarray was firstly described in 1990 [99]. Fluorescent 
molecules absorb photons from an external light source, causing excitation of 
electrons within the molecule andemission of light at a different wavelength to the 
excitation one. Light emission can be quantified with great sensitivity using CCD 
detection systems. 
Fluorescence gives high dynamic range relative to colorimetric methods, from 
violet (405nm) through green (532nm), yellow (594nm) and red (635nm) regions. 
Combining each antibody with a dye presenting a unique excitation and emission 
spectra can allow the detection of multiple signals in a single assay. The 
disadvantages of visible wavelength fluorescence-based detection include 
problems of non-specific auto-fluorescence from proteins and other components 
that cause significant reduction in signal-to-noise ratios.  
Recently, the use of near-infrared (NIR; 680-800nm) fluorescence dyes has 
proved to dramatically increase signal-to-noise ratios with minimal auto-
fluorescence, with reduction of the background noise [100]. It is however 
advantageous when using nitrocellulose and fluorescent reporter dyes. The use of 
two dyes on the same printed spot to detect two target has a very high sensitivity. 
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4 Signalling pathways studied in this thesis 
Additional mechanisms linking innate immune-mediated inflammation with a 
variety of cellular processes, including protein misfolding, oxidative stress and 
mitochondrial dysfunction, have been recognised to play a role in the 
pathogenesis of some monogenic autoinflammatory conditions [101]. Those 
processes can later activate other inflammatory pathways with host defence 
function, such as MAPK, JNK, and NF-κB pathways. Along these pathways, 
inflammasomes are more than ever believed to play a central role in the 
recognition of exogenous and endogenous danger signals in autoinflammatory 
diseases [102]. Fig. 10 and 11 present schematic diagrams of the pathways, 
known to be involved in autoinflammatory diseases and analyzed in this thesis. 
 
4.1 NF-κB pathway 
NF-κB is a transcription factor that controls the expression of many genes 
involved in immune responses, cell proliferation, cell differentiation, cell 
apoptosis, inflammation, and oncogenesis. In mammals, NF-κB is considered to 
be the master regulator of both innate and adaptive immunity, inflammatory 
responses, cell survival and organ development [103]. 
NF-κB is a member of the Rel family proteins (that can bind to specific DNA 
sequences) which includes five related members that share the so-called Rel 
homology domain (RHD), about 300 amino acids long that is located toward the 
N-terminus of the protein and is responsible for dimerization, DNA binding and 
interaction with IkB (the cytoplasmic inhibitor of NF-κB).  
Expression of NF-κB is regulated by diverse stimuli including pro-inflammatory 
cytokines such as tumour necrosis factor (TNFα) and interleukin-1, bacterial 
products including lipopolysaccharide (LPS), various viral proteins such as 
human T-cell leukemia virus type 1 (HTLV-1) and physical stress, for instance 
ultraviolet radiation and reactive oxygen stimuli (ROS) [104]. During resting 
conditions, NF-κB is present in the cytoplasm as an inactive form bonded with 
inhibitory proteins IkBα (inhibitor of IkBs family, which includes seven members 
all characterized by ankyrin repeats that mask the NF-κB nuclear localization 
domain and inhibit both its targeting to the nucleus and its DNA-binding activity 
[105]. All IkB proteins have two Serine (S) residues within their N-terminal 
domain. In response to stimulation, phosphorylation of these conserved S residues 
by IkBkinase (IKK) leads to the immediate polyubiquitination of IkB proteins by 
ubiquitin ligase E3 complex, rapid degradation of ubiquitinated IkB proteins by 
the 26S proteasome [106] and release of NF-κB from inhibition, allowing its 
nuclear translocation. IkB Kinase (IKK) is a 700-900 kDa complex, containing 
two catalytic subunits, IKKα and IKKβ and a regulatory subunit NEMO (NF-κB 
essential modulator). IKKα and IKKβ are Serine/Threonine kinases with protein 
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interaction motifs including a leucine zipper (LZ) and a helix loop helix (HLH) 
domain in their C-terminal domains [107]. HSP-90/Cdc37, a chaperone, may also 
associate with the IKK complex, whereas many upstream kinases may regulate 
the IKK activity, such as MEKK1 or TGFβ-Activated Kinase 1 (TAK1). 
Once in the nucleus, NF-κB binds specific promoters that ensure transcription of 
the target genes encoding numerous pro-inflammatory cytokines, chemokines, 
adhesion molecules, growth factors, immune receptors and prosurvival proteins 
[108]. 
There are two main pathways for activation of NF-κB in response to stimulation. 
The canonical pathway in response to cytokines such as TNFα, microbial products 
and stress, depends on activation of IKK complex and results in nuclear 
translocation of NF-κB [109]. The non-canonical or alternative pathway depends 
on activation of IKK complex that results in processing of p100 NF-κB protein 
and release of p52. This pathway occurs mainly in B cells [109]. 
The known mechanism underlying NF-κB activation by NOD2 is related to a 
changing conformation of NOD2 in response to bacterial components. The 
conformational change results in activation of NOD2, downstream engagement of 
receptor interacting protein-2 (RIP2) and subsequent activation of NF-κB [110]. 
RIP2 is an adaptor protein and is a CARD-containing Serine/Threonine kinase 
that physically associates with the CARD domains of NOD2; these homotypic 
CARD–CARD interactions are important for the activation of NF-κB [111]. 
Recent results proved the essential role of RIP2 in the modulation of both innate 
and adaptive immunity triggered by NOD2 ligands [112] and, in RIP2-deficient 
mice, it was established that RIP2 played a critical role not only in NF-κB, but 
also in mitogen-activated protein kinase signalling (MAPK) [113]. However, 
NOD2-dependent but RIP2-independent signalling also exists: Travassos and 
colleagues demonstrated that in RIP2-deficient cells a NOD2 dependent induction 
of autophagy occurs, and this involves the direct recruitment of the autophagy 
protein ATG16L1 to the activated NOD2 complex [68]. 
Negative feedback for NF-κB is necessary to prevent chronic inflammation 
caused by continues activation of NF-κB. One of the regulatory molecules is 
IkBα, which is a target gene of the active NF-κB transcription factor; another one 
is A20, that negatively activates NF-κB by binding to key regulators such as 
NEMO or NOD2 in active form and causes de-ubiquitination [114].  
 
4.2 PI3K/AKT pathway 
PI3K is a heterodimeric lipid enzyme that belongs to a large family of PI3K 
related kinases capable of phosphorylation of phosphoinositides (rare lipids). 
PI3K activates intracellular signalling proteins that play a crucial role in cell 
survival, differentiation, proliferation and migration pathways in different cell 
types including cells of innate and adaptive immunity [115]. 
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PI3K presents a catalytic and regulatory subunit [116]. The catalytic p110 subunit 
has Serine/Threonine protein kinase activity as well as phosphoinositide kinase 
activity [117].The regulatory p85 subunit consists of multiple domains including 
Proline rich domains and SH domains for binding [118]. 
PI3K activation requires two steps: the assembly of p85/p110 heterodimer and the 
interaction with the activator proteins, that may plasma membrane receptors 
(receptors of platelet, epidermal or insulin-like growth factor) or non-receptor 
such as cytokines and cell attachment to the extracellular matrix such as p60 Src 
[119].  
Activated PI3K phosphorylates phosphoinositides (PtdIns), generating 
Phosphoinositide (PtdIns) phosphates (PtdIns 3,4-P2or PtdIns 3,4,5-P3). These 
rare lipids help to recruit pleckstrin homology (PH) domain containing proteins 
such as Akt and PDK1 (phosphoinositide dependent kinase 1) to the cell 
membrane. PI3K is associated with membrane receptor complexes that bring 
PI3K into the proximity of Jak2 and c-Src. This will allow Jak2 and c-Src (non 
receptor tryrosine kinases) to activate PI3K and its downstream target, Akt [120]. 
PTEN is a lipid phosphatase that inhibits the ability of PI3K to phosphorylate Akt 
[121]. 
Akt (also known as protein kinase B, PKB) is a Serine/Threonine protein kinase 
and is an important regulator of cell survival and proliferation. Akt activation is 
achieved by site-specific phosphorylation at Threonine 308 and Serine 473, after 
PI3K activation.  
However, PI3K independent activation of Akt has been reported: cAMP-elevating 
agents such as prostaglandin-E1, 8-bromo-c-AMP, forskolin and 
chlorophenylthio-cAMP were demonstrated to activate Akt through Protein 
Kinase A (PKA) [122].  
Akt can bealso activated by Ca2+/calmodulin-dependent kinase, cellular stress 
and heatshock protein especially as Hsp-27 [123]. 
Upon activation, Akt is recruited to the plasma membrane through the pleckstrin 
homology (PH) domains, and then recruits many downstream substrates that 
promote cell survival or inhibit apoptosis. These substrates include Bad, GSK-3β, 
transcription factors, Caspase-9 and IKK [124].  
There are different mechanisms of anti-apoptotic effects of the PI3K/Akt 
pathway. In some cells NF-κB is the main target of PI3K/Akt [125].However, 
there are survival mechanisms other than NF-κB that can activate several survival 
targets, including components of cell death machinery (such as BAD, cFLIP) 
[126].  
The PI3K/Akt signalling pathway is involved in regulating the inflammatory 
response. The role of the PI3K/Akt pathway in inflammation-mediated diseases 
such as rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive 
pulmonary disease, psoriasis, and atherosclerosis has been reported [127, 128]. 
PI3K is predominantly expressed in leukocytes and is critical to the inflammatory 
response and the function of leukocytes [129]. The role of Akt in inflammation is 
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still under investigation. However, Di Lorenzo and colleagues demonstrated the 
critical role of Akt1 in acute inflammation by vascular permeability that leads to 
oedema and leukocyte extravasations [130]. 
 
4.3 MAPK pathway 
Mitogen activated protein kinases (MAPK) are Serine/Threonine protein kinases 
that are activated by various extracellular stimuli as proinflammatory cytokines, 
heat shock, mitogen, osmotic stress and other stimuli. MAPK regulate different 
cell activities including gene expression, cell survival, cell proliferation, and 
apoptosis.  
Several groups of MAPK family have been identified, including extracellular 
regulatory kinase (ERK1/2/5, also known as classical MAPK), p38MAPK and c-
Jun N-terminal kinase/stress activated protein kinases (JNK1/2/3/SAPKs). 
Activation of each group requires dual phosphorylation of Threonine and 
Tyrosine within the activation loop of the MAPK through a cascade composed of 
MAPK, MAPK kinases (MEKs) and MAPKKK. MEKs are specific for each 
isoform of MAPK family. For instance ERK1/ERK2 are activated by MEK1 and 
MEK2, JNK is activated by MEK4 and MEK7, and p38 MAPK is activated by 
MEK3 and MEK6 [131]. 
One of the most important and most studied MAPK pathway is ERK1/2. 
There are many stimuli that can activate the ERK1/2 MAPK pathway such as 
growth factors, serum, and phorbol esters and to a lesser extent, cytokines, 
osmotic stress, ligands of theheterotrimeric G protein-coupled receptors, and 
microtubule disorganization [132]. Activation of ERK1/ERK2 starts at the plasma 
membrane where cell surface receptors transmit signals that allow subsequential 
binding between Ras, Raf-1 kinase (a member of MEKK family) and protein 14-
3-3 [133]. That enables Raf activation by membrane kinases such as protein 
kinase C (PKC) family, Src. After Ras/14-3-3/Raf-1 activation, the signal is 
transmitted to the next step in this cascade, MEKs (MEK 1 and 2) that can be 
activated mainly by Raf-1 involving serine phosphorylation [134]. Activated 
MEKs in turn initiate dual phosphorylation of ERK1/ERK2 within a conserved 
Thr-Glu-Tyr (TEY) motif in their activation loop. This dual phosphorylation 
allows nuclear translocation of activated ERK1/2 [135]. 
ERK1/2 can phosphorylate large number of nuclear, cytosolic and structural 
regulatory proteins that control several cellular processes mainly cell 
transcription, proliferation, cytoskeletal rearrangment and translation [136]. For 
example, ERK1/2 can indirectly regulate some kinases responsible for controlling 
transcription by phosphorylation of regulatory molecules such as NF-κB, c-AMP 
or glycogen synthase kinase 3 (GSK 3) [137].  
p38 MAPK was firstly studied in 1993 [138]. Different extracellular stimuli 
including pro-inflammatory cytokines, TNFα, interleukin-1, protein synthesis 
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inhibitors, and chemically stressful stimuli can all activate p38 MAPK pathway. 
The upstream activators of p38 MAPK are two specific MKK family members, 
MEK3 and MEK6 [139]. Recently, another upstream molecule named MEK5 
(also called TAK1) may serve as an upstream kinase of MEK3 and 6 [140]. 
Activation of the p38 results from phosphorylation of a conserved Thr-Gly-Tyr 
(TGY) motif in their activation loop by the MKK3/6. Active p38 MAPK targets 
several downstream protein kinases including: MAP kinase-activated protein 
kinase 2 and 3 (MAPKAPK2 and 3) and MSK1/2 [141]. MAPKAPK2 
phosphorylates and activates heat-shock protein27 (HSP-27), while MSK1/2 can 
phosphorylate and activate transcription factors that regulate survival, such as 
CREB. Cellular response to p38 MAPK activation changes depending on the cell 
type and the stimulus and p38 MAPK has been reported to promote both cell 
survival and cell death [142]. There are important associations between 
expression of p38 MAPK and inflammation as p38 MAPK is activated mainly by 
numerous inflammatory stimuli and there after affects directly or indirectly the 
transcription of genes encoding inflammatory molecules [143].  
JNK family was firstly isolated in 1990 [144]. There are three main forms of JNK: 
JNK1,JNK2, and SAPK that are widely expressed in all cells. Stress factor stimuli 
activate JNKs, such as cytokines, UV irradiation, growth factor deprivation, 
DNA-damaging agents, and, to a lesser extent, some G protein coupled receptors, 
serum, and growth factors [138]. Upon stimulation, signals are transmitted to 
several MAPKKs that phosphorylate MEK4 and MEK7 which in turn causes dual 
phosphorylation on Tyrosine and Threonine residues within a conserved Thr-Pro-
Tyr (TPY) motif. Between the transcription factors that are phosphorylated by 
active JNKs, c-Jun is the most well known. Serine phosphorylation of c-Jun by 
JNK leads to increased c-Jun-dependent transcription [145]. Other transcription 
factors that also can be phosphorylated by active JNKs are: ATF-2, NF-ATc1, 
HSF-1, and STAT3 [145].  
 
4.4 JAK2/STAT3/c-Src pathway 
JAKs (Janus family of tyrosine kinases) are a family of large non-receptor 
tyrosine kinase proteins, including Jak1, Jak2, Jak3 and Tyk2 [146]. They are 
widely expressed, except Jak3 restricted to myeloid and lymphoid cells. 
Stimulation of JAKs results in STAT transcription factor activity. 
STATs (signal transducers and activators of transcription) comprise a family of 
seven structurally and functionally related proteins: Stat1,Stat2, Stat3, Stat4, 
Stat5a and Stat5b, Stat6f. Activated STATs play a critical role in regulating innate 
and acquired host immune responses [147].  
Src family is non-receptor protein Tyrosine kinase that was first discovered in 
1979 [148].  
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Some cytokine receptors lack catalytic kinase activity and depend on JAK family 
of tyrosine kinases to provide this activity. It has been shown that JAKs are 
constitutively associated with a Proline-rich, membrane proximal domain of these 
receptors [149]. JAK pathway activation initiates by binding of the cytokine to the 
corresponding receptor, which leads in turn to conformational changes in the 
cytoplasmic side bringing JAKs into the proximity of each other. Activated JAKs 
act as docking sites for STATs and other regulatory molecules. Recruitment of 
STAT to the receptor initiates its phosphorylation and activation. Activated 
STATs separate from the receptor, dimerize and translocate to the nucleus [147]. 
SHP-2 protein has been found to negatively regulate JAKs activity by 
dephosphorylation [150]. Activated STATs target specific genes, SOCS 
(suppressors of cytokine signalling), which antagonise STATs activity and 
establishing an important and classic negative feedback mechanism [151]. 
Another down regulation or inhibition mechanism of STAT pathway is 
modification of STATs protein as dephosphorylation, methylation or formation of 
truncated isoforms of STATs [152]. 
C-Src is activated by dephosphorylation of Tyrosine527 by SHP-1 phosphatase 
tyrosin kinase [153]. 
 
4.5 INFLAMMASOME pathway 
The structure of the inflammasome has first been described by Tschopp and co-
workers in 2002 [154]. The macromolecular complex includes a NOD-like 
receptor (NLR) associated with ASC (apoptosis-associated speck-like protein 
containing a caspase recruitment domain (CARD)) and procaspase 1 [155]. 
According to the structure of the NLR involved, 4 types of inflammasomes have 
been described to date. The NLRP1-inflammasome may be activated by a toxin 
derived from anthrax, the NLRC4-inflammasome by bacterial flagellin and an 
inflammasome of the PYHIN (pyrin and HIN domain-containing protein) family, 
termed AIM2-inflammasome (“absent in melanoma 2”) by binding to viral and 
bacterial double-stranded DNA from intracellular pathogens [156,157]. 
External and endogenous “dangers” are recognized by these “danger sensors” and 
are able to induce an inflammatory reaction. In addition to PAMPs and DAMPs, 
the inflammasome may interact with and be stimulated by proteins such as pyrin, 
proline–serine–threonine phosphatase-interacting protein 1 (PSTPIP1) and 
mevalonate kinase (MK) [158].  
The most studied inflammasome is the NLRP3-inflammasome. It may also be 
regarded as the most important, since it can be activated by a large variety of 
PAMPs and DAMPs. In addition activation may be achieved by reactive 
oxygenspecies (ROS), proteases released into the cytosol by lysosomal damage 
caused by amyloid-β, silica, cathepsin B or cholesterol crystals, or potassium 
efflux from the cell [159-160]. 
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The NLRP3 protein has a tripartite domain organization: an amino-terminal death-
fold domain (a pyrin domain), a central NACHT nucleotide-binding domain with 
ATPase activity and a role in the oligomerization of the protein, and carboxy-
terminal leucine-rich repeats (LRRs) with regulatory functions and involved in 
ligand interaction [33]. The death-fold domains of the NLR protein interact with 
those of ASC and/or caspase. ASC is an adaptor protein encoded by PYCARD 
and consists of two death-fold domains: one pyrin domain and one caspase 
activation and recruitment domain (CARD). ASC interacts with the upstream 
inflammasome sensor molecules via the pyrin domain. This interaction triggers 
the assembly of ASC into a large protein consisting mainly of multimers of ASC 
dimers. Using its CARD, ASC brings monomers of pro-caspase 1 into close 
proximity [162]. 
Upon activation of the inflammasome, procaspase 1 will be activated to caspase 1 
which in turn cleaves inactive pro-interleukin-1β to its active form IL1β. IL1β is, 
besides TNFα, one of the major mediators of fever and inflammation in humans. 
IL1β has also been called the “prototypic alarm cytokine” [162], recognizing its 
pivotal role in innate immunity. Once released, IL1β leads to dimerization of the 
IL1 receptor accessory protein (IL1RAcP) with the IL1-receptor type 1 (IL1R1). 
This causes a cascade of downstream signals which finally result in the activation 
of NF-κB and the production and release of other inflammatory cytokines. The 
IL1 receptor antagonist (IL1-RA) may prevent recruitment of IL1RAcP and has 
an important role in regulating the process [163, 164]. 
As a consequence of inflammasome activation, a large variety of cytokines are 
produced and released by cells of the innate immune system (monocytes, 
macrophages, dendritic cells) [165]. They include the IL1 family (IL1, IL18, 
IL33), the TNF family (TNFα, LTα), the IL6 family (IL6,IL11), the IL17 family 
(IL17A, IL25), and type 1 IFNs (IFNα, IFNβ) [165]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig. 10: Signalling pathway analyzed in this thesis work
Inflammasome pathway (modified from [
pathways (Cell Signaling Technology®)
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Fig. 11: p38, Erk and SAPK/JNK MAPK Signalling pathways (Cell Signaling Technology®). 
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5 Pro-inflammatory cytokines discussed in this thesis  
The disease-based discovery of the molecular basis for autoinflammatory 
disorders has led not only to a rapidly growing number of clinically and 
genetically identifiable diseases, but has unmantled key inflammatory pathways 
such as the potent role of the interleukin IL1 and other pro-inflammatory 
cytokines.  
5.1 Interleukin 1 (IL1) 
The IL1 family plays an important role in inflammation and host defence. Up to 
11 members of this family have been identified to date [167]. Of those, only five 
have been thoroughly studied: IL1α, IL1β, IL18, IL1RA and the recently reported 
IL33 [168]. The remaining six (IL1F5; IL1F6; IL1F7; IL1F8; IL1F9; IL1F10) 
have been shown to be expressed in various cell types or tissues but their 
functions remain to be determined. 
IL1α and IL1β are pro-inflammatory cytokines. Both are synthesized as precursor 
molecules (pro-IL1α and pro-IL1β) by many different cell types. Pro-IL1α is 
biologically active and needs to be cleaved by calpain to generate the smaller 
mature protein. By contrast, pro-IL1β is biologically inactive and requires 
enzymatic cleavage by caspase-1 in order to become active. IL1α is primarily 
bound to the membrane whereas IL1β is secreted and thus represents the 
predominant extracellular form of IL1 [169,170]. Because IL1β is the most 
powerful endogenous fever-inducing molecule (pyrogen) known, there are 
multiple checkpoints to control its production and effects, including both the 
regulation of inflammasome activation and the control of its end-organ activity 
through IL1Ra. Although the major sources of IL1β are blood monocytes, tissue 
macrophages, and dendritic cells [171], it should be noted that leukocytes 
producing this cytokine are found in immunologically privileged organs, such as 
the kidney, heart, skeletal muscle, and brain [172]. Interleukin 1 is involved in the 
pathogenesis of numerous diseases with an inflammatory component [173]. In 
particular, as presented by Agostini and colleagues, IL1β has a prominent role in 
autoinflammatory diseases activated by NALP3 inflammasome [174]. The 
observation that metabolic substrates that accumulate in target tissues can 
stimulate the NLRP3 inflammasome to release IL1β has led to studies of the use 
of IL1 blocking agents in some diseases. Despite the success of IL1 blocking 
therapy, the use in a wider spectrum of autoinflammatory conditions has 
uncovered disease subsets that are not responsive to IL1 blockade.  
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5.2 Interleukin 6 (IL6) 
The IL6 family is composed of IL6, IL11, leukaemia inhibitory factor (LIF), 
oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1) 
and cardiotrophin-like cytokine (CLC). Members of this family display pro- but 
also anti-inflammatory effects and play a central role in hemopoiesis as well as in 
innate and adaptive immune responses. 
Activation of IL6 signalling is mediated through the IL6/sIL6R complex, a 
process known as “trans-signalization” and a unique example of a soluble 
cytokine receptor displaying agonistic effects. IL6 is secreted by many cell types, 
including B and T lymphocytes, monocytes, fibroblasts, keratinocytes, endothelial 
cells, mesenchymal cells and certain types of tumor cells. IL6 induces the 
differentiation of B lymphocytes into plasma cells as well as the proliferation of T 
lymphocytes, differentiation of cytotoxic T cells and IL2 production. IL6 also 
induces the differentiation of macrophages and megakaryocytes [175]. 
Recently, IL6 has been described to participate in the differentiation of a novel T 
cell subset, Th17, which displays pro-inflammatory functions [176]. IL23 is 
responsible for the expansion of Th17 previously differentiated, while IL6 and 
TGF-β are responsible for the differentiation of Th17 from their naïve precursors 
[177]. 
IL6 is likely to be involved in the pathogenesis of inflammatory diseases. It is also 
found at high level in serum of periodic fever patients [178] and also in complex 
disorders such as Still's and Behçet diseases [179, 36]. 
5.3 Interleukin 8 (IL8) 
Interleukin 8 is a member of the CXC chemokine family and was initially 
identified as a neutrophil chemotactic and activating factor [180]. Since then, a 
variety of other proinflammatory activities have been attributed to IL8, including 
immune cell activation and promotion of angiogenesis [181,182]. IL8 can be 
produced by a variety of cell types involved in inflammation, including 
monocytes and endothelial cells. Activation of cells occurs after binding to the 
IL8 receptors, CXCR1 and CXCR2, expressed on neutrophils, monocytes, 
endothelial cells, astrocytes, and microglia [183]. IL8 expression is regulated by 
different mechanisms, including NF-κB pathway [184].  
IL8 is implicated in chronic inflammation, as suggested for inflammatory diseases 
such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis [185,186]. 
IL8 levels are increased in the serum of diverse autoinflammatory diseases 
affected subjects, in particular it can be a marker of activity in Behçet patients 
[187]. 
 
 
 
 38 
5.4 Tumour Necrosis Factor α (TNFα) 
Among all the members of the tumour necrosis factor family, TNFα and TNFβ are 
the most pleotropic cytokines. Although they share biological activities and 
homology, they are structurally different as TNFα presents cysteine residues 
[188]. TNFα is produced by activated immune cells including macrophages, 
monocytes, lymphocytes such as T-cells and natural killer cells (NK) and other 
cells including fibroblasts, smooth muscle cells and epithelial cells. TNFα is 
synthesised as a homotrimer type II transmembrane pro-TNFα that is cleaved by a 
metalloproteinase to release C-terminal soluble TNFα [189]. 
TNFα controls and orchestrates the immune responses at several levels [190]. It 
has also a protective role against many infections and an important function in 
organogenesis [191, 192].The pathological effects of TNFα includes involvement 
in cancers, inflammation, autoimmune diseases [193]. 
5.5 Interferons (IFNs) 
The IFNs were originally discovered as agents that interfere with viral replication. 
They are classified into type I and type II according to receptor specificity and 
sequence homology. 
IFNγ is the sole type II IFN. It is structurally unrelated to type I IFNs, binds to a 
different receptor, and is encoded by a separate chromosomal locus. It is secreted 
by B cells, NKT cells, and professional antigen-presenting cells (APCs) 
[194,195]. IFNγ production by professional APCs (monocyte/macrophage, 
dendritic cells) acting locally may be important in cell self-activation and 
activation of nearby cells. IFNγ secretion by NK cells is likely to be important in 
early host defence against infection. IFNγ production is controlled by cytokines, 
such as IL12 and IL18. These cytokines serve as a bridge to link infection with 
IFNγ production in the innate immune response [196]. IFNγ is known to heighten 
immune surveillance and immune system function during infection [197]. 
5.6 Interleukin 12, 17, 22 and 23 (IL12, IL17, IL22 and IL22) 
IL12 is produced primarily by monocytes, macrophages, dendritic cells, and B 
cells. The major functions of IL12 include induction of IFNγ production from 
natural killer (NK) cells and T cells, enhancement of cytotoxity of NK and 
cytotoxic T cells, and differentiation of naïve T cells into Th1 effectors, 
suggesting a key role for IL12 in the development of cell-mediated immunity 
[198]. Although IL12 is important for host defence, over expression of IL12 can 
cause persistent inflammation leading to autoimmune disorders such as multiple 
sclerosis. 
The recent discovery of IL23 has led to a re-evaluation of interleukin 12 biology, 
as they share a common p40 subunit. IL23 is a cytokine that drives autoimmune 
diseases, including psoriasis and inflammatory bowel diseases [199,200]. IL23 is 
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secreted by human DCs exposed to gram-negative bacteria. The main 
distinguishing feature of IL23 is its ability to induce CD4+ Th17 cells to produce 
IL17 [201]. The IL23-IL17 pathway plays an important role in terms of the 
induction of inflammatory cytokines contributing to autoimmunity as well as 
protective responses against infection. 
IL17 is a potent proinflammatory cytokine that amplifies ongoing inflammation 
by inducing expression of TNFα, IL1β, and IL6 in epithelial and endothelial cells 
as well as other cell types such as keratinocytes, synoviocytes, fibroblasts, and 
macrophages.  
Interestingly, a recent report brings to light a potential role for Th17 cells in the 
autoinflammatory disorder adult-onset Still’s disease (AOSD) [202]. 
Th17 cells produce also IL22, a cytokine that is important for the modulation of 
tissue responses during inflammation. Through activation of STAT3 signalling 
pathway, IL22 induces proliferative and anti-apoptotic pathways, as well as anti-
microbial molecules that help prevent tissue damage and aid in its repair. IL22 
plays also an important role in inflammation, including chronic inflammatory 
diseases and infectious diseases [203]. 
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AIM OF THIS WORK 
The autoinflammatory diseases are a heterogeneus group of inflammatory 
syndromes caused by primary dysfunction of the innate immune system, without 
evidence of adaptive immune dysregulation. They comprise both hereditary (such 
as FMF, MKD, TRAPS, CAPS and Blau syndrome) and multifactorial (Still's and 
Behçet's diseases) disorders. Despite major advances in genetics and 
pathophysiology of these diseases, the signalling pathways and the inflammatory 
mediators related to autoinflammatory disorders are far to be deeply investigated.  
 
There are two main aims in this project: 
1. Functional characterization of the Blau syndrome-associated mutation 
(p.E383K), recently found in the affected members of an Italian family, by 
studying in vitro its pathogenic potential from NOD2-transfected HEK293 
cells. To confirm the preliminary in vitro results, additional ex vivo studies 
were performed using protein microarray techniques. 
2. Characterization at molecular level of a wide range of hereditary and 
multifactorial autoinflammatory diseases, in order to identify possible 
predictive or diagnostic biomarkers for each disease and to develop 
preventive and therapeutic strategies. We evaluated both signalling 
intermediates and inflammatory mediators in pathways known to be 
involved in inflammatory responses by means of protein microarray based 
systems 
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MATERIALS AND METHODS 
1 Genetic and functional studies on Blau syndrome 
1.1 Clinical Evaluation 
The study involved subjects belonging to an Italian family, affected by BS and 
followed by the Rheumatic Unit, University of Padua for the past 25 years (Fig. 
12a) [204]. Clinical diagnosis for BS was based on physical features, such as 
chronic bilateral uveitis, symmetrical arthritis involving fingers wrists and feet, 
and skin manifestations, consisting of widespread papules. Skin biopsies have 
revealed non-caseating granulomas with multinucleated giant cells which, at 
electron microscopy, revealed "comma-shaped bodies" in epithelioid cells, 
thought to be a marker for BS (Fig. 12b). Each patient underwent all routine 
laboratory investigations, including serum lipids, rheumatoid factor and 
antinuclear antibodies, that were within normal limits. The proband showed 
asymptomatic, diffuse, miliary brownish papule and firm subcutaneous nodules, 
varying in size from 5 to 30 mm diameter, on the dorsa of hands and feet and on 
the extensor leg surfaces. No specific treatment was prescribed to the 
probandexceptfor NSAIDs, which were to be taken when necessary for a few 
days' time for pain control. Her daughter, instead, followed a low doses of oral 
steroids treatment which yielded a good response [205]. 
Blood sampling for DNA, PBMC cytokine assays and functional analysis were 
performed under informed consent, according to the pertinent Italian legislation. 
Fig. 12: Blau syndrome family.  
A) Pedigree structure of the proband and her family. Filled-in symbols indicate clinically affected 
family members, both proband (subject II-4) and her daughter (subject III-2). Shaded symbol 
represents proband's granddaughter (subject IV-1), an asyntomatic carrier of the p.E383K 
mutation. Absence (-) or presence (+) of p.E383K mutation is indicated.  
B) Clinical and histological aspects of Blau syndrome. a) Asymptomatic diffuse brownish papulae, 
firm subcutaneous nodules, on the extensor surfaces of the legs. b) Enlargement of interphalangeal 
joints. c) Skin biopsy from the right forearm. Non-caseating granulomas, containing several 
histiocytes and multinucleated giant cells with strong PAS positivity and rare lymphocytes and 
eosinophils. d) Granulomatous uveitis. 
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1.2 Screening for mutations 
Genomic DNA was extracted from blood samples and its concentration is 
determined with Nanodrop (ND 1000 Spectrophotomer). All PCR primers used in 
this thesis were designed by PRIMER3 (http://frodo.wi.mit.edu) and produced by 
Invitrogen. The primers obtained from PRIMER3 were chosen after analysis with 
BLAT (http://genome.ucsc.edu) to avoid both SNPs presence within their 
sequences and annealing in additional wrong regions. 
 
1.2.1 DHPLC analysis 
PCR Amplification 
The analysis of CARD15/NOD2 gene in 3 BS patients were performed firstly by 
denaturing high-performance liquid chromatography (DHPLC). Samples were 
amplified in a final volume of 50μl containing approximately 100ng of genomic 
DNA, 10X PCR buffer II (Applied Biosystems), 25mM MgCl2 (Applied 
Biosystems), 6pmoli of each primer (Invitrogen), 5mM deoxinucleotide 
triphosphates (Invitrogen) , and 2.5U of DNA TAQ GOLD polymerase (Applied 
Biosystem).  
PCR conditions for all the DNA fragments were as follows: an initial denaturation 
cycle of 95°C for 7 minutes followed by 35 cycles composed by a denaturation 
step (95°C) for 30 seconds, an annealing step for 30 seconds, and an extension 
step (72°C) for 45 seconds. A final extension of 72°C for 7 minutes completes the 
amplification. The amplification product was verified using 2% agarose gel, and 
visualized using Gel Red™ Nucleic Acid Gel Stain (Biotium) and ultraviolet 
light. As the length of fragment suitable for DHPLC analysis is less than 400bp, 
this long exon was split in shorter amplicons. All primer sequences and PCR 
conditions used are reported in the below table (Tab. 2). 
 
AMPLICON Tm Base pair 
T°c DHPLC+TIME 
SHIFT FORWARD 5' 3' REVERSE 5'3' 
4a 60°C 550bp 61.5°C 63.5°C CGCTGGCTCTCCTATCCCTT  TTGACCAACATCAGGCCAACAG 
4b 60°C 487bp 61°C 63.1°C + 0.5 CTGCAGGGCAAGACTTCCA AGGGCTGAGGTCTCTTGGA 
4c 60°C 524bp 62.4°C 63.2°C TCCGCACCGAGTTCAACCTC CGCGGCAAAGAAGCACTGGA 
4d 60°C 490bp 62.2°C GCCAAGAGCGTGCATGCCAT CACCAGACCCAGCACATAGG 
4e 60°C 494bp 63.9°C 62.5°C + 1 ACCTTCAGATCACAGCAGCC GCTCCCCCATACCTGAAC 
Tab. 2: Condition for PCR amplification and DHPLC analysis of CARD15/NOD2 gene for BS-
associated mutation. 
 
DHPLC Analysis 
Denaturing high-performance liquid chromatography (DHPLC) compares two or 
more DNA sequences as a mixture of denatured and reannealed PCR amplicons, 
revealing the presence of a mutation by the differential retention of homo- and 
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heteroduplex DNA on reversed-phase chromatography supports under partial heat 
denaturation [206]. 
DHPLC analysis was performed on a Transgenomic Wave DNA Fragment 
Analysis System (Model 3500HT; Transgenomic) with a DNASep column 
(Transgenomic). PCR fragments were denatured for 5min at 95°C and then left to 
re-anneal slowly at room temperature to promote the formation of heteroduplex. 
Separation was performed at a flow rate of 0.9ml/min for Mutation Detection 
application (8min). The acetonitrile gradient was adjusted to elute the amplicon at 
half run, around 4min for Mutation Detection application and 1.5min for Rapid 
DNA application. The gradient was obtained by mixing Buffer A (0.1M TEAA, 
pH 7.0) and Buffer B (0.1M TEAA, pH 7.0, 25% acetonitrile). Buffer B increase 
was 2% per min (with flow rate 0.9ml/min) and 5% per min (with flow rate 
1.5ml/min). Column temperatures were calculated by NAVIGATOR software 
(Transgenomic). Whenever fragments showed different melting domains, 
additional analyzing temperatures were used, to optimize resolution. These 
temperatures should give the 75-80% of double strand DNA within the fragments. 
DHPLC conditions used to analyze CARD15/NOD2 gene are listed in the Tab. 2 
presented above. 
 
Fig. 13: DHPLC scheme.  
When two DNA molecules, differing by as little as a single mismatch, are heated and cooled 
together, two homoduplex and two heteroduplex species are formed. The chromatographic 
separation of homo- and heteroduplex is the basis of the DHPLC technique. 
 
1.2.2 DNA Sequencing 
Whenever a putative mutation was detected with DHPLC technique, a DNA 
sequencing was performing to confirm it. Primers and dNTPs unconsumed during 
the PCR amplification can interfere with the sequencing method. The purification 
was provided by usage of two hydrolytic enzymes, Exonuclease I and Shrimp 
Alkaline Phosphatase (EXO-SAP). After mixing together 5µl of PCR 
amplification and 0.5µl of each enzyme, the solution has to be incubate firstly at 
37°C for 15min to activate and then at 80°C for 15 min to inactivate the reaction. 
The sequencing reaction requires 3ng of purified DNA per 100bp and 10pmol of 
primer for sequencing (forward o reverse). PCR amplicons were sequenced at the 
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BMR genomics by an ABI 3730XL DNA sequencer (Applied Biosystems). 
CHROMAS software (Version 2.33; Technelysium) and the LASERGENE 
software package (SeqMan II, DNASTAR) were used to edit, assemble and 
translate sequences.  
 
1.3 Cytokines release from PBMC 
Collection of PBMC 
Single paired samples of blood were collected from the two adult Blau syndrome 
patients described previously and three healthy controls. PBMC were isolated by 
Ficoll-density gradient separation, as the protocol below. 
 Thaw blood sample (collected in EDTA tube) and transferred to a sterile 
50ml tube.  
 Add PBS+2%FCS at 1:2 ratio, then gentle mixing the tube. 
 Layer 3ml of Histopaque-1077 at the bottom of a new tube and then 
carefully layer the blood sample using a Pasteur pipette. Do not mix the 
blood and Histopaque. 
 Spin at 900×g for 30min at room temperature. 
 Using a Pasteur pipette carefully remove the white 'buffy coat layer' and 
transfer it to a new universal container. This layer contains PBMCs. 
 Wash the cells in PBS+2%FCS (make up total volume to approximately 
15ml). Centrifuge cells at 400×g for 10 minutes at room temperature.  
 Pour off supernatant very gently and resuspend cells in 8ml of an 
hemolysis solution (8,26g NH4Cl, 1g KHCO3, 0,037g EDTANa4) for 
10min, shaking sometimes. 
 Add PBS+2%FCS until the final volume of 15ml and then centrifuge at 
400×g for 10 minutes at room temperature. 
 Pour off the supernatant and wash the pellet with PBS. Centrifuge cells at 
400×g for 10 minutes at room temperature. 
 Pour off supernatant gently and resuspend cells in 10ml of RPMI complete 
media (10%FCS+1%Glutamine). 
 Count the cells using Bürker chamber and diluting the cells in Trypan 
Blue. To obtain the concentration of the suspension, use the formula: 
 
cell/ml=mean of readings × titration factor × 10 
Cell culture and stimulation of PBMC 
Fresh PBMC were seeded in 12-well plate inRPMI media containing 
1%Glutamine and 10%FCS in an atmosphere of 95/5% air/CO2 at 37°C at a 
density of 2·106cell/2ml. The cells were cultured for 7 and 24 hours either without 
stimulation or in the presence of muramyldipeptide [10µg/ml] (Sigma-Aldrich), 
purified lipopolysaccharide from E.Coli 055:B5 [100ng/ml] (Sigma-Aldrich) or a 
combination of both. All experiments were made in duplicate. 
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Muramyldipeptide (MDP) is a synthetic immunoreactive peptide consisting of N-
acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln 
[207]. Lipopolysaccharide (LPS) is a TLR -4 agonist and the major component of 
the outer membrane of Gram-negative bacteria.  
 
ELISA analysis 
At the expected times, the cell culture were proceeded as follow: 
 Collect the surnatant of each well in different marked eppendorf. 
 Centrifuge at 400×g for 10 minutes at room temperature to pellet 
accidental cellular materials. 
 Collect the surnatant and store at -80°C. 
 In a specific tube, each surnatant was diluted at 1:50 in a total volume of 
1ml BSA4% solution and store at -20°C until cytokine assays were 
performed 
 
Cytokines levels were measured through enzyme-linked immunosorbent assay 
(ELISA) by Hospital Laboratories. ELISA is a simple technique that allows rapid 
screening or quantification of a large number of samples for the presence of an 
analyte or the antibody recognizing it. ELISA, however, remains popular because 
of its ease of performance and automation, accuracy, and the ready availability of 
inexpensive reagents. One limitation of the ELISA technique is that it provides 
information on the presence of an analyte but no information on its biochemical 
properties, such as molecular weight or its spatial distribution in a tissue. 
 
1.4 CARD15/NOD2 constructs for in vitro experiments 
To directly evaluate the pathogenic potentials of the mutation identified in the 
Italian BS patients (p.E383K), the starting point is to create a construct with the 
wild-type and mutated CARD15/NOD2 cDNA cloned inside. The CARD15/NOD2 
wild-type construct was already available in the lab, presenting the cDNA cloning 
into pCMV-Tag2c vector. I did a mutagenesis step to introduce p.E383K in the 
wild-type construct. Having a construct carrying another BS-associated mutation 
should be very useful, especially as a positive control for the further experiments. 
p.R334W mutation is one of the most frequent and deeply studied BS-associated 
mutation. Due to the hardness of mutagenesis in the region full of tandem repeats 
, I used a different way to obtain the p.R334W mutated construct. I have started 
from a different construct pcDNA3-R334W, presenting the mutated p.R334W 
CARD15/NOD2 cDNA. 
A couple of restriction enzymes (BamHI and XhoI) are used to cut this construct 
to obtain the linear strand of p.R334W CARD15/NOD2 cDNA. The same 
restriction enzymes cut the pCMV-Tag2c-CARD15/NOD2 wild-type construct to 
get the vector pCMV-Tag2c with compatible ends for ligation with the previously 
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obtained cDNA. DNA ligase catalyzes the joining using the 5´-phosphate and the 
3´-hydroxyl groups of adjacent nucleotides in the sticky-ended configuration 
[208]. This allows the "pasting" together of p.R334W CARD15/NOD2 cDNA 
insert and receptive pCMV-Tag2c vector. So, those constructs are ready for 
further transfection experiments. 
 
1.4.1 Vectors 
pcDNA3 
In the lab p.R334W CARD15/NOD2 cDNA was available kindly provided by Dr 
G Núñez (Ann Arbor, MI, USA) cloning into pcDNA3 vector. This plasmid offers 
the following features, as shows in Fig. 14: 
 Cytomegalovirus (CMV) enhancer-promoter for high-level expression 
 Large multiple cloning site with 11 unique restriction enzyme sites and 
either forward (+) or reverse (-) orientations 
 Bovine Growth Hormone (BGH) polyadenylation signal and transcription 
termination sequence for enhanced mRNA stability 
 Ampicillin resistance gene and pUC origin for selection and maintenance 
in E. coli 
 
B 
 
 
C 
 
Fig. 14: pcDNA3 plasmid. 
A) pcDNA3 plasmid circle map (Life Technology); B) List of features and their position; C) 
Multiple cloning site region with position of restriction enzymes. 
A 
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pCMV-Tag2c 
The expression vector used for this thesis work is pCMV-Tag2c (4.3 kb), kindly 
provided by Dr T Kufer with CARD15/NOD2 wild-type cDNA (GenBank 
NM_022162.1) cloning inside. pCMV-Tag2c is an N-terminal FLAG® 
mammalian expression vector (Fig. 15). The FLAG epitope is a small, highly 
immunoreactive tag, composed of 8 amino acid residues (DYKDDDDK) and is 
not likely to interfere with the function of the target protein. A Kozak consensus 
at N-terminal sequence provides optimal expression of the fusion protein. The 
neomycin-resistance gene is under control of both the prokaryotic β-lactamase 
promoter to provide kanamycin resistance in bacteria and the SV40 early 
promoter to provide G418 resistance in mammalian cells. The multiple cloning 
site (MCS) of the plasmid allows for a variety of cloning strategies.  
 
 
 
 
 
Fig. 15: pCMV-Tag2c plasmid. 
A) pCMV-Tag2c plasmid circle map (Sigma); B) List of features and their position; C) Multiple 
cloning site region with position of restriction enzymes and FLAG® tag. 
 
  
A B 
C 
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1.4.2 One step direct Mutagenesis for p.E383KCARD15/NOD2construct 
Site-directed mutagenesis is an effective technique for introducing mutations or 
short deletions into a gene of interest. The important starting step is the design of 
the mutagenic primers. 
 
Mutagenic primers design 
The mutagenic oligonucleotide primers were designed using the following 
guidelines: 
 The mutagenic primers for point substitutions or insertion must contain the 
desired mutation, whereas the mutagenic primers for deletions must skip 
the sequence corresponding to the lost oligonucleotides. 
 Primers should be between 25 and 45 bases in length, with a melting 
temperature (Tm) of ≥78°C. Primers longer than 45 bases may be used, but 
using longer primers increase the likelihood of secondary structure 
formation, which may affect the efficiency of the mutagenesis reaction. 
The following formula is commonly used for estimating the Tm of 
primers: 
 = 81.5 + 0.41(% !) − 675 &' − %()*(+,-ℎ , 
where N is the primer length in bases. 
For calculating Tm for primers intended to introduce insertions or 
deletions, there is a modified formula to use: 
 = 81.5 + 0.41(% !) − 675 &'  , 
where N does not include the bases which are being inserted or deleted. 
 Τhe desired mutation should be in the middle of the primer with 10-15 
bases of correct sequence on both sides. 
 The primer optimally should have a minimum GC content of 40% and 
should terminate in one or more C or G bases. 
 Primers for insertion or deletions must be purified by polyacrylamide gel 
electrophoresis (PAGE). Failure to purify the primers results in a 
significant decrease in mutation efficiency. 
 
One step direct mutagenesis  
Site-directed mutagenesis was performed on CARD15/NOD2 wild-type - pCMV 
Tag2c construct, in order to reproduce the mutation p.E383K (c.1147G>A) 
presents in our BS patients. 
The following mutagenic primers were used separately and with different 
annealing condition (60°C-62°C). This allowed to choose the better primer and 
temperature for a higher mutagenesis yield. 
 
E383K-F: CCTTTGATGGCTTTGACAAGTTCAAGTTCAGGTTC; 
E383K-R: GAACCTGAACTTGAACTTGTCAAAGCCATCAAAGG 
 
Materials and Methods 
51 
Set up PCR reaction: 
 
Template DNA (327ng/μl stock) 1.1μl 
Primer F or R (1μM) 5μl 
dNTPs (10mM) 1.5μl 
10X Pfu Buffer 2.5μl 
Pfupolymerase 
(Stratagene, 2.5U/μl) 0.5μl 
Sterile water 15μl 
Final volume 25μl 
 
PCR conditions: 
Denaturation: 95°C for 3min 
Then 23 cycles of: 62°C for 30sec 
62°C for 90sec 
68°C for 18min 
 
1μl of Dpn I, a methylation-sensitive restriction enzyme, was added to the PCR 
product and then was incubated for 1-2 hours at 37°C to get rid to the wild-type 
methylated host strand.  
 
1.4.3 Construction of p.R334W CARD15/NOD2 pCMV-Tag2c plasmid 
 
Digestion 
The cDNA of human p.R334W CARD15/NOD2was kindly provided by Dr G 
Núñez (Ann Arbor, MI, USA) cloning into pcDNA3 vector. The mammalian 
vector pCMV-Tag2c was kindly provided by Dr T Kufer with CARD15/NOD2 
wild-type cDNA cloning inside. It is necessary to digest both constructs in order 
to obtain the vector pCMV-Tag2c with compatible ends with the p.R334W 
CARD15/NOD2 cDNA. BamHI and XhoI (NEB, UK) are the more suitable 
couple of restriction enzymes in this case for a double digestion. 
 
Set up restriction reaction: 
 
CARD15/NOD2 wild-type- pCMVTag2c p.R334W CARD15/NOD2 - pcDNA3 
Construct 15 μg Construct 15 μg 
Buffer3 10X 3 μl Buffer3 10x 3.5μl 
XhoI 3μl XhoI 3μl 
BSA 100X 0.3 μl BSA 100X 0.35 μl 
water 6.7 μl water 4.15 μl 
Final volume 30 μl Final volume 35μl 
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• Digestion O/N at37°C 
• Stop restriction at 65°C for 20min 
• Add 3 μl of BamHI 
• Digestion at 37°C for 4 hours 
 
 
 
 
  
 
 
Purification 
A particular good purification of the digestion products is necessary to obtain the 
higher amount of linearized pCMVTag2c vector and p.R334W CARD15/NOD2 
cDNA insert. 
The Wizard® SV Gel and PCR Clean-Up System (Promega) is a membrane-
based method designed to extract and purify DNA fragment up to 10kb from 
standard agarose gels. It is based on the ability of DNA to bind to silica 
membrane in the presence of chaotropic salts. 
 
Ligation 
T4 DNA Ligase (Promega) catalyzes the joining of pCMVTag2c linearized vector 
and p.R334W CARD15/NOD2 cDNA between the 5 ́-phosphateand the 3 ́-
hydroxyl groups of adjacent nucleotides in a cohesive-ended configuration. The 
following formula is commonly used for estimating the optimal quantity of cDNA 
to be used: 
/0 12 34-,15 × 67 *)84 12 )/*45,
67 *)84 12 34-,15
× (19+5 5+,)1 12 )/*45, 34-,15' = /0 12 )/*45, 
Set up ligation reaction: 
Reagents Quantity Reagents Quantity 
Vector pCMVTag2c 180ng Vector pCMVTag2c 180 ng 
p.R334W CARD15/NOD2 
insert 
134 ng p.R334W CARD15/NOD2 
insert 
402 ng 
Ligase 10X Buffer 1 µl Ligase 10X Buffer 1 µl 
T4 DNA ligase 1.2 µl T4 DNA ligase 1.2 µl 
Nuclease-free Water 5.75 µl Nuclease-free Water 4.15 µl 
Final volume 10 µl Final volume 10 µl 
Ratio insert/vector = 1:1 Ratio insert/vector = 3:1 
 
To increase the efficiency rate of the ligation reaction, I have tested different 
conditions. I used two molar ration of insert:vector (1:1 and 3:1) and two 
incubation temperature (4°C and 16°C O/N). 
Expected bands from digestion of 
p.R334W CARD15/NOD2 - pcDNA3 
5.400 bp Linearized vector 
3200 bp Insert 
Expected bands from digestion of 
CARD15/NOD2 wild type- pCMVTag2c  
4300bp Linearized vector 
3200bp insert 
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1.4.4 One shot chemical transformation and preparing cultures of 
bacteria 
All the constructs prepared above were cloned in Top10 chemically competent 
E.Coli (Life Technology). To maximise the transfected efficiency, a key 
parameter is the purity of plasmid DNA. The constructs have to be deprived of 
phenols, ethanol, proteins and detergents.  
The protocol consists of these following steps: 
 Thaw on ice one 50μl vial of One Shot® TOP10 cells (Life Technology) 
for each transformation. 
 Add 2μl of plasmid DNA directly into the aliquot of bacteria and mix 
gently without pipetting. 
 Incubate on ice for 30min and then heat-shock the cells for 30sec at 42°C 
without shaking. The cells are highly sensitive to mechanical lysis caused 
by pipetting. 
 Immediately transfer the tubes to ice and add 250μl of SOC medium 
previously warmed at room temperature. SOC is a rich medium composed 
by 2% Tryptone, 0.5% Yeast extract, 10mM NaCl, 2.5mM KCl, 10mM 
MgCl2, 10mM MgSO4, 20mM glucose 
 Cap the tube tightly and shake the tube (200rpm) at 37°C for 1 hour 
 Incubate at 37°C for 30minutes two plates (LB plates containing 50μg/μl 
ampicillin) for each transformation 
 Spread 50μl and 200μl from each transformation on 2 pre-warmed plates. 
Spreading the plates with different volume ensured that at least one plate 
would have well-spaced colonies. The bacteria selection medium was LB 
(Luria-Bertani: 1%Tryptone, 0.5% Yeast extract, 1% NaCl) added with 
1.5% Select-Agar and containing 50μg/μl Kanamycin. 
 Incubate at 37°C O/N 
 
1.4.5 Purification of plasmid 
Wizard® Plus SV Minipreps DNA Purification System (Promega) 
This miniprep procedure provides a simple, reliable method for rapid isolation of 
any plasmid DNA from E.coli hosts, most efficiently when the plasmid is less 
than 20 kb in size. An overnight colture is harvested with centrifugation and 
subjected to a modified alkaline-SDS lysis procedure followed by adsorption of 
the plasmid DNA onto silica in the presence of high salts. Contaminants are then 
removed by a spin wash step. Finally, the bound plasmid DNA is eluted in water 
or Tris-EDTA buffer.  
The recovered plasmid DNA, predominately in its supercoleid form, is checked in 
a 1% agarose gel. 
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PureYield™ Plasmid Midiprep System (Promega) 
The system provides a rapid method for purification using a silica-membrane 
column. The bacterial cells are lysed by a set of buffers based on the NaOH/SDS 
lysis method. After equilibration of the column together with the corresponding 
column filter, the entire lysate is loaded by gravity flow and simultaneously 
cleared by the equilibrated filter. Plasmid DNA is bound to the silica resin and 
after a washing step is eluted, precipitated and dissolved in a suitable buffer for 
further use. From 50ml of an overnight recombinant E.coli culture is possible to 
isolate more than 50μg of high copy plasmid DNA. 
The recovered plasmid DNA has to be checked in a 1% agarose gel. 
 
1.4.6 Sequencing of the final constructs 
Each plasmids were verified for unwanted variations both in the insert sequence 
and in the functional region of the plasmid (CMV promoter and FLAG). The three 
final constructs have been sequenced using the primers listed below. 
The primer CARD15_vect1R verified the accuracy of the FLAG, the promoter 
CMV and BamHI restriction site. The primer CARD15_vect9F identified the 
accuracy of the XhoI, whereas the primer CARD15_vect4F showed the two 
mutations inserted in CARD15/NOD2.  
For the sequencing, we used the service provided by the BMR genomics and 
prepared 200ng of each plasmid DNA and 1µl of each primers. 
 
SEQUENCING PRIMERs 
INSERT SEQUENCE FUNCTIONAL REGIONS OF 
pCMVTag2c VECTOR 
CARD15_vect1F 
CACGATGAGGAGGAAAGAGC 
CARD15_vect6F 
TGCTGCTACGTGTTCTCAGC 
CARD15_vect1R 
TGGAAGCCCTCGTAGTCCTC 
CARD15_vect1R 
TGGAAGCCCTCGTAGTCCTC 
CARD15_vect7F 
CAGATCACAGCAGCCTTCCT 
CARD15_vect9F 
TCCGAGGCAACACCTCCTTG 
CARD15_vect2F 
TACTTGGGCCTGTCAGAAGC 
CARD15_vect8F 
GAGTGTGCTGCCCTGGCCTT 
E7901CMV-F 
GCCATTGCATACGTTGTATC 
CARD15_vect3F 
GCTGCCACATGCAAGAAGTA 
CARD15_vect9F 
TCCGAGGCAACACCTCCTTG 
 
CARD15_vect4F 
CAGTGGCAAGAGCACGCTCC 
CARD15_vect10F 
CTGAAGTTGTCCAATAACTG 
CARD15_vect5F 
CATCCGCACCGAGTTCAACCT 
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1.5 In vitro experiments on transfected HEK293 cells 
 
Fig. 16: Main procedures in in vitro studies on transfected cells.  
Both microarray techniques are explained in the microarray section. 
 
1.5.1 HEK293 cell cultures 
The HEK293 cell line, derived from human embryonic kidney cells, has been 
extensively used as an expression tool for recombinant proteins. Although of 
epithelial origin, its biochemical machinery is capable of carrying out most of the 
post-translational folding and processing required to generate functional, mature 
protein [209]. The principal characteristics of these cells are their quick and easy 
reproduction and maintenance, amenability and high efficiency of transfection 
using a wide variety of methods. These, and other attributes, also mean that 
biochemical and cell biological evaluations of expressed proteins can be 
performed in concert with functional analyses.  
HEK293 cells grow adherent in T75 flasks at 37°C in an atmosphere of 95% 
air/5% CO2 and remain biochemically active at 50-70% confluency. The cells are 
expected to double approximately every 12 hours. This cell line requires complete 
DMEM High glucose 90% medium (Life Technology) supplemented with 
Gentamycin (final concentration 0.1%), 10%FCS and 2% L-glutamine.  
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1.5.2 Transfection 
The ability to generate HEK cell phenotypes by the introduction of exogenous 
nucleic acid depends on a range of transfection techniques. Lipofectamine™ 2000 
(Life Technologies) represents one of the more recent cationic lipid encapsulation 
reagents which deliver DNA to the cells by fusion and incorporation of lipid 
microsomes into the cells' lipid bilayer. 
After the transfection, the cells are able to express human wild-type or mutated 
(p.R334W or p.E383K) CARD15/NOD2 gene. These exogenous proteins should 
be recognized by the N-terminal FLAG sequence. 
 
Preparing cultures 
HEK293 cells were seeded in 6-well plates incomplete DMEM without 
Gentamycin. The density of cells must be sufficient to achieve 70% confluence at 
the time of transfection. 
 
Transfection technique 
Each construct was transfected in triplicate, increasing the likelihood of positive 
transfected cells. 
The following protocol is to intend for single well: 
 Prepare for each construct two dilutions: one with 0.4µg/µl of plasmid 
DNA in a final volume of 250µl of DMEM reduced serum medium, the 
other with 10µl of Lipofectamine™ 2000 in 240µl of DMEM reduced 
serum medium. 
 Add the diluted plasmid DNA to the diluted Lipofectamine™ 2000, mix 
and incubate for 20min at room temperature 
 In the meantime, discard the medium in 6-well plate and add DMEM 
reduced serum medium 
 Add the mixing DNA/Lipofectamine drop by drop and incubate at 37°C 
for 6hours 
 Discard the medium and add complete DMEM medium to increase the 
proliferative growth. 
 After 48hours post-transfection, the positive HEK293 cells were 
undergone to selection with Geneticin G418 [0.8 mg/ml] 
 The three transfected cell lines are maintained in selection, let expanding 
in T75 flasks and froze. 
 
 
1.5.3 Localization of NOD2 
The aim of this experiment is to localize in the transfected HEK293 cells the wild-
type and the two mutated NOD2 protein.  
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Preparing cultures 
Each transfected cell cultures were seeded in 6-well plates in duplicate and 
allowed to growth in ethanol flame-cleaned coverslips coated with poly-l-lysine 
solution (Sigma Aldrich). The working density of cells was around 70% 
confluence. Before proceeding with the immunofluorescence assay, it is necessary 
to fix and permeabilize the cells to ensure free access of the antibody to its 
antigen. Perfect fixation would immobilize the antigens, while retaining authentic 
cellular and subcellular architecture and permitting unhindered access of 
antibodies to all cells and subcellular compartments. Fixation with 
Methanol/Acetone would also permeabilize the cells, removing lipids and creating 
holes in membrane. 
 Discard the medium and wash each well three times with PBS 
 Add 2ml of Methanol/Acetone 1:1 and incubate at -20°C for 20min 
 Discard the fixative solution, cover and store at -20°C  
 
Immunostaining 
Each transfected and fixated cell cultures were undergone to indirect 
immunofluorescence, using a specific primary antibody against N-terminal FLAG 
sequence of exogenous NOD2. 
 Hydrate each well with PBS for 10min at room temperature 
 To avoid aspecific binding, each coverglass is treated with PBS+1%BSA 
for 1hour at room temperature 
 Wash twice with PBS for 5min each 
 Pour drop by drop 100µl of primary antibody ANTI-FLAG (Sigma 
Aldrich) at 1:300 in PBS+1%BSA and incubate O/N at 4°C in humid 
atmosphere. 
 Wash 3 times with PBS for 5min each at room temperature  
 Pour drop by drop 100µl of secondary antibody Cy3-conjugated Anti-
Rabbit (Listarfish) at 1:400 in PBS+1%BSA and incubate at room 
temperature for 1hour in the dark. 
 Wash 3 times with PBS for 5min each at room temperature  
 Mounting each coverslip in a ethanol flame-cleaned slide with mounting 
solution containg DAPI at 1:10,000. 
 Store the slides at 4°C in the dark 
 
Confocal Imaging 
Slides were inspected and photographed using first an optical fluorescence 
microscope (Leika 5000) and then a confocal fluorescent microscope (Radiance 
2000, BioRad) using multitracking (line switching) for two-colours imaging 
(40X). Image acquisition was performed with Laser Sharp Scanning software 
(Bio-Rad Laboratories). The fluorescence microscope was used to visualize 
fluorescent tagged proteins and blue-fluorescent nuclei, whereas confocal 
fluorescent microscopy was used to accentuate the 3D nature of the samples. 
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1.5.4 Proteins expression 
The aim of these experiments is to evaluate the expression of wild-type and 
mutated (p.R334W and p.E383K) NOD2 proteins after exposition to relevant 
pathogen-associated molecular patterns (PAMPs). Another goal is to investigate 
the NF-κB pathway activation through indirect evaluation of phosphorylation of 
NF-κB inhibitor, IKBα. 
 
Stimulation and lysis of cells 
A selection of PAMPs were used as stimuli to trigger the inflammatory response 
associated to NOD2. The pathogen-associated molecular patterns (PAMPs) are a 
diverse set of microbial molecules which share a number of different recognizable 
biochemical features that alert the organism to intruding pathogens [210]. In 
literature, NOD2 is described as a general detector of intracellular invasive 
bacterial infections, sensing small peptides such as muramyl dipeptide (MDP), a 
degradation product from both Gram-positive and Gram-negative bacterial 
peptidoglycan [64].  
 
 The three transfected HEK293 cell lines are seeded in duplicate at 105 
cell/ml in 6 well-plate and grown in complete DMEM medium. 
 One day before stimulation, the culture medium was replaced by 
starvation medium, i.e. serum free DMEM medium. The goal of starvation 
is to stop the cellular proliferation in order to synchronize cell cycle and 
reduce unwanted signalling effects.  
 
The experimental condition used was the same to test different hypotesis: 
 different concentrations of MDP, to test the sensitivity of the cells; 
 different concentrations of MDP, to observe the consequences of NF-κB 
signalling pathway. 
 
For the "sensitivity" experiment and also cytokines detection: 
 Add drop by drop different concentrations MDP [0ng/ml, 1µg/ml, 
10µg/ml, 50µg/ml, 100µg/ml] 
 Stimulate for 7hours or 24hours at 37°C  
 At the proper time, collect the surnatants, lyse the cells and store at -80°C  
 
For the NF- κB pathway activation experiment: 
 Stimulate with MDP [0ng/ml, 1µg/ml, 10µg/ml] and collect surnatants and 
lysated cells after 7 or 24hours 
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The lysis protocol followed these steps: 
 Wash the cells twice with ice-cold PBS 
 Add 200µl of Lysis Buffer, composed by 1X RIPA buffer an 1X 
Phosphatase and protease inhibitor (Thermo Scientific) and 5U/ml 
Benzonase (Sigma Aldrich). 
 Keep the plate on ice for 20min shaking frequently 
 Scrape each well and collect the lysates in pre-chilled tubes 
 Centrifuge at 16,000×g for 10min at 4°C  
 Store the surnatants at -80°C 
 
BCA assay 
To assess yields in whole cell lysates, the BCA assay (Thermo Scientific) 
measures the absorbance at 562nm of total protein compared to a protein standard. 
The method relies on the formation of a Cu2+-protein complex under alkaline 
conditions, followed by reduction of the Cu2+ to Cu1+. The amount of reduction is 
proportional to the protein present in the lysated samples. 
 
Protein detection (electrophoresis and Western blotting) 
Separation of proteins was achieved through an SDS-PAGE gel according to the 
Laemmli method [211], whereas detection of the proteins of interest was achieved 
by ECL Western blotting. This technique is a light emitting non-radioactive 
method performed by the oxidation of luminol by the HRP in the presence of 
phenols. 
 Prepare samples adding 1.3µg/µl of lysates in 20µl of 1X SDS loading 
buffer (SDS and 1X β-mercaptoethanol) 
 Add Blue Bromophenol powder and heatthe samples at 95°C for 5min  
 Place the gel into Western tank. The wells facing inwards with blank on 
other side if only running one gel. 
 Load 30µl into each well of the 4-20% precast Tris glycine gel (Novex, 
Life Technology)  
 Load 5µl in the first well of Spectra™ Multicolour Broad Range Protein 
Ladder (Thermo Scientist) to check the transfer from gel to membrane 
 Load 5µl in the last well of MagicMark™ XP Western Protein Standard 
(Life Technologies) specifically designed for ECL detection 
 Gels were run at 150V for 90min in 1X running buffer (Tris/Glycine/SDS 
buffer, BioRad) using a XCellSureLockTM Mini-Cell and Novex Power 
Ease 500 Power Supply (Life Technologies) 
After electrophoresis, proteins were transfected to nitrocellulose membrane by 
wet transfer and detected by Chemiluminescence with the specific primary and 
secondary HRP labelled antibodies listed in Tab. 3. 
 Soak blotting papers, sponges and nitrocellulose membrane in 1X transfer 
buffer (Tris/Glycine buffer, 20% Methanol)  
 Prepare the blotter as the follow diagram: 
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 Protein transfection took place under 125mA for 2hours 
 Block non-specific binding site soaking the membranes in 25ml of 
blocking buffer (5% non-fat dried milk, 0.1% v/v Tween20 in TBS) for 
1hour at room temperature on a shaker 
 Rinse the membranes 3 times for 5min each in 15ml TBS-Tween20  
 Incubate the membranes with 10ml primary antibodies diluted 1:1,000 in 
5%BSA/TBS/Tween20 O/N at 4°C with shaking.  
 Wash the membranes 3 times for 5min each in 15ml TBS-Tween20 
 Incubate the membranes with 10ml secondary Horseradish peroxidase 
conjugate antibodies (1:2,000) for 1hour at room temperature on shaking  
 Wash the membranes for 5min in 15ml TBS-Tween20 
 Incubate the membranes with 4ml Enhanced Chemiluminescence (ECL) 
Detection Reagent (GE healthcare) for 1min 
 In a film case, overlay the enveloped membranes with a sheet of Kodak 
film for different exposure time (5sec to 30min) 
 Soak the film in Developer solution (Sigma Aldrich), fix in Fixer solution 
(Sigma Aldrich), wash in water and dry 
 ImageJ software was used to measure the densities of the resulting bands. 
 
PRIMARY ANTIBODIES SECONDARY HRP CONJUGATED ANTIBODIES 
ANTI-NOD2 1:250 eBioscience Anti-rabbit  
HRP conjugated 1:2,000 Dako 
ANTI-IKBα 1:1,000 Cell Signaling Anti-mouse  
HRP conjugated 1:2,000 Dako 
ANTI-P 
IKBα 
1:1,000 Cell Signaling    
 
Tab. 3: List of primary and secondary antibodies used for Western Blotting.  
The ANTI-NOD2 was a mouse antibody, whereas ANTI-IKBα and ANTI-P IKBα were rabbit 
antibodies.  
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Following ECL detection, it is possible to complete remove the primary and 
secondary antibodies from the membranes to sequential reprobing of membrane 
several times.  
 Submerge the membrane in Stripping buffer (100mM β-Mercaptoethanol, 
2% SDS, 62.5mM Tris-HCl pH 6.7) and incubate at 50°C for30 min with 
occasional agitation. 
 Wash the membrane twice for 10min each in TBS-Tween20 at room 
temperature. 
 Block the membrane with Blocking buffer (5% non-fat dried milk in TBS-
Tween20) for 1 hour at room temperature. 
 Repeat the immuno detection protocol, adding primary and secondary 
antibody as above 
 
2 Microarray experiments 
2.1 Samples 
The microarray-based proteomic technologies described in this chapter have 
employed different kind of samples: lysated peripheral blood mononuclear cells 
(PBMCs) and sera from subjects affected by autoinflammatory diseases; lysates 
and surnatants from wild-type and mutated NOD2-transfected cells.  
Concerning the transfected cells, most of the samples were described in the 
previous section. In addition, the transfected HEK293 cells underwent to another 
lysis experiment. The NE-PER® Nuclear and Cytoplasmic Extraction Reagents 
(Pierce, Thermo Scientific) enabled stepwise separation and preparation of 
cytoplasmic and nuclear extracts from cultured cells. Nuclear extracts are 
generally preferred to whole cell lysates for gene regulation studies. 
After stimulation of wild-type and mutated (p.R334W and p.E383K) cells with 
MDP [10µg/ml] for 7hours, the cultures were trypsinized and cellular pellet was 
collected as dry as possible. Following the company protocol's steps, the addition 
of Cytoplasmic Extraction Reagents allows to obtain the cytoplasmic fraction in 
surnatants. Further processing of obtained pellet with ice-cold Nuclear Extractio 
Reagent concentrates the nuclear fraction in surnatant. Both extracts are then 
stored at -80°C. 
Besides the transfected cells, the other samples used for the microarray 
experiments were PBMCs and sera from 40 patients affected by different 
autoinflammatory diseases such as FMF, TRAPS, MVK, Blau syndrome, Still’s 
disease, Behçet disease, CAPS. All patients underwent genetic screening for 
mutations on the genes involved in periodic fevers, inflammasome-related 
diseases and Blau syndrome, using standardised techniques. In addition to the 
patients, 27 samples from healthy controls subjects were collected.  
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Tab. 4 summarizes all observed mutations and polymorphisms, therapy and other 
information useful to depict each patient.  
Single paired samples of blood were collected from patients and healthy controls 
on approval of the Hospital of Padova Ethics Committee for Clinical Research. 
Sera were obtained by centrifugation of blood samples in a single-clot tube at 
400×g for 10min. PBMCs were isolated by Ficoll-density gradient separation, as 
describe previously but then the cells were lysated and stored as in the follow 
protocol to be ready for microarray assays. 
 
 Centrifuge the PBMCs at 400×g for 10min at room temperature. 
 Pour off the supernatant and wash the pellet with PBS. Centrifuge cells at 
400×g for 10 minutes at room temperature. 
 Pour off the supernatant and add 100µl of lysis buffer (RIPA Buffer, 1X 
Protease Phosphatase Inhibitors 100X EDTA Free, 5U/ml Benzonase). 
 Incubate the tube in ice and vortex for 15sec every 5min, for a total of 
30min. 
 Centrifuge the tubes at 10,000×g for 10min at 4°C. 
 Aliquot 30µl of lysated in eppendorf tubes and add 10µl of 4XSDS 
solution (0.25% M TrisHCl ph 6.8, 30% Glycerol, 8% SDS and 10% β-
mercaptoethanol) 
 Boil at 95°C for 5min then spin the tubes. 
 Store the tubes at -80°C. 
 
 
 
 
  
Tab. 4: Database of 40 enrolled patients (A) and healthy controls (B) used for microarray experiments presented in this thesis. 
A. Classification of patients. Subjects from P1 to P29 refer to UOC Reumatologia-University of Padua, whereas subjects from P30 to P40 belong to the Research Centre 
of Autoimmune and autoinflammatory diseases-Siena 
N. SEX AGE DISEASE GENE MUTATIONS POLYMORPHISMS TREATMENTS 
P1 M 19/12/1969 Behçet  MVK / c.78+61 A>G, c.510C>T, c.632-18A>G, 
c.885+24G>A 
Cyclosporine 200mg/day, 
Colchicine 1g/day 
P2 M 22/07/1988 Still MVK S52N (hetero) 
 
Kineret 100mg/day 
P3 F 15/10/1974 Still MVK / c.371+8C>T, c.632-18A>G Colchicine 1g/day 
P4 F 27/04/1980 Still MVK / c.371+8C>T, c.632-18A>G Methotrexate 
P5 M 02/05/1942 TRAPS TNFRSF1A S59P (hetero) 
 
Methyprednisolone 4mg  
P6 F 04/01/1982 FMF MEFV E148Q (hetero) 
 
Colchicine until 2 years ago 
P7 F 25/04/1967 Behçet  MVK, 
TNFRSF1A / 
MVK: c78+61A>G, c632-18 A>G, c.885+24 G>A 
TNFRSF1A: c.473-33 C>T, c.625+10 A>G Colchicine 
P8 F 15/11/1980 Behçet  negative for MVK 
  
Kineret 
P9 F 29/04/1953 Blau NOD2 E383K (hetero) 
 
Humira 40mg for 14 days 
P10 F 30/03/1978 Blau NOD2 E383K (hetero) 
 
None 
P11 F 19/09/1964 FMF MEFV,MVK, 
TNFRSF1A 
MEFV: E148Q, 
M680I 
MVK: S52N 
MEFV: R314R, E474E, D510D, Q474Q    
MVK: D170D, c.632-18A>G, c.885+24G>A    
TNFRSF1A: c.473-33C>T, c.625+10C>T 
Colchicine 1mg/day 
P12 M 14/10/1974 FMF MEFV, 
TNFRSF1A MEFV: R202Q 
MEFV: G138G, A165A, E474E, D510D, Q474Q     
TNFRSF1A: c.473-33C>T Colchicine 
P13 M 04/04/1972 Still TNFRSF1A / c.625+10C>T None 
P14 M 01/11/1951 Still TNFRSF1A / c.625+10C>T prednisolone 2,5 mg/day 
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P15 F 01/06/1985 BEHÇET  MVK / D170D, C.632-18A>G, C.885+24G>A STEROIDS ON DEMAND 
P16 F 20/07/1993 FMF MEFV, MVK / MEFV: R314R  MVK: D170D, c.632-18A>G, c.885+24G>A None 
P17 F 01/07/1966 TRAPS 
MEFV, 
TNFRSF1A, 
MVK 
R92Q (hetero) 
MEFV: D102D, G138G, A165A 
TNFRSF1A: c.625+10A>G 
MVK: c.885+24G>A 
Infliximab 
P18 F 16/09/1975 Schnitzel No screening 
  
Kineret 
P19 F 13/08/1967 Still No screening 
  
Kineret 
P20 F 04/06/1968 Still No screening 
  
Kineret 
P21 F 31/05/1978 FMF MEFV, 
TNFRSF1A 
MEFV: E148Q, 
P369S(hetero) TNFRSF1A: c.625+10A>G Colchicine 
P22 M 10/04/1990 TRAPS MVK, 
TNFRSF1A / 
MEFV: R314R;  
TRAPS: c.625+10A>G, c.626-32G>T None 
P23 F 15/11/1980 Behçet negative for MVK 
  
Kineret 
P24 M 21/08/1985 TRAPS+ 
Behçet 
MEFV, 
TNFRSF1A, 
MVK 
/ 
MEFV: D102D, G138G,A165A, R202Q, R314R 
TNFRSF1A: c.625+10A>G 
MVK: c.885+24G>A 
Colchicine 1g/day 
P25 F 01/06/1985 Behçet MVK 
 
D170D, c.632-18A>G, c.885+24G>A Steroids on demand 
P26 M 02/05/1955 Behçet 
+FMF 
MVK, 
TNFRSF1A / 
MEFV: D102D, G138G,A165A, R202Q, R314R 
TNFRSF1A: c.625+10A>G Colchicine 
P27 F 25/04/1967 Behçet  MVK, TNFR1A / MVK: c78+61A>G, c632-18 A>G, c.885+24 G>A  
TNFRSF1A: c.473-33 C>T,c.625+10 A>G Colchicine 
P28 F 26/06/1987 Behçet  No screening 
  
None 
P29 F 16/01/1948 Still 
MEFV, 
TNFRSF1A, 
MVK 
/ 
MEFV: D102D,R314R,D723D 
TNFRSF1A: c.473-33C>T 
MVK: D170D, c.632-18A>G, c.885+24G>A 
Anti-IL1ra 
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P30 M 28/06/1998 MKD MVK V377I (HOMO) N.P. UNKNOWN 
P31 M 10/03/1976 FMF MEFV M694I (hetero) n.p. None 
P32 F 06/04/1976 TRAPS TNFRSF1A V95M (hetero) n.p. 
Canakinunab 
150mg/8weeks 
P33 M 31/07/1978 TRAPS TNFRSF1A delY103-R104 n.p. Etanercept 50mg/week 
P34 M 02/10/1974 NAPS12 NLRP12 G448A (hetero) n.p. None 
P35 M 07/12/1980 TRAPS TNFRSF1A T50M (hetero) 
 
None 
P36 F 31/07/1958 TRAPS TNFRSF1A R104Q (hetero) n.p. Anakinra 100mg/day 
P37 M 03/12/1971 TRAPS TNFRSF1A T50M (hetero) n.p. Anakinra 100mg/day 
P38 M 31/07/1978 TRAPS TNFRSF1A R92Q (hetero) n.p. None 
P39 F 01/01/1994 TRAPS TNFRSF1A D12E (hetero) n.p. Anakinra 100mg/day 
P40 F 17/08/1956 TRAPS TNFRSF1A R92Q (hetero) n.p. Anakinra 100mg/day 
 
B. Classification of healthy controls.  
N. SEX AGE N. SEX AGE N. SEX AGE N. SEX AGE 
1 F 25 8 F 47 15 F 39 H4 M 35 
2 F 41 9 F 55 16 M 41 H5 M 39 
3 F 30 10 F 32 17 F 33 H6 M 33 
4 F 32 11 M 24 18 F 29 H7 F 55 
5 M 30 12 F 53 H1 M 15 H8 M 42 
6 M 46 13 M 34 H2 M 37 H9 M 30 
7 F 46 14 F 32 H3 F 37    
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 2.2 Reverse Phase Protein Array
Reverse Phase Protein Array (RPPA) technique 
different signalling pathways
comparison to healthy contro
 
Fig. 17: Principles of RPPA microarray.
Lysated cells were prepared in 384
slide by a MicroGrid II robot. The slides were probed with Immunohistochemical staining and 
protein expressions were calculated using revers
were graphically presented as heatmaps, scatter plot or cluster density maps.
 
2.2.1 Protocol 
The cells lysates were loaded into a 384
diluted 3 times in 1X SDS buffer
described).  
Normalization of the protein
housekeeping protein. β-actin 
unaffected by the experimental conditions. Us
technique, it was possible to incubate antibody against 
species together with the target specific antibodies and detect these at a different 
wavelength. Using this approach, the normalizer signal and t
signal were generated from the same spot
antibodies were purchased from LICOR Bioscience.
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was optimized and used to study 
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-well plate (Genetix, UK) and serially 
 (4XSDS diluted in lysis buffer, previously 
 of interest was achieved through the detection of an 
is expected to be expressed at a constant level, 
ing the near-infrared 
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Samples were spotted onto nitrocellulose-coated glass slides (FASTSlides, 
Whatman, Schleicher&Schuell) with a microarrayer (MicroGridII, BioRobotics 
Inc.) using silicon pins. Before starting up printing the slides, the arrayer was set 
as following: 
 Replace the main wash station with clean distilled water.  
 Clean the silicon pin heating in the oxidizing flame and wash twice in the 
wash station  
 Edit the array pattern, the pitch between spots and the format 
 Adjust the target height at 0.5mm (distance the pin moves towards the 
slide) and the dwell time at 0.5sec (time the pin pauses on the slide). 
 Optimise the humidity of the arrayer to 60% to prevent samples 
evaporation from the plate and the pin 
 
Probing slides 
Make sure all reagents and chemicals up to room temperature 
 Place the printed slides in slide holders, ensuring each nitrocellulose pad 
fit in the holder. 
 Block the slides adding in each pad 200µl of I-Block buffer prepared 
dissolving 50mg I-block powder (Applied Biosystem) in 25ml of PBS-
0.01%Tween 20 
 Cover the slides to prevent evaporation and leave O/N at 4°C with 
constant rocking.  
 Prepare 200µl dilution of each antibody (see Antibodies list in Tab. 5) in 
antibody Diluent (Dako) with 1:1,000 mouse monoclonal anti-Actin 
antibody (Sigma Aldrich) 
 Discard the I-block buffer and wash 5 times for 3min each with 1X TBS-
0.01%Tween20 with constant rocking 
 Add each antibody dilution in the correct pad and cover with foil to avoid 
evaporation 
 Leave the slides O/N at 4°C with constant rocking 
 Prepare dilution of infrared secondary antibodies anti-rabbit and anti-
mouse 1:5,000 in 1X TBS-0.01%Tween20 
 Wash the slides 5 times for 3min each with 1X TBS-0.01%Tween20 with 
constant rocking 
 Add 200µl of the diluted secondary antibodies in each pad 
 Incubate for 30min at room temperature with constant rocking and foil 
cover 
 Wash the slides 5 times for 3min each with 1X TBS-0.01%Tween20 with 
constant rocking 
 Disassemble the slide holders and rinse the slides with ultra pure water 
 Dry the slides by centrifugation at 500×g for 5min 
 Scan the slides with an Near-Infrared Odyssey scanner (LI-COR, 
Biosciences) with high resolution (21µm) in both channels 700nm and 
 800nm, for detection of anti
respectively. 
 
Fig. 18: Near Infrared detection of signals. 
The arrayed slide was incubated with primary antibody followed by secondary antibodies l
with infrared dye against β-actin 
 
Analysis of microarray data 
The RPPA data analysis consists of calculating the concentration of each samples, 
after background correction and normalization, using signal intensities data gained 
from a image software. Axon
was the bioinformatics tool 
spots generating gpr files
statistical language that was developed b
read RPPA data and to perform the basic analysis on them. 
freely available as an R
project.org/).  
• After scanning the slides with LICOR Odyssey,
gray scale TIFF file
• Import in GenePix Pro software each scanned image and the gal file saved 
from the arrayer. This file gave s
size, and name of each spot on the slide 
• Combine together th
text files contain the localization,
on the array and a fluorescence intensity that represents the raw expression 
values.  
• Prepare two additional sources of in
holds all pheno-data of the individual samples, describing the 
corresponding position in the source well plate. The slide description file
containing the description of the array features and the information of the 
antibodies used, represents the feature data of the experiment and provides 
the key to link the corresponding GPR files. 
• Import data in R, open
method exchange [21
The first element contains a matrix of foreground signals (pixel intensities 
per spot) and the second element corresponds to local background. The 
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third and fourth elements contain the feature and phenotypic information 
respectively. 
• Correct the background using the subtract method.  
• Calculate the relative protein concentration by calculating the median of 
the replicate spots at the highest concentration if the sample dilution series 
showed linear correlation with the total protein concentration [214].  
• Normalize the data to correct differences of total protein concentration on 
the spot which resulted from preparation and spotting of the samples. The 
level of each antibody signal was adjusted to the housekeeping protein 
signal (β-actin) from the same spot. That means every individual spot had 
its own normaliser signal, providing the most accurate data. 
 
The data, exported in excel files, could be visualized and undergone to other 
statistical analysis. Their significance was tested using non-parametric analysis 
and graphed with GraphPad Prisms5 software. P value was considered significant 
if it is less than 0.05. Column and scatter graphs were used to visualize the 
distribution of the data points in order to assess differential expression of proteins 
in comparison to a control group. Heatmaps were another tool to visualize the 
protein expression and show structures of the data with the use of a hierarchical 
clustering. To obtain heatmaps, the normalized data need extra manipulations, 
such as be transformed in log2 and adjusted for technical variability inside an 
array using the dye effect correction. To create and analyse heatmaps, in this 
thesis I used both MeV software and J-Express Pro software. MeV software is a 
tool for data analysis that provides an intuitive graphical interface for clustering, 
classification and statistical tests. J-Express Pro is the best choice for clustering 
analysis, in particular supervised cluster analysis and self-organizing maps.  
 
2.2.2 Antibodies 
Testing primary antibodies:  
In reverse phase protein arrays, the primary antibodies used for the detection of 
specific antigen in the printed lysates should be tested before use, to ensure that 
each antibody provides a defined single specific signal band. In this study the 
primary antibodies were tested by Western Blot technique.  
 Mix together lysates of different cell lines under different treatment 
conditions  
 Prepare loading samples adding mixing lysates in 1X SDS loading buffer 
(SDS and 1X β-mercaptoethanol) at 1:4 dilution 
 Add Blue Bromophenol powder and heatthe loading samples at 95°C for 
5min  
 Load 200µl into in the single well of a precast 12% Tris Glycine Gel 
(Novex, Life Technologies) 
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 Run to separate the proteins and transfer to a nitrocellulose membrane as 
describe previously (1.5.3) 
 Block non-specific binding site soaking the membranes in 25ml of 
blocking buffer (5% non-fat dried milk, 0.1% v/v Tween20 in TBS) for 
1hour at room temperature on a shaker 
 Rinse the membranes 3 times for 5min each in 15ml TBS-Tween20  
 Insert the membrane in a blotter (Miniblotter, Immunetics) 
 Add 200µl primary antibodies in each separate strip chambers created by 
the blotter. 
 Dilute the primary antibodies 1:1,000 in 5%BSA/TBS/Tween20 O/N at 
4°C with shaking.  
 Wash the membranes 3 times for 5min each in 15ml TBS-Tween20 
 Detection of the bands by Chemiluminescence (ECL) technique as 
described before.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab. 5: List of Primary and Secondary Antibodies used in RPPA experiments.  
(*) All the listed Primary antibodies were produced in Rabbit except IL1β produced in Mouse. The 
Primary antibodies were purchased from Cell Signaling Technology® (next page). 
 
  
MAPK PATHWAY NF-ΚB PATHWAY PI3/AKT PATHWAY 
Antibody  Dilution Antibody Dilution Antibody  Dilution 
p MKK3/MKK6 (Ser189/Ser207) 1;100 NF-κB 1:250 p eNOS (Ser1177) 1;500 
p P38 MAPK (Thr180/Tyr182) 1;1,000 p NF-κB p65 (Ser536) 1:100 p BAD (Ser136) 1;500 
p SAPK/JNK (Thr183/Tyr185) 1;1,000 IKBα 1:100 p AKT (Thr308) 1;50 
TRAF2 1;500 p IKBα (Ser32) 1:500 p AKT (Ser473) 1;25 
TRAF6 1;500 IKKα 1:250 PI3K p100α 1;250 
p HSP27 (Ser82) 1;50 IKKβ 1:250 PI3K p85 1;250 
p c-JUN (Ser63) 1;200 p IKKα/β (Ser176/Ser177) 1:250 p PDK1 (Ser259) 1;1,000 
p ERK1/2 (Thr202/Tyr204) 1;2,000 IKKγ 1:250 p GSK 3β (Ser9) 1;500 
MEK1/2 1;250 p IRAK1 (Thr209) 1:3,000 p c-RAF (Ser259) 1;1,000 
p MEK1/2 (Ser217/Ser221) 1:250 A20/TNFAIP3 1:150 p PTEN (Ser380) 1;1,000 
p SEK1/MKK4 (Ser257/Thr261) 1;250 
  
MKK7 1;100 INFLAMMASOME PATHWAY and MyD88 
p TAK1 (Ser412) 1;100 Antibody Dilution 
p ATF2 (Thr71) 1:250 IL1β (*) 1;100 HOUSEKEEPING ANTIBODIES 
 
p STAT1 1;250 Antibody  Dilution 
p STAT4 1;100 Actin (Mouse) 1:1,000 
SRC/JAK/STAT3 PATHWAY ASC (TMS1) 1:150 Actin (Rabbit) 1:1,000 
Antibody  Dilution CASPASE1 1;250 
 p STAT3 (Tyr705) 1;100 CLEAVED CASPASE1 1;50 
p c-SRC (Tyr416)  1;10,000 NALP1 1;150 
SOCS3  1;500 BCL-XL 1;250 SECONDARY IRD ANTIBODIES 
SHIP2  1;2,000 BCL-2 1;250 Antibody  Dilution 
p RIP2 (Ser176) 1;500 p BCL-2 1;100 Infrared Mouse IgG 1:5,, 
p JAK2 (Tyr1007) 1;1,000 MyD88 1:50 Infrared Rabbit IgG 1:5,000 
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 2.3 Antibody Array
The antibody microarray is an array
serum proteins levels from transfected cells surnatants and sera from both
autoinflammatory diseases patients and healthy controls.
This technique is summarized in 
 
Fig. 19: Principles of antibody microarray.
Capture antibodies dilutions were prepared in 384
slide by a MicroGrid II robot. A cocktail of recombinant protein standards are added to the slides, 
along with serum, to enable quantification. A cocktail of biotinylated detection antibodies are 
added to each block followed by amplification using Bio
Streptavidin-conjugated cy5 is finally added and read serum levels of cytokines ar
data were graphically presented as column or time course plots
 
2.3.1 Protocol 
The following protocol varies related to the samples that have to be tested. Serum 
needs amplification of the microarray signals enhancing the signal detection, 
whereas it is not necessary for surnatants. There are different methods of 
amplification that can be used. we 
fluorescent dyes (Ultra Amp™, Genisphere) or a common used Tyramide 
amplification (Bio-Rad Amplification Reagent)
non specific background especially due to sampl
of biotin-binding protein , 
before detection with Streptavidin Secondary Antibodies.
 
72 
 
-based system to measure cytokines and other 
 
Fig. 19. 
 
-well plates and spotted on the poly
-Rad Amplification Reagent. 
e calculated. The 
- 
have tested either a kit based on dendrimers an 
, presented in Fig. 20. To avoid 
es containing abundant quantities 
Avidin/Biotin blocking kit (Invitrogen) was tested 
 
 
 
-l-lysine 
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Printing step 
Be sure that Capture Antibodies and Printing Buffer were at room temperature 
 Add 100µg/ml of each Capture antibody in 384well plate, diluting them in 
Printing Buffer (50mM Trehalose, 1X PBS, 0.01% Tween-20) as shown in 
Tab. 6 
 Spot Capture antibodies onto poly-l-lysine coated glass slides (Sigma 
Aldrich) with a microarrayer (MicroGrid II, BioRobotics Inc.) using 
silicon pins.  
 Before starting up printing the slides, set up the arrayer as previous 
described for RPPA. 
 
Probing slides 
Make sure all reagents and chemicals up to room temperature 
 
The following protocol is for sera samples. It described Avidin/Biotin block 
(within square brackets) and Ultra Amp™ amplification (within curly brackets): 
 Block the slides with I-Block (dissolving 50mg I-block powder in 25ml of 
PBS-0.01%Tween 20) adding 100µl into each pad and incubate on the 
shaker at room temperature for 1hour. 
 Prepare the Standard Antibodies Master Mix, mixing all the cytokines to 
be tested at top concentration of 1,000pg/ml each in 400µl of Reagent 
Diluent  
 Prepare a serial dilution from the Master Mix in Reagent Diluent as: 
1,000pg/ml, 500pg/ml, 250pg/ml, 125pg/ml, 62.5pg/ml, 31.3pg/ml, 
15.5pg/ml, 7.8pg/ml and 0pg/ml (Blank) 
 Wash the slide 3 times with PBS-0.01%Tween20 for 3min each with 
constant rocking 
 Add 100µl of Standard Antibodies dilution and sera one in each pad and 
incubate 1hour with constant rocking 
 Wash the slides 3 times with PBS-0.01%Tween20 for 3min each with 
constant rocking 
 Apply 2 drops of Avidin in each pad and incubate for 10min at room 
temperature 
 Wash 6 times for 1min each with PBS-0.01%Tween20 
 Apply 2 drops of Biotin in each pad and incubate for 10min at room 
temperature 
 Wash 6 times for 1min each with PBS-0.01%Tween20 
 Prepare the Detection Antibodies, mixing all the detection Antibodies in 
Reagent diluent as shown in Tab. 6 
 Add 100µl of Detection Antibodies Mix to each pad and incubate 1hour 
with constant rocking 
 
 
  Prepare a Ultra Amp™ stock solution at 1:1
addicted with DNA Blo
 Wash the slides 3 times with PBS
constant rocking 
 Add 100µl of Ultra Amp™ solution and incubate at the dark for 15
with constant rocking
 Rinse the slides with ultra pure water
 Spin for 5min at 1,200×
 Scan at 635nm with 
 
The Tyramide amplification
catalysed deposition of reactive biotinylated tyramine a
[95]. The kit used in this thesis was from BioRad
 After the detection step with Detection Antibodies mix (as reported in the 
protocol above), wash the slides 3 times with PBS
3min each with constant rocking
 Add 100µl of Streptavidin Biorad HRP at 1:1,000 for 15
rocking 
 Wash the slides 3 times with PBS
 Add 100µl of BioRaD AMPLIFICATION UNIT mix (Reagent2X, 
Reagent4X and ultra pure water at the ratio 4:1:4)
 Wash the slides 3 times with 20%DMSO/PBS
 Wash the slides 3 times with PBS
 Add 100µl of Streptavidin Cy5 prepare
 Incubate for 15min with constant rocking in the dark
 Rinse the slides with ultra pure water
 Spin for 5min at 1,200×
 Scan at 635nm with Axon 
 
Fig. 20: Tyramide amplification and Genisphere Ultra Amp amplification.
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,000 in BSA1X in PBS 
ck  
-0.01%Tween20 for 3min each with 
 
 
g at room temperature 
Axon 4200AL scanner 
 is based on the horseradish pexoridase (HRP) 
t site of immunoreactivity 
. 
-0.01%Tween20 for 
 
min with constant 
-0.01%Tween20 
 
-0.01%Tween20 
-0.01%Tween20 
d as 1:1,000 in 3%BSA  
 
 
g at room temperature 
4200AL scanner 
 
min 
 
For surnatants samples, the protocol was similar to the previous one without 
amplification steps. T
Fluorescent Conjugated 
 Block the slides with I
the shaker at r
 Prepare the Standard Antibodies
concentration 
 Do not dilute the surnatants 
 Wash the slide 3 times with PBS
shaker. 
 Add 100µl of Standard Antibodies and samples dilutions
them on the shaker 1h
 Wash the slide 3 times with PBS
 Dilute the Detection Antibodies in Reagent Diluent and add 100
pad 
 Incubate the slides on the shaker 1h
 Wash the slides 3 times
 Add 100µl of Streptavidin Cy5 to each pad 
BSA. 
 Incubate for 15
 Rinse the slides with ultra pure water
 Spin for 5min
 Scan at 635nm with 
 
Fig. 21: Cy5 fluorescence detection at 635nm.
 
Analysis of data 
The antibody microarray data analysis consists of calculate the concentration of 
each cytokine for all the samples using a standard curve and the intensity's data 
gained from the image software. 
software was the bioinformat
of the spots generating
were evaluated using GraphPad Prism 5 (GraphPad, San Diego, USA). The 
standard data plots a linear regression line through 
samples interpolates on that regression line and measure their concentration.
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he detection was achieved trough Standard Streptavidin 
Antibodies. 
-Block adding 100µl to each pad and incubate on 
oom temperature for 1hour 
 as a mix containing the 
(1,000pg/ml) and serial dilute it in Reagent Diluent
 
-0.01%Tween20 for 3min each on the 
our. 
-0.01%Tween20 
our 
 with PBS-0.01%Tween20 
prepared as 1:1,000 in 3% 
min on the shaker in the dark 
 
 at 1,200×g at room temperature 
Axon 4200AL scanner 
 
 
Axon GenePix Pro-6 Microarray
ics tool used to determine the raw signal intensities 
 gpr files. Means and Standard Deviation of the samples 
at least 6 points whereas the 
 
the 
Cy5 
cytokines at top 
.  
 and incubate 
µl to each 
 Image Analysis 
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 After scanning with Axon 4200AL, save the image as a 16-bit gray scale 
TIFF file 
 Import in GenePix Pro software each scanned image and the gal file saved 
from the arrayer. This file constructs an array of blocks to match the size 
and positioning of printed features gaving specific information about the 
location, size, and name of each citokine printed on the slide  
 Combine together those files to obtain the gpr files. These tab delimited 
text files contain the localization and an identification variable of the 
samples on the array and a fluorescence intensity that represents the raw 
expression values.  
 Create an excel file reporting the median of the raw expression values 
without the background signal for each samples and the standards 
 Calculate the average and the standard deviation for each cytokines 
 Import the average and standard deviation data from standards in 
GraphPad Prism 5.0 software 
 Plot a linear regression to obtain a standard curve for each cytokine 
 Imported the samples average and standard deviation data and interpolate 
the intensity values on the appropriate standard curve. 
 
The data could be visualized and undergone to other statistical analysis. Their 
significance was tested using non-parametric tests and graphed with GraphPad 
Prisms5 software. Column and scatter graphs were used to visualize the 
distribution of the data points in order to assess differential level of cytokines in 
comparison to a control group. 
 
2.3.2 Antibodies 
In antibody microarray, the set of antibodies used for capture and detect each 
specific analyte was purchased from the DuoSet ELISA kit (R&D). Each kit 
contains the basic components required for the development of sandwich ELISAs 
to measure a specific cytokine: capture antibody, biotinylated detection antibody 
and a protein standard. 
In the following Tab. 6, all the antibodies used in these assays are listed, 
correlated with the working concentrations. 
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A 
CYTOKINE CAPTURE  ANTIBODY 
DETECTION  
ANTIBODY 
PROTEIN  
STANDARD  
IL1β Ci 720 µg/ml Cf 100 µg/ml 
Ci 36 µg/ml 
Cf 200ng/ml 
Ci 90 ng/ml 
Cf 1,000pg/ml 
IL6 Ci 350 µg/ml Cf 100 µg/ml 
Ci 9 µg/ml 
Cf 50ng/ml 
Ci 120 ng/ml 
Cf 1,000 pg/ml 
IL8 Ci 720 µg/ml Cf 100 µg/ml 
Ci 3.6 µg/ml 
Cf 20ng/ml 
Ci 100 ng/ml 
Cf 1,000 pg/ml 
TNFα Ci 720 µg/ml Cf 100 µg/ml 
Ci 90 µg/ml 
Cf 500ng/ml 
Ci 370 ng/ml 
Cf 1,000 pg/ml 
IFNγ Ci 720 µg/ml Cf 100 µg/ml 
Ci 9 µg/ml 
Cf 50ng/ml 
Ci 55ng/ml 
Cf 1,000 pg/ml 
IL17 Ci 720 µg/ml Cf 100 µg/ml 
Ci 27 µg/ml 
Cf 150ng/ml 
Ci 25ng/ml 
Cf 1,000 pg/ml 
IL12 Ci 720 µg/ml Cf 100 µg/ml 
Ci 18 µg/ml 
Cf 100ng/ml 
Ci 210 ng/ml 
Cf 1,000 pg/ml 
IL22 Ci 360 µg/ml Cf 100 µg/ml 
Ci 45 µg/ml 
Cf 250ng/ml 
Ci 340 ng/ml 
Cf 1,000 pg/ml 
IL23 Ci 1,080 µg/ml Cf 100 µg/ml 
Ci 72 µg/ml 
Cf 400ng/ml 
Ci 530 ng/ml 
Cf 1,000 pg/ml 
 
B 
ANTIBODY DILUTION COMPANY 
Streptavidin Cy5 1:1,000 Life Technology 
Streptavidin HRP 1:1,000 BioRad 
 
Tab. 6: List of antibodies for microarray assay. 
A) List of antibodies and concentrations used in Antibody Microarray assays. All of them were 
purchased from R&D. Ci stands for initial concentration, whereas Cf for final concentration. 
B) Streptavidin antibodies used for amplification or biotinylated complex detection. 
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RESULTS 
1 Genetic and functional studies on Blau syndrome 
1.1 Mutation screening of CARD15/NOD2 gene 
The caspase recruitment domain gene CARD15/NOD2 has been mapped in the 
chromosomal region 16q12.1–13 [42]. The identification of CARD15/NOD2 as 
the gene responsible for Blau syndrome was the major breakthrough for BS 
research [215]. Up to date, 11 Blau-associated genetic mutations have been 
identified within this gene, almost in heterozygous state. Two of these mutations 
(p.R334Q and p.R334W) account for more than 50% of the mutated alleles [216], 
making codon 334 a genetic hot spot for mutations (Fig. 21). The genetic 
sequence of CARD15/NOD2, composed of 11 exons, was also divided into 
fragments in order to easily amplified and analyze the gene. The exon 4 was for 
example split into 5 amplicons, due to its length. Since all the mutations known to 
be correlated with BS are located in exon 4, only this sequence underwent to the 
genetic screening. 
In 2005, van Duist and colleagues have found a new mutation p.E383K in the 
only Italian family affected by BS [56]. We have repeated the screening for BS 
mutations in this family, including the new members using denaturing high-
performance liquid chromatography (DHPLC) and subsequent direct DNA 
sequencing. 
 
EXON 4 MUTATION: c.1147 G>A → p.E383K 
DHPLC analysis and sequencing showed only a nucleotide variation in all the 
affected subjects (Fig. 22A and B). The mutation detected was the already found 
c.1147G>A leading to a missense variation Glu383Lys in exon 4. All other family 
members screened for such mutations resulted negative for CARD15/NOD2 
mutations. Sequence alignment of the involved 4th exon fragment of 
CARD15/NOD2 with corresponding sequences of different mammals shows that 
p.E383K mutation occurred in a conserved sequence. 
 
 
 A 
B 
C 
D 
Fig. 22: c.1147 G>A → p.E383K. 
A) DHPLC elution profiles of CARD15/NOD2
the patient (in violet), compared with the single peak 
elution profile was due to a heterozygous substitution (c.1147G>A), as shown by DNA 
sequencing (B). C) The aminoacid involved in this mutation (Glu383) is known to be a residue 
conserved among different species.
information about this variation (
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 exon 4 amplicon: two peaks were observed for 
of the control (in green).This
 D) From Infevers database, the genetic and clinical 
http://fmf.igh.cnrs.fr/ISSAID/infevers/index.php). 
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1.2 Functional analysis of mutant p.E383K NOD2 protein
To evaluate pathogenic potentials of the 
full-length wild-type 
vector to obtain a fusion protein with FLAG. 
carrying p.R334W mutation as a 
the most frequent and deeply studied
proteins carrying p.E383K
wild-type construct. 
paste technique between the 
sequence (Fig. 23B). 
 
              A 
 
             B 
Fig. 23: NOD2 expressions vectors. 
A) Electrophoresis test in agarose gel 1% (w/v) of the p.E383K mutated pCMVTag2c
wild-type plasmid. The direct sequencing has confirmed the presence of the inserted mutation 
(starred nucleotide). B) Electrophoresis separation in agarose gel 1% (w/v) of 
plasmids, pCMVTag2c-
subsequent ligation reaction are the highlighted bands related to pCMVTag2c linearized
(4.3 kb) and p.R334W NOD2 cDNA (
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NOD2 missense mutation p.
cDNA was directionally cloned in eukaryotic expression 
Furthermore, we used
positive control, since this variation is 
 in Blau syndrome (Fig. 23A).
 were obtained by site directed mutagenesis of the 
p.R334W mutated proteins derived instead fr
wild-type construct and the mutated coding 
 
 
NOD2 wild-type and pcDNA3-R334W NOD2.Important for the 
3.2 kb). 
Results 
 
E383K, 
 NOD2 
one of 
 Mutated 
om cut and 
-NOD2 
the digested 
 vector 
 The starting point for create th
conditions and ligation reaction. Concerning the mutagenesis, two primers 
(forward and reverse) and a range of 
for obtaining p.E383K mutation in NOD2. Base on the 
use of primer forward and annealing temperature of 62°C gave the highest yield 
of mutagenesis. Concerning the ligation reaction between p.R334W mutated 
NOD2 and expression vector pCMVTag2c, different condition
increase the efficiency of the reaction. Setting
ration 3:1 gave in this case the major yield and number of positive clones.
 
1.2.1 Localization 
Constructs were transfected
extensively used as an expression tool for recombinant proteins since it was 
generated over 25 years ago. Although of epithelial origin, its biochemical 
machinery is capable of carrying out most of the post
processing required to generate
of both mammalian and non
On these transfected cells, indirectly 
display the cellular localization of human 
the appropriate antibodies (anti
conjugated with rhodamine).
Indirect immunofluorescence
pronounced cytoplasmic localization of the 
addition to the protein signal, it is possible to discriminate the nuclei detected in 
blue with DAPI. Protein carrying mutations p.E383K and p.R334W were 
predominantly localized in the cytoplasm, although a lower amount of rhodamine 
signal was detectable in the membra
C). These results are comparable to the one referred to 
suggesting that there is no evidence of altered localization of NOD2 in relation 
with the different carried mutat
Moreover, immunostaining results showed a reduced fluorescence signal between 
wild-type and mutated NOD2, suggesting a lower expression of mutated proteins 
in transfected cells. 
Fig. 24: Transfection studies in HEK293 
Wild-type NOD2 is localised at the cytoplasm 
detected in the cytoplasm (B and C).
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ese plasmids is the optimization of mutagenesis 
annealing temperature were tested separately 
results of those tests, the 
s were tested to 
-up a ligation reaction with molar 
 in the human embryonic kidney cell lines HEK293, 
-translational folding and 
 functional, mature protein from a wide spectrum 
-mammalian nucleic acids [209].  
immunofluorescence assay was performed to 
wild-type and mutant NOD2
-FLAG primary and anti-mouse 
 
 analysis in transfected HEK293 cells revealed 
wild-type fusion protein (Fig. 24A
ne of p.R334W mutated cells (Fig. 24B and 
wild-type
ions.  
cells.  
(A),as well as p.E383K and p.R334W
 
 
, choosing 
secondary 
). In 
 protein, 
 
 mainly 
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1.2.2 NOD2 expression 
In order to detect the expression of the exogenous protein NOD2, both wild-type 
and mutated, Western blotting analysis was performed in the lysates obtained 
from in the transfected HEK293 cells.  
 
First of all, the expression of NOD2 in HEK293 cells has been compared with the 
expression of the wild-type exogenous NOD2 in transfected HEK293 cells, to 
assess the influence of endogenous protein in further experiments. 
Following the protocol previously explained in Materials and Methods, the 
HEK293 cell lines both transfected and untransfected were lysated and proceeded 
to be ready for Western blotting.  
As shown in Fig. 25A, the contribution of endogenous NOD2 protein can be 
considered negligible compared to the expression of exogenous wild-type protein 
in absence of stimulation.  
We also made this endogenous/exogenous protein comparison after stimulation 
with bacterial wall components, like the peptidoglycan muramyl dipeptide 
(MDP).  
In the absence of the receptor for LPS, we did not evaluate this TLR agonist in 
vitro, but only ex vivo in PBMC from patients. Fig. 25A showed also that MDP 
did not enhance the endogenous NOD2 expression, whose level seemed to be 
several times lower than exogenous wild-type NOD2. 
 
Furthermore, different concentrations of MDP were tested in wild-type NOD2 
transfected HEK293 cells, to assess the sensitivity of these cells and to choose the 
better stimulus concentration. MDP at 0µg/ml, 1µg/ml and 10µg/ml stimulated 
the wild-type NOD2 transfected cells for 7 and 24 hours, as described previously. 
Western blotting results were presented in fig. 25B. After 7 hous, unstimulated 
cells seemed to express more wild-type protein, compared to the 1µg/ml MDP 
stimulated cells. The expression level at 10µg/ml MDP stimulation are 
definitively higher than at 1µg/ml but slightly lower than at 0µg/ml stimulation. 
The same trend was observed for the 24hours stimulation.  
Higher concentrations of MDP [50µg/ml and 100µg/ml] were tested as well, but 
the cell cultures died before the 7 hours have passed. This result showed that 
concentrations above the 10µg/ml were not compatible with regular cellular 
growth. Then, 10µg/ml was the concentration choosed for the experiments 
performed with NOD2 transfected HEK293 cells. 
 
From the analysis of the wild-type NOD2 expression, the following step was to 
evaluate the expression of the two mutant forms p.E383K and p.R334W in 
transfected HEK293 cells. As presented in the materials and methods, these cells 
were cultured for 7 and 24 hours in the presence or absence of stimulation MDP 
and then lysed for western blotting. 
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As shown in Fig. 25C, the signal related to the expression of p.E383K NOD2 after 
24 hours did not seem to vary with or without stimulation. This result was 
comparable for the control mutation p.R334W. In figure 25C the results after 7 
hours were not shown as they presented an identical trend to the one reported for 
24 hours, although with lower levels of expression. 
Moreover, comparing the expression levels of wild-type and mutated NOD2, we 
could not spot any differences in the expression trend shown pre/after stimulation. 
 
 
Fig. 25: NOD2 expression.  
A) Comparison of endogenous NOD2 (upper lane) and exogenous wild-type NOD2 (bottom lane) 
with or without MDP stimulation [10µg/ml]. B) Different MDP concentrations [0-1µg/ml-
10µg/ml] after 7 and 24 hours stimulation of wild-type NOD2 transfected cells. C) Mutated NOD2 
(p.E383K and p.R334W) expression in presence or absence of 10µg/ml MDP stimulation after 
24hours.  
 
1.3 Pathway NF-κB studied from patients PBMC and NOD2 
transfected HEK293 cell lines 
In order to carry on the evaluation of the pathogenic potential of p.E383K 
mutation in Blau syndrome, we examined both in vitro and ex vivo the ability of 
this mutation to activate the signalling pathway NF-κB known to be associated 
with this autoinflammatory disease. Foregoing in vitro studies have reported that 
Results 
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HEK293 cells transfected with a NOD2 construct engineered to contain a Blau 
syndrome mutation demonstrated elevated basal activity of an NF-κB reporter 
compared with cells transfected with a wild-type NOD2 construct and higher 
amounts of NF-κB reporter activation in response to muramyldipeptide [217,218]. 
From these in vitro observations, a “gain of function” hypothesis has been 
proposed for BS mutations, which predicts that patients with Blau syndrome 
would spontaneously release more cytokines that can be transcriptionally up-
regulated by NF-κB activity (such as IL1β). 
The follow study may help to have a complete view in the NF-κB pathway 
involved in Blau syndrome. 
 
1.3.1 IN VITRO analysis 
 
The starting point for the in vitro studies were HEK293 cells stably transfected 
with constructs engineered to contain the CARD15/NOD2 gene in the wild-type 
and mutated forms p.E383K and p.R334W. These cells were cultured in the 
presence or absence of stimulation mediated by MDP and lysated after 7 and 24 
hours, as described in materials and methods. NF-κB activity has been evaluated 
in vitro through two different technique: Western blotting and Reverse Phase 
Protein Array (RPPA).  
 
Western blotting 
The Western blot technique is an immunochemical technique that allows to 
identify the presence of a particular protein in a mixture of proteins separated 
though electrophoresis, by means of the recognition by specific antibodies. 
Although the technique is not strictly quantitative , it is possible to evaluate the 
protein expression relative to a constitutively active protein (e.g. β-actin). By 
measuring the density of the protein band of interest and normalizing to β-actin, 
we obtained values of relative density that allowed to a more closely evaluation of 
the bands observed in the blot membrane. 
With this technique, we studied indirectly the activity of NF-κB in vitro in 
HEK293 cells expressing wild-type and mutated NOD2. Remembering that NF-
κB is activated by phosphorylation and degradation of IKBα induced by NOD2 
and translocates to the nucleus where it promotes the transcription of 
proinflammatory genes, we evaluated the expression of IKBα and its 
phosphorylated form. Therefore, if IKBα would be mostly present in the 
phosphorylated form, this may mean an activation of NF-κB and subsequent 
cascade activation of the inflammatory response mediated by the pathway.  
Starting materials were the whole lysates of HEK293 cells transfected with wild-
type and p.E383K mutated NOD2, obtained after stimulation for 7 and 24 hours 
with MDP [10µg/ml]. 
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In Fig. 26 was presented the blotting results at 7 (upper) and 24 (middle) hours 
and relative profile plot with relative density data (bottom). 
Observing the graph on the left, under unstimulation condition in the wild-type 
NOD2 transfected cell the expression of IKBα were higher than the 
phosphorylated protein, whereas MDP stimulation seemed to provoke a slightly 
increase of phospho IKBα, as expected from literature data. The graph on the right 
concerning p.E383K NOD2 showed a similar trend in the two protein expression 
in presence or absence of stimulation. IKBα were higher expressed than the 
phosphorylated protein, implying a failure to activate NF-κB pathway. 
 
 
Fig. 26: Western blot analysis of IKBα and phospho IKB α expression in HEK293 cells presenting 
wild-type and p.E383K mutated NOD2.  
Equal loading was confirmed by stripping the immunoblot and reprobing it for β-actin. The graphs 
under the western blotting images represent relative density of the bands (IKBα in violet and 
phospho IKBα in green) normalized to β-actin and are referred to 24h stimulation data. 7h 
stimulation data were not plotted since the trend is similar to the one at 24h. 
 
  
Reverse Phase Protein Array (RPPA) 
To confirm and deeply investigate the results obtained from Western blot, we 
performed a protein microarray, a 
samples wasting than Western Blot.
The whole lysates of HEK293 cells transfected with 
mutated NOD2, obtained after stimulation for 7hours were used for a first analysis 
of NF- κB pathway activation.
Reverse phase protein array technique was applied to measure the level of several 
component of the NF
phosphorylation forms.
proteins was normalized to actin as a house keeping protein.
IKBα and phospho IKB 
In absence of stimulation, 
the two proteins levels
10µg/ml of MDP, in the 
phospho IKBα compared to IKB
one (p<0.05). The mutated NOD2, instead, 
levels, that were comparable to the unstimulated ones. 
 
Fig. 27: Comparison between 
type NOD2 and B) p.E383K
*p<0.05, as statistical significant 
 
IKKα and IKKβ levels
In wild-type NOD2 cells, 
were showed after stimulation with 10
absence of stimulation, we could see a slightly higher level of IKK
wild-type cells compared to p.E383K NOD2
statistically significant. In presence of MDP stimulation, these comparison was 
definitively slight but statisti
In p.E383K mutated NOD2 cells, no differences between stimulated and 
unstimulated levels of
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high-throughput assay more sensitive and less 
 
wild-type
 
-κB signalling pathway, such as IKBα, IKK
 In these experiments the expression level of the analysed 
 
α levels was presented in Fig. 27. 
wild-type NOD2 cells did not show any difference in 
, as seen for p.E383K NOD2 cells. After stim
wild-type NOD2 cells there were a significant increase of 
α level and also compared to the unstimulated 
did not show any increase in proteins 
 
IKBα and phospho IKBα in whole lysates obtained from A) 
 NOD2 transfected HEK293 cells  
level. 
 was presented in Fig. 28. 
slight but consistently higher level of IKK
µg/ml of MDP (p<0.05).
α
 cells, even if the increase was not 
cally consistent (p<0.05).  
 both IKKα and IKKβ were shown.  
Results 
 and p.E383K 
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Fig. 28: Comparison between IKKα and IKKβ levels in whole lysates obtained from A) wild-type 
NOD2 and B) p.E383K NOD2 transfected HEK293 cells.  
Ns indicates absence of stimulation, whereas MDP stands for stimulation with [10µg/ml] of 
muramyl dipeptide. *p<0.05 as statistical significant level  
 
Activation of the NF-κB transcription factor in HEK293 transfected cells with 
mutant NOD2 (p.E383K and p.R334W) was investigated and compared to that 
with the wild-type transfectant. Nuclear extracts are generally preferred to whole 
cell lysates for this protein regulation studies, since NF-κB is known to move to 
the nucleus to control transcription of pro-inflammatory genes. 
To study NF-κB behaviour, transfected HEK293 cells were stimulated with MDP 
[10µg/ml] for 7hours and then nuclear cytoplasmic separation was performed 
using the NE-PER® Nuclear and Cytoplasmic Extraction Reagents (Pierce, 
Thermo Fisher Scientific) as described in the methods. 
The expression of NF-κB p65 and the phosphorylated form was determined 
together with other NF-κB pathway components, such as IKBα, IKKα/β, and their 
phosphorylated form in the nuclear fractions of wild-type and mutated cells. Even 
for this analysis, technique of choice was lysate microarray (RPPA) and all the 
results were normalized to the levels of the house keeping protein.  
The heatmap in Fig. 29 summarizes the activity of NF- κB pathway in the nuclear 
fraction, while Fig. 30 showed the RPPA data analyzed for each NF-κB pathway 
components. 
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Fig. 29: Heatmap of NF-κB signalling pathway in nuclear fraction of NOD2 transfected HEK293 
cell lines.  
The multiple different proteins are outlined on the horizontal axis, and the lysates phenotype is on 
the vertical axis. Red and green colours indicate highand low protein expression, respectively. 
 
As regards the mutation p.R334W, the data obtained for the basal activity of NF-
κB are in line with those reported in the literature.  
The mutation in fact revealed a ~2-fold increase in basal level of NF-κB 
compared to wild-type allele (p<0.05). The NF-κB activity of R334W was further 
enhanced by addition of MDP (p<0.01). This mutation also leaded to a slight 
increase of expression of the phosphorylated form of NF-κB to the basal level by 
comparing it to the wild-type (p<0.05). We could note that the stimulation with 
MDP further increased the expression of phospho NF-ΚB both in wild-type and in 
p.R334W (p <0.01). Active phospho NF-ΚB level in p.R334W cells is similar to 
the one in wild-type cells (p>0.05). The results showed also similar level of 
phospho IKBα in p.R334W cells compared to wild-type cells, but a statistical 
enhance of both levels after MDP stimulation (p<0.05). A similar trend was 
shown by the other observed pathway components.  
Regarding the mutation p.E383K at baseline, it was showed no statistically 
significant difference in the level of NF-κB compared to wild-type, not even an 
increase in production as a result of stimulation with MDP. The phosphorylated 
form of NF-κB instead showed a significant decrease (p <0.01) compared to wild-
type at the basal level. After stimulation with MDP, we noted a clear decrease 
compared to wild-type (p<0.01). IKBα, IKKα, IKKβ and their phosphorylated 
forms showed instead a similar level to wild-type in absence of stimulation, except 
for IKBα (p<0.05). Even with MDP stimulation, the proteins did not show 
enhanced expressions, except for IKBα (p<0.05). These levels appeared to be 
statistically lower than wild-type (p<0.05 for IKBα, phospho IKBα, IKKβ and 
phospho IKKα/β; p<0.01 for IKKα).  
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Fig. 30: Comparison of RPPA data for NF-κB, IKBα, IKKα/β and their phosphorylated forms 
obtained from nuclear fraction of lysated wild-type and mutated NOD2 transfected HEK293 cells.  
In blue unstimulated data; in green data after 7h stimulation with MDP.  
*p<0.05, **p<0.01, ***p<0.005 as significant statistical values in comparison between ns (non 
stimulated) and MDP. 
§p<0.05, §§p<0.01 as statistical significant values in comparison wild-type/ mutated proteins. 
 
 
 
1.3.2 EX VIVO analysis
NF-κB signalling pathway has been studied in detail in lysated PBMC samples 
from Italian Blau syndrome patients and all data were compared to healthy 
controls, matched by similar age and sex. 
Patients PBMC were purified and proceeded as described previous
and methods. Reverse phase protein array technique was applied to measure the 
level of several component of the NF
α, IKKα/β and their phosphorylation forms. In these experiments the expression 
level of the analysed proteins was normalized to 
protein. 
Fig. 31 summarizes the activity of NF
controls. 
 
Fig. 31: Heatmap of NF-κ
The multiple different proteins are outlined on the 
the vertical axis. Red and green 
From the figure the levels of different regulat
healthy controls. 
 
The lysates microarray data showed higher level of 
phospho IKBα, IKKα
in healthy controls (p value <
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1.4 Cytokines release from patients PBMC and NOD2 transfected 
HEK293 cell lines
To define the biological effects of pE383K BS
both in vitro and ex vivo the ability of this mutation to produce cytokines in the 
absence or presence of activating stimuli. 
patients cells and NOD2 transfected cells 
of cytokines and inflammatory markers 
1.4.1 IN VITRO analysis
The starting point for the 
with the home-made constructs containing the 
type and mutated forms p.E383K and p.R334W. These cells were cultured in the 
presence or absence of stimulation mediated by MDP and the supernatants were 
collected after 7 and 24 hours.
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 in Blau syndrome.  
2 Blau syndrome patients and healthy controls 
 at p value <0.05. 
 
-associated mutation, we examined 
This study using Blau syndrome 
may help to have a better understanding 
involved in Blau syndrome. 
 
in vitro studies were HEK293 cells stably transfected 
CARD15/NOD2 gene in the 
 
wild-
It has been chosen to use the technique antibody microarray to evaluate th
production of cytokines from supernatants. The method and the specific 
amplification was widely explained in materials and methods
Since HEK293 cells produce only a limited set of cytokines and markers of 
inflammation, it was evaluated only the producti
induce an inflammatory response to external stimuli.
Analyzing the data obtained after 7 hours, we
stimulation (ns) the levels 
statistically higher (p <0.05)
33). Stimulation with MDP showed a
while there was a high increase of IL8 levels 
(p<0.05). Concerning the mutation p.E383K, there 
concentration in the presence or absence of the stimulus.
A similar trend for all the three cell lines 
24 hours. 
 
Since it is known that exposure to M
MDP administration (called MDP tolerance) in NOD2 
to determine whether this condition was induced also by p.E383K mutated 
NOD2.Transfected cells were treated with MDP for 4 hours, then w
restimulated with MDP
wild-type showed a tolerant state in response to subsequent MDP treatment, 
resulting in the reduced release of IL8 upon th
(Fig. 34). Concerning the p.E383K mutated NOD2,
pretreatment with MDP 
MDP treatment. IL8 concentration seemed to be slightly increased after the 
second MDP stimulation, but the difference wa
 
Fig. 33: Production of IL8 by supernatants of NOD2 transfected cells, both 
Stimulation: none (ns) and muramyl dipeptide (MDP [10
** p<0.05 as statistical significant value
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on of IL8, chemokine known to 
  
 noted that in the absence of 
of IL8 in cells expressing wild-type 
 than those presented by p.E383K mutated cells 
 similar level in the wild-type
in cells expressing p.R334W NOD2 
was not
 
was noted for the secretion of IL8 after 
DP causes an impared response to su
wild-type 
 for 24hours. Consistent with the literature data, NOD2 
e second MDP stimulation (p<0.01
 the results showed that 
did not inhibit proinflammatory response to subsequent 
s not statistically significant.
wild
µg/ml]) for 7 or 24 hour.
 
Results 
e 
NOD2 were 
(Fig. 
 NOD2 cells, 
 differences of 
bsequent 
[218], we aimed 
ashed and 
) 
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Fig. 34: Production of IL8 by supernatants of NOD2 wild-type and p.E383K transfected cells, 
after a subsequent treatment with muramyl dipeptide (MDP [10µg/ml]).  
The cells were pretreated with MDP for 4h, washed and restimulated with MDP for 24h.  
**p<0.05 as statistical significant value 
 
1.4.2 EX VIVO analysis 
Cytokines and other markers of inflammation production has been evaluated ex 
vivo by means of two different technique: ELISA and antibody Microarray. In 
addition to assessing the sensitivity and accuracy of the two different techniques, 
this choice was dictated by the availability of pairs capture/detection antibodies 
for the microarray technique.  
 
ELISA technique 
Enzyme-linked immunosorbent assay (ELISA) allowed rapid quantification of the 
levels of several cytokines and other inflammatory markers from PBMC 
surnatants obtained from Blau syndrome patients and healthy controls. These cells 
were cultured in presence or absence of inflammation stimuli, LPS [100ng/ml] 
and MDP [10µg/ml], for 7 hours.  
The classical pro-inflammatory cytokines (IL1β, IL6, TNFα), chemokines (IL8) 
and interferon-gamma (IFNγ) were tested in the surnatants collected from patients 
and controls PBMC.  
The results are presented in the graphs in Fig. 35 and 36. In absence of 
stimulation, no statistical differences in cytokine levels were detected between 
patients and controls, except for IL8 that was secreted at higher titre by healthy 
controls (p<0.05) (Fig. 35A).  
In the presence of stimulation with the TLR agonist (LPS), the release of 
cytokines by Blau patients PBMC was not elevated compared to that of healthy 
controls. The concentration values were indeed very similar or even statistically 
significant lower, such as for IL6 (p<0.05) (Fig. 35B). Despite this results, the 
cytokines levels after LPS stimulation in patients showed a significant increase 
compared to the non stimulated ones, as expected (Fig. 36A). IL6, IL8 and TNFα 
Results 
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concentrations were highly release after LPS stimulation (p<0.005, p<0.005 and 
p<0.05 respectively), with the exception of IL1β and IFNγ.  
Even the NOD2 agonist (MDP) did not seem to stimulate a high cytokine release 
in patients compared to healthy controls. IL8 was the only marker that showed a 
significant decrease in concentration in Blau syndrome patients (p<0.005) (Fig. 
35C). Evaluating only Blau syndrome patients (Fig. 36A), it was notable that 
there was an increase of production of only IL8 (p <0.05), while levels of all other 
cytokines were similar to the non-stimulated ones or statistically lower to LPS 
stimulated ones (p <0.005 for IL6 and TNFα). 
This study failed to identify an increase in cytokine production in patients 
following double stimulation, but this could be seen in controls (Fig. 35D). IL1β, 
IL6 and TNFα showed higher concentration in controls (p<0.005 for all the 
cytokines). In patients, a synergistic effect was detected in IL6, IL8, and TNFα 
production when the MDP were supported with the NLR agonist (p<0.005, 
p<0.05, p<0.05 respectively) (Fig. 36B). 
 
 
Fig. 35: Production of cytokines by supernatant of PBMC obtained from Blau syndrome patients, 
in presence or absence of stimulation after 7 hours.  
LPS [100ng/ml] and MDP [10µg/ml] are used as individually or associated stimuli. The data 
shown are means of data from duplicate experiments and the error bars indicate standard 
deviation. *p<0.05; **p<0.005: p values less than 0.05 are considered statistical significant. 
 
 Fig. 36: Production of cytokines levels in Blau syndrome patients in presence or absence of 
stimulation after 7 hours. 
The data shown are means of data from dup
deviation. A) Comparison between individual stimuli and absence of stimulation. B) Comparison 
between double stimulation and MDP stimulus.
*p<0.05;**p<0.005: p values <0.05 are statistical significan
 
Antibody microarray 
Cytokines and other markers of inflammation
through antibody Microarray technique from serum samples 
patients affected by different autoinflammatory diseases. 
cytokines level as described in materials and methods, all 
compared to Italian healthy controls data.
The range of cytokines in analysis was expanded to all
to play an important role in inflamm
inflammatory cytokines, such as IL1
for the production of novel inflammation
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 compounds that are known 
ation. Other than only testing the typical pro
β IL6 TNFα, the serum samples are evaluated 
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and IL17. This study using 9 cytokines and inflammatory markers may help to 
have a better understanding of inflammatory processes involved in Blau 
syndrome. 
 
Comparison between concentrations of cytokines and inflammatory markers in 
Blau syndrome patients and healthy controls are shown in Fig. 37 The most 
notably difference was detected for IL22 and IL23, highly expressed in several 
different inflammatory condition and presenting pro-inflammatory properties. The 
concentration of IL22 in patients was >80-fold (p<0.005) higher than in controls, 
while IL23 concentration was 13-fold (p<0.005) higher. Statistically significant 
differences between patients and controls were also detected for IL17 and IL12, 
even though for the latter cytokine the level in patients are 3-times (p<0.05) lower 
than in controls. Concerning IL17, the concentration in patients was found to be 
13-fold higher than in controls (p<0.05).  
The concentration of all other cytokines was not statistically different from 
controls. 
 
Fig. 37: Graphs of cytokines and marker of inflammation concentrations in serum from Blau 
syndrome patients compared to healthy controls.  
The data shown are means of data from triplicate experiments and the error bars indicate standard 
deviation.  
* p<0.05; ** p<0.005: p values less than 0.05 are statistical significant. 
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2 Evaluation of possible biomarkers in autoinflammatory 
diseases 
Biomarkers are defined as "characteristics that are objectively measured and 
evaluated as indicators of normal biological processes, pathogenic processes or 
pharmacologic responses to a therapeutic intervention". They provide an objective 
measure to assess disease severity, progression, risk and survival. Since 
identification of biomarkers patterns is a sizeable problem, the use of an array-
based system to measure cytokines/other serum proteins and signalling 
intermediates would represent an enormous advance. Reverse phase protein array 
(RPPA) and antibody microarray are the techniques used in this thesis work. 
These proteomic technologies are currently employing by the MBTI Research 
Group at Nottingham University, where they have been developed and optimised. 
2.1 Optimisation of assays 
The optimisation of assay conditions is another major challenge for microarray 
technology.  
The provision of optimal binding conditions is a crucial feature of the antibody 
microarray support. The demand for even higher densities as well as the need for 
decreased sample consumption and quantification led to the application of glass 
slides as solid supports with coated surfaces. The optimal substrate was defined as 
one that bound the greatest amount of antibody with minimal background. For the 
antibody microarray experiments presented in this thesis, poly-l-lysine enhanced 
surface slides gave the greatest degree of binding along with a minimal 
background. Due to the low abundance of some cytokines, a main issue is to 
provide a good signal through a correct amplification. The best results were 
achieved using simple Tyramide amplification rather than Genisphere or 
Avidin/Biotin blocking, as shown in Fig. 38. It is clear that the Genisphere 
amplification method (Fig. 38A) generates a signal directly from the sample, with 
a presence of detectable background. The addiction of Avidin/Biotin blocking 
steps showed surprisingly low signals and higher background (Fig. 38B), even if 
the Avidin/Biotin blockage meant to decrease the aspecific signals. Tyramide 
amplification, provided by Cy5 dye, seems to give virtually undetectable 
background staining and higher samples signals (Fig. 38C). 
In RPPA, printing of lysates is a complicated process and requires printing buffer 
that keeps protein denatured, reduced and soluble at room temperature. Also, the 
blocking buffer is important in decreasing the detection background and provide 
good signal to noise ratios. The highest specific signal intensity was obtained 
when I-Block was used as the blocking buffer and SDS is added to the printing 
buffer, as shown in Fig. 39. 
 
Fig. 38: Amplification assessment
Each capture antibody was printed twice and 10 times in a raw onto poly
described. A cocktail of recombinant standards were added, along with sera. Biotinylated detection 
antibodies were added, followed by diffe
A) Genisphere Ultra Amp amplification, 
amplification. 
 
Fig. 39: Background assessment
Cell lysates were prepared and diluted (2 fold 2 times); doubling dilution series was printed onto 
nitrocellulose-coated slides as described. Individual arrays were then probed with anti 
antibody and all arrays were then visualized by applying 680 
A) green signals from tested molecules; B) red signals from
 
Testing the specificity of primary antibodies for RPPA
Western blotting is a valuable technique to test t
antibodies before using in
defined product (often one band) 
antibodies. 
All antibodies, listed in 
associated with autoinflammatory, were
lysated cells. The results
bands of the tested antibodies at 
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Fig. 40: Western blotting for testing antibodies 
used in NF-κB study. 
This figure shows western blotting results of 
testing antibodies specific for the NF
pathway components including a protein marker 
on the left. The three "green" antibodies were 
detected by near infrared detection method.
 
 
 
 
 
Fig. 41: Western blotting for testing antibodies 
used in PI3K/Akt study. 
This figure shows western blotting strips for
antibodies to PI3K/Akt pathway components
including a protein marker (on left). Some 
antibodies, such as PI3K and phospho
show weak secondary bands but these are at 
relatively low level compared to the known 
target band in each case 
 
 
 
Fig. 42: Western b
testing antibodies used in
MAPK study. 
This figure shows western 
blotting strips for antibo
to MAPK pathway 
components including a 
protein marker
ERK1/2, MKK3/MKK6 and 
P SEK1/MKK4 reveal the 
characteristic 2 bands
-κB 
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Fig. 43: Western blotting for testing antibodies used 
in STAT3/Jak2/c-Src study. 
This figure shows western blotting strips for 
antibodies to STAT3/Jak2/c
components including a protein marker (left)
 
 and MyD88  
 
 
 
Fig. 44: Western b
antibodies used in
study and MyD88. 
This figure shows western blotting 
strips for antibodies to 
inflammasome pathway components
including a protein marker 
MyD88 protein (right)
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2.2 NF-κB pathway in autoinflammatory diseases 
NF-κB signalling pathway has been studied in detail in lysated PBMC samples 
from Italian patients affected by different autoinflammatory diseases. All data 
were compared to healthy controls, matched by similar age and sex.  
As described in the introduction, NF-κB activation in turn activates IKK complex 
that phosphorylates IkBα, which normally binds to NF-κB complex and inhibits 
its action. Phosphorylated IkBα is ubiquitinated and addressed to proteasomal 
degradation, while NF-κB can translocated to the nucleus. In the nucleus, NF-κB 
mediates inflammatory gene transcription, cell survival and cell proliferation. 
Patients PBMC were purified and proceeded as described previously in materials 
and methods. Reverse phase protein array technique was applied to measure the 
level of several component of the NF-κB signalling pathway, such as NF-κB, 
IKBα, IKKα/β and their phosphorylation forms. In these experiments the 
expression level of the analysed proteins was normalized to β-actin as a house 
keeping protein. 
Fig. 45 summarizes the activity of NF-κB pathway in both patients and healthy 
controls. 
 
 
Fig. 45: Heatmap of NF-κB signalling pathway.  
The multiple different proteins are outlined on the horizontal axis, and the lysates phenotype is on 
the vertical axis. Red and green colours indicate high and low protein expression, respectively.  
From the figure the levels of different regulatory molecules of NF-κB are down-regulated in 
healthy controls and in some sporadic patients. 
 
  
2.2.1 Behçet disease
The lysates microarray data showed higher level of 
phospho IKKα/β, IKKγ
value <0.05) (Fig. 46)
statistically significant difference from the controls.
 
Fig. 46: NF-κB signalling pathway in
Statistically significant comparisons between expression levels of phospho NF
phospho IKKα/β, IKKγ and A20 
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 2.2.2 Adult onset Still's
In PBMC lysates obtained from Still 
expression of NF-κB, phospho NF
phosphorylated form, IKKγ
<0.05 or less (Fig. 47). 
Fig. 47: NF-κB signalling pathway in
Statistically significant comparisons
IKKα/β, IKKγ and A20 levels between 
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patients and controls, the level
-κB, phospho IKBα, IKKα/β
 and A20 was statistically significant as p values were
 AOSD.  
 of NF-κB, phospho NF-κB, phospho IKBα, IKKα β
patients and controls. 
 of the 
 and the 
 
/ , phospho 
Results 
105 
2.2.3 TRAPS 
The data obtained from TRAPS patients and controls showed a statistically 
significant increased level of NF-κB and phosphorylated form, phospho IKBα, 
IKKγ, IKKα/β in patients compared to controls (p value <0.05). Also the 
phosphorylated form of IKKα/β and IRAK1 presented higher expression in 
patients (p value <0.005) (Fig.48). 
 
Fig. 48: NF-κB signalling pathway in TRAPS.  
Comparisons of NF-κB, phospho NF-κB, phospho IKBα, IKKγ, IKKα/β, phospho IKKα/β and 
phospho IRAK1 levels between patients and controls are statistically significant. 
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2.2.4 FMF 
Data from FMF patients showed higher expression (p value < 0.05) of only IKKβ 
and phospho IRAK1 compared to healthy controls (Fig. 49). 
Fig. 49: NF-κB signalling pathway in FMF.  
Comparison of IKKβ and phospho IRAK1 levels is significant between patients and healthy 
controls. 
 
2.2.5 Blau syndrome 
The NF-κB signalling pathway was extensively described previously. 
 
2.2.6 Other autoinflammatory diseases 
Since the number of patients does not allow accurate statistical analysis, for 
Schnitzel, MKD and NALPS12 diseases patients we may only study the heatmap 
and see if the expression of pathway components are higher or lower compared to 
healthy controls.  
The patient affected of Schnitzel disease seemed to show an activation of the NF-
κB pathway, while the NALPS12 patient data was comparable to the controls. For 
the MKD patient, it is possible to notice increased expression of the IKK 
complex, an over-expression of P IRAK1 and a strong sub-expression of IKBα. 
 
 
  
2.3 PI3K/Akt pathway in autoinflammatory diseases
PI3K/Akt signalling pathway has been studied in detail in lysated PBMC samples 
from Italian patients affected by different autoinflammatory diseases. Patients data 
were then compared to healthy controls. 
As previously described, 
tyrosine kinases (Src). Active PI3Kactivates many downstream targets including 
Akt, ERK and JNK. Akt is phosphorylated byPDK1 and this will in turn stimulate 
different downstream signalling that inhibits apoptosis.
Patients PBMC were proceeded as described previously
applied to measure the level of 
pathway, in both phosphorylated and not phosphorylated form.
experiments the expression l
actin as house keeping protein.
The heatmap shows the activity of PI3K/Akt pathway in both patients and healthy 
controls (Fig. 50). 
 
Fig. 50: Heatmap of PI3K/Akt
The multiple different proteins are outlined on the 
the vertical axis. Red and green 
From the figure the levels of different regulatory
healthy controls and in some sporadic patients.
2.3.1 Behçet disease
The data obtained from lysate
AKT and PI3K p85 a statistically significant increase of expression, compa
controls (p values <0.05 or less)
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Fig. 51: PI3K/Akt signalling pathway in Behçet disease.  
Significant comparison of phospho Akt and PI3K p85 levels between patients and controls. 
 
  
2.3.2 Adult Onset 
Fig. 52 showed higher level of 
PTEN, cRAF, and GSK
Still patients than in healthy controls (p value <0.05 or less).
Fig. 52: PI3K/Akt signalling pathway in
Statically significant comparison between patients and controls of phospho Akt, phospho eNOS, 
phospho c-RAF, phospho GSK
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Still's disease 
phosphorylated forms of AKT (T308), eNOS, 
-3β and the two subunit p85 and p100 of PI3 protein in 
 
 AOSD.  
-3β, PI3 p85, PI3 p110, phospho PTEN and phospho BAD
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2.3.3 TRAPS 
The data obtained from lysates microarray showed for phospho AKT (T308 and 
S473), PI3p100 and PI3p85, and phospho GSK-3β a statistically significant 
increase of expression, compared to controls (Fig. 53). P values are less than 0.05 
for phospho GSK-3β and lower for other components. 
 
Fig. 53: PI3K/Akt signalling pathway in TRAPS.  
Significant comparison of phospho Akt, PI3 p85, PI3K p100 and phospho GSK-3β levels between 
patients and controls. 
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2.3.4 FMF 
The microarray data showed significant higher expression only for PI3 p85 
compared to healthy controls (p value <0.005) (Fig. 54). For the inflammasome 
pathway components, no statistically significant comparison was found. 
 
Fig. 54: PI3K/Akt signalling pathway in FMF. Comparison of PI3K p85 level between patients 
and controls is statistically significant. 
 
2.3.5 Blau syndrome 
In PBMC lysates obtained from Blau syndrome patients and controls, PI3p85 and 
the phosphorylated forms of eNOS, GSK-3β, AKT (S473), and BAD are 
statistically more expressed than in controls (p values <0.05) (Fig. 55). 
 
Fig. 55: PI3K/Akt signalling pathway in Blau syndrome.  
Comparisons of phospho eNOS, phospho GSK-33β, phospho Akt, PI3K p85 and phospho BAD 
levels between patients and controls are statistically significant. 
 2.3.6 Other autoinflammatory diseases
Evaluating the heatmap for the remaining individual autoinflammatory patients
both Schnitzel and MKD patient
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 2.4.2 Adult Onset Still
The data obtained from lysate
MKK3/MKK6, phospho SAPK/JNK, TRAF2, phospho ERK1/2, MEK1/2, 
MKK7, phospho TAK1 and phospho ATF2 a statistically significant increase of 
expression, compared to controls, with p values less than 0.05 (Fig. 58).
Fig. 58: MAPK signalling pathway in
Significant comparisons of phospho MKK3/6, phospho Erk, MEK1/2, MKK7, TRAF2, phospho 
SAPK/JNK, phospho TAK1, phospho ATF2 and phospho MEK1/2
controls. 
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2.4.3 TRAPS 
In PBMC lysates obtained from TRAPS patients and controls, the level of the 
expression of TRAF2, MEK1/2 and phosphorylated form, phospho SAPK/JNK, 
MKK7, phospho ERK1/2 and phosho ATF2 was statistically significant as p 
values were <0.05 or lower (Fig. 59). 
 
 
Fig. 59: MAPK signalling pathway in TRAPS.  
Statistically significant comparisons of TRAF2, phospho SAPK/JNK, MEK1/2, phospho MEK1/2, 
MKK7, phospho Erk and phospho ATF2 levels between patients and healthy controls. 
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2.4.4 FMF 
Fig. 60 showed higher expression of MEK 1/2 and the phosphorylated forms of 
SAPK/JNK, ERK1/2 and HSP27 compared to healthy controls. Significant P 
values are <0.05 or less. 
 
Fig. 60: MAPK signalling pathway in FMF.  
Significant comparisons of phospho SAPK/JNK, phospho Erk, phospho HSP27 and MEK1/2 
levels between patients and controls. 
 
2.4.5 Blau syndrome 
The data obtained from Blau syndrome patients and controls showed that the 
expression level of phospho HSP27 and phospho P38 was statistically significant 
(P values <0.05) (Fig. 61). 
 
Fig. 61: MAPK signalling pathway in Blau syndrome.  
Significant comparisons of phospho HSP27 and phospho P38 levels between patients and controls. 
 
2.4.6 Other autoinflammatory diseases 
Observing the heatmap, MKK7, phospho TAK1 and phospho HSP27 levels 
seemed to be increased in Schnitzel patient. MKD patient showed an higher 
expression of phospho SAPK/JNK and phospho MEK1/2, while NALP12 patient 
showed a slightly higher expression of phos
and ERK1/2. 
 
2.5 JAK/STAT/c
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2.5.1 Behçet disease 
The data obtained from lysates microarray (Fig. 63) showed only for phospho 
STAT1 a statistically significant increase of expression, compared to controls (p 
value <0.05). For the other pathway components, the expression varies along 
patients.  
 
Fig. 63: JNK/STAT/c-Src signalling pathway in Behçet disease.  
Comparison of phospho STAT1 between patients and controls is statistically significant. 
 
2.5.2 Adult Onset Still's disease 
In PBMC lysates obtained from Still disease patients and controls, the level of the 
expression of phospho Src, SOCS3, phospho STAT1 and STAT3 was statistically 
significant as p values were <0.05 or lower (Fig. 64). 
 
Fig. 64: JNK/STAT/c-Src signalling pathway in AOSD.  
Significant comparisons of phospho Src, SOCS3, phospho STAT1 and phospho STAT3 levels 
between patients and controls. 
Results 
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2.5.3 TRAPS 
The lysate microarray data, shown in Fig. 65, presented higher level of SOCS3 
and phosphorylated form of Src, STAT1, JAK2, RIP2, STAT3 in TRAPS patients 
than in healthy controls (p value <0.05). 
 
Fig. 65: JNK/STAT/c-Src signalling pathway in TRAPS.  
Statistically significant comparisons of phospho Src, phospho STAT1, phospho JAK2, phopsho 
RIP2, phospho STAT3 and SOCS3 between patients and healthy controls. 
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2.5.4 FMF 
FMF patients showed a higher level of phosphrylated form of Src and RIP2 
compared to healthy controls (p values <0.005) (Fig. 66). 
Fig. 66: JNK/STAT/c-Src signalling pathway in FMF.  
Significant comparisons of phospho Src and phospho RIP2 between patients and controls. 
 
2.5.5 Blau syndrome 
In BS lysates, only phospho STAT1 showed an higher level (p value <0.05) 
compared to healthy controls data (Fig. 67). 
 
 
Fig. 67: JNK/STAT/c-Src signalling pathway in Blau syndrome.  
Comparison of phospho STAT1 between patients and controls is statistically significant. 
 
2.5.6 Other autoinflammatory diseases 
Observing the heatmap, MKD and NALP12 patients showed a similar up-
regulation of the JNK/STAT/c-Src pathway components, whereas in Schnitzel 
patient this pathway seemed not to be activated. 
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Fig. 68: Heatmap of Inflammasome signalling pathway. 
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2.6.1 Behçet disease 
The lysates microarray data showed a statistical increased expression only for 
MyD88 in Behçet patients than in healthy controls (p value <0.05) (Fig. 69). 
Concerning the inflammasome pathway components, the variability between 
patients seems to be too high for a statistical analysis. 
 
Fig. 69: Significant comparison of MyD88 level in Behçet patients versus healthy controls. 
 
2.6.2 Adult Onset Still's disease 
In PBMC lysates, the level of the expression of MyD88, phospho BAD, 
CASPASE 1 and cleaved form, BCL-2 and the phosphorylated form was 
statistically significant as p values were <0.05 or less (Fig. 70). 
 
Fig. 70: Inflammasome signalling pathway in AOSD.  
Significant comparisons of caspase1, cleaved caspase1, BCL-2 and phospho BCL-2 between 
patients and controls. Also MyD88 level is statistically significant. 
Results 
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2.6.3 TRAPS 
The data obtained from lysates microarray showed only for MyD88, cleaved 
caspase 1 and BCL-XL a statistically significant increase of expression, compared 
to controls (p<0.005) (Fig. 71).  
 
Fig. 71: Inflammasome signalling pathway and MyD88 level in TRAPS.  
Statically significant comparisons of cleaved caspase1 and BCL-XL between patients and controls.  
 
2.6.4 FMF 
The microarray data showed higher level of ASC, NALP1 and BCL-XL in FMF 
patients than in healthy controls (p value <0.05 or less) (Fig. 72). 
 
Fig. 72: Inflammasome signalling pathway in FMF.  
Significant comparisons of ASC, NALP1 and BCL-XL between patients and healthy controls. 
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2.6.5 Blau syndrome 
Data from BS patients did not show any statistically significant difference in the 
expression of inflammasome components, compared to healthy controls. Even 
MyD88 level was not significantly higher in BS patients than in controls.  
 
2.6.6 Other autoinflammatory diseases 
Evaluating the data from the heatmap, Schnitzel patient showed a higher 
expression of all the inflammasome components compared to healthy controls, 
while NALP12 patient had a profile similar to the controls. MKD patient showed 
an increased expression only for STAT4 and NALP1. 
 
 
2.7 Cytokines in autoinflammatory diseasesCytokines and other 
markers of inflammation production has been evaluated through antibody 
Microarray technique from serum samples obtained by Italian patients affected by 
different autoinflammatory diseases. Once measured the cytokines level as 
described in materials and methods, all data were compared to Italian healthy 
controls presenting similar age and sex.  
We focused on a wide range of cytokines and compounds that are known to play 
an important role in inflammation, IL1β in primis. We expanded the analysis from 
typical pro-inflammatory cytokines, such as IL1β IL6 TNFα, to novel 
inflammation-associated pro-inflammatory cytokines, such as IL22, IL23 and 
IL17. This study using 9 cytokines and inflammatory markers may help to have a 
better understanding of inflammatory processes involved in the autoinflammatory 
diseases. 
 
2.7.1 Behçet disease 
Concentrations of systemic cytokines and markers of inflammation in Behçet 
disease are shown in Fig. 73. The most notably difference was detected for IL22, 
a cytokine that plays an important role in inflammation, including chronic 
inflammatory diseases and infectious diseases. In patients, the concentration of 
IL22 was more than 10-fold (p<0.005) higher than in controls. Statistically 
significant differences between patients and controls were also detected for IL8, 
IL17 and IL12, even though for the latter cytokine the level in patients are 2-times 
(p<0.05) lower than in controls. Concerning IL8, the concentration in patients was 
found to be 5-fold higher than in controls (p<0.01). The same trend was observed 
for IL17 (p<0.05).  
The concentration of all other markers was not statistically different from 
controls.  
Results 
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For IL23, the patients cytokine level was slightly increased, even if the value was 
not significant. 
 
Fig. 73: Graphs of cytokines and marker of inflammation concentrations in serum from Behçet 
patients compared to healthy controls.  
The presented data are means of data from triplicate experiments and the error bars indicate 
standard deviation.  
* p<0.05; ** p<0.01; ***p<0.005, as statistical significance is for p values less than 0.05 
 
2.7.2 Adult Onset Still's disease 
Fig. 74 showed the concentration levels of cytokines and inflammatory markers in 
AOSD disease. The results showed that all the analyzed cytokines and markers 
presented a statistically significant difference between patients and controls. In 
patients, the concentration of IL1β was 10-fold higher than in controls (p<0.05) 
and the same trend was also observed for IL6 and IFNγ. Extremely high IL22 and 
IL23 concentrations were detected in patients, with the eight-fold (p<0.05) and 
six-fold (p<0.05) increase over the values obtained for control subjects, 
respectively. Increased concentration levels were also observed for IL8, IL12 and 
TNFα, presenting respectively 10-fold, 12-fold and 6-fold higher values than 
controls. An extremely higher increase (50-fold, p<0.01) was found for IL17 
concentration level in patients, compared to controls. 
 
Fig. 74: Graphs of cytokines and marker of inflammation concentrations in serum from Still 
disease patients compared to healthy controls.  
The data shown are means of data from triplicate experiments and the error bars indicate standard 
deviation. * p<0.05; ** p<0.01: p values less than 0.05 are considered statistical significant 
* * 
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2.7.3 TRAPS 
Comparison between concentrations of cytokines and inflammatory markers in 
TRAPS patients and healthy controls are shown in Fig. 75 The most notably 
difference was detected for IL23, member of the IL12 family of cytokines with 
pro-inflammatory properties. It is a key participant in central regulation of the 
cellular mechanisms involved in inflammation. The concentration of IL23 in 
patients was more than 50-fold (p<0.01) higher than in controls. Statistically 
significant differences between patients and controls were detected for all the 
analyzed markers, except for IL1β, L6 and IL12. IL6 showed a slightly increased 
but not significant concentration level in patients.  
The level of IFNγ was found to be 4-fold higher in patients compared to controls 
(p<0.05). Increased concentration levels were also observed for IL8, IL17 and 
TNFα, presenting respectively 7-fold, 14-fold and 6-fold higher values than 
controls with p values <0.05 or less. An extremely higher increase (>200-fold, 
p<0.005) was found for IL22 concentration level in patients, compared to 
controls.  
Fig. 75: Graphs of cytokines and marker of inflammation concentrations in serum from TRAPS 
patients compared to healthy controls.  
The data are means of triplicate experiments results and the error bars indicate standard deviation.  
* p<0.05; ** p<0.01; ***p<0.005. Statistical significance is for p values less than 0.05 
 
2.7.4 FMF 
Concentrations of systemic cytokines and markers of inflammation in FMF are 
shown in Fig. 76. Interesting cytokines with an high concentration in FMF 
patients were IL22 and IL23, highly expressed in several different inflammatory 
condition and related to each other since IL22 is an effector cytokine downstream 
of IL23. The concentration of IL22 in patients was 15-fold (p<0.01) higher than in 
controls, while IL23 concentration was 5-fold (p<0.01) higher. The level of IL1β 
was found to be 19-fold higher in patients compared to controls (p<0.05). The 
same trend was observed for IFNγ (p<0.05). Incredibly high increase of 
concentration was found in patients for IL6 and IL17 with 40-fold and >60-fold 
increase respectively over the values obtained for control subjects. Increased 
Results 
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concentration level was also observed for IL8 presenting a 12-fold higher values 
than controls (p <0.05).  
The concentration of IL12 and TNFα was not statistically different from controls, 
even if both cytokines showed a slightly higher concentration value than controls. 
 
 
Fig. 76: Graphs of cytokines and marker of inflammation concentrations in serum from FMF 
patients compared to healthy controls.  
The data are means of data from triplicate experiments and the error bars indicate standard 
deviation. * p<0.05; ** p<0.01; p values less than 0.05 are considered statistical significant. 
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DISCUSSION 
The autoinflammatory diseases are a heterogeneous group of inflammatory 
syndromes caused by primary dysfunction of the innate immune system, without 
evidence of adaptive immune deregulation. While initially focused on hereditary 
recurrent fevers (HRFs), autoinflammatory diseases now encompass a wide 
spectrum of disorders ranging from rare monogenic (such as Blau syndrome) to 
more frequent multifactorial diseases (as Behçet and Still’s diseases). Different 
genome-wide association studies have begun to elucidate the molecular basis of 
autoinflammatory diseases. Most of these studies underline the prominence of the 
IL1β-activating inflammasome and its regulation in a large number of diseases. 
More recently, additional mechanisms linking innate immune-mediated 
inflammation with a variety of cellular processes, including protein misfolding, 
oxidative stress and mitochondrial dysfunction, have been recognized to play a 
role in the pathogenesis of some monogenic autoinflammatory conditions. Those 
processes can later activate other inflammatory pathways with host defense 
function, such as MAPK, JNK and NF-κB pathways. Even though important 
aspects of the pathogenesis of autoinflammatory diseases have been clarified, all 
the inflammatory-related signalling pathways and cytokines possibly involved are 
far to be deeply investigated. 
 
1 Functional studies on p.E383K Blau syndrome-associated 
mutation 
The CARD15/NOD2 gene encodes a cellular recognition molecule (NOD2) 
mediating NF-κB activation in response to the muramyldipeptide component of 
bacterial peptidoglycan. A distinct group of mutations in this gene causes, in 
heterozygous state, the rare autoinflammatory disease, named Blau syndrome.  
Up to date, 11 mutations have been identified to be associated at this disease and 
those referred to codon 334 were more frequently presented (p.R334Q/W). 
In 2005, our group has identified the mutation p.E383K in an Italian family 
affected by Blau syndrome [56].  
This mutation is located in the central NACHT domain and changes Glutamate 
E383 to Lysine. Up to date, no functional studies are presented in literature 
concerning this mutation. Its pathogenicity is strongly supported by several, 
although indirect, pieces of evidence. As shown in Fig.12 and Fig.22, p.E383K 
clearly cosegregates with the disease in a dominant manner and the glutamate 
E383 is known to be a conserved residue among different species. 
As reported in literature, NOD2 expression has mainly occurred in the cytosol of 
myelomonocytic cells [219], dendritic cells [58] and Paneth cells [59]. More 
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recently NOD2 was shown to be associated with the plasma membrane of 
intestinal epithelial cells [60]. 
In vitro immunofluorescent studies on transfected HEK293 cells demonstrated 
that both missense mutations studied (p.E383K and p.R334W) did not affect the 
normal cytosolic cellular localisation of NOD2, suggesting that there is no 
evidence that the protein localization is not related to the carried mutation. 
Interesting would be studying also the localization of p.E383K mutated NOD2 in 
patients cells.  
In vitro expression study by means of Western blotting techniques showed that 
wild-type NOD2 expression on transfected cells did not increase after stimulation 
with muramyl dipeptide (MDP), a degradation product from bacterial 
peptidoglycan. The expression of both mutated NOD2 proteins showed a similar 
trend. To better understand these data, a further study at transcriptional level has 
to be performed, maybe using also patients monocytes.  
 
1.1 NF-κB pathway activation  
To define the biological effect of p.E383K mutation in Blau syndrome, we 
examined the NF-κB activation both in vitro and ex vivo.  
HEK293 cells transfected with human recombinant NOD2 either wild-type or 
p.E383K mutant form were used as a possible in vitro model for studying the 
activation of this pathway. Firstly, indirect test of NF-κB activation was 
performed, detecting the expression of NF-κB inhibitor (IKBα) and its 
phosphorylated form by Western blotting. A higher expression of phospho IKBα, 
revealing an activation of NF-κB, was seen only for wild-type NOD2 after 
stimulation with MDP. This result was confirmed also by microarray data on 
IKBα and phospho IKBα obtained from whole lysated transfected cells. We also 
observed an increase on IKK complex levels in wild-type NOD2 after stimulation. 
This result could suggest that increased IKB kinase (IKK) levels were associated 
with a more active IKBα, implying a higher level of its phosphorylated form. 
Taking together all these findings, we could conclude that NF-κB activity was 
increased only in wild-type NOD2 cells after stimulation. 
A wider overview in NF-κB pathway in vitro was obtained by microarray analysis 
of nuclear extracts of both wild-type and mutated (p.E383K and p.R334W) 
NOD2. At basal level, RPPA data showed increased level of NF-κB and its 
phosphorylated form in p.R334W mutant compared to wild-type, while a similar 
or even decreased level of NF-κB and phospho NF-κB was seen in p.E383K 
mutant compared to wild-type protein. Addition of MDP to p.R334W NOD2 cells 
showed a similar or slightly higher level of NF-κB and phospho NF-κB compared 
to wild-type NOD2 cells. No increased levels of other pathway components were 
observed for p.E383K NOD2 cells. All these data suggested that at basal level 
p.E383K NOD2 cells did not present an increase of NF-κB activity, compared to 
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the wild-type. p.R334W mutated NOD2, instead, significantly increased the basal 
NF-κB activity compared to the wild-type, as similarly presented in previous 
studies in literature [43, 217]. In contrast, addition of MDP to p.R334W mutant 
further elevated the NF-κB activity up to almost the same level as the case of the 
wild-type NOD2. This data is comparable to the one referred to the same mutation 
reported by Kanazawa and colleagues [43]. In p.E383K mutant, NF-κB persisted 
to present a reduced activity compared to wild-type NOD2 after MDP stimulation.  
To verify the results concerning p.E383K mutation, we evaluated the pathway by 
means of lysate microarray ex vivo, using patients PBMC carrying this missense 
variation. The expression levels of phopho IKBα and phospho NF-κB, as well as 
IKK protein complex, were higher in patients than in controls, implying pathway 
activation. An increase on IKK levels were associated with a more active IKBα, 
as shown in the results. These ex vivo findings are opposite to the ones previously 
observed in vitro. It is possible that in vitro p.E383K mutants may need enhancer 
factors at genetic or protein levels, probably presented in patients cells, to increase 
the inflammatory response. From these results, HEK293 cells did not seem to be a 
good in vitro model for p.E383K mutation in Blau syndrome. Future studies could 
focus on the evaluation of different other cell lines for creating a better in vitro 
model. Given that NOD2 is naturally expressed in myelomonocytic cells, THP-1 
cells would be a good option [220]. THP-1 is a human monocytic cell line, able to 
differentiate in macrophages and perfect to study pro-inflammatory cytokines 
secretion and IL1β in primis, although these cells are known to be difficult to 
transfect. It would be interesting also to perform further ex vivo studies on 
different cell lineages other than PBMC, since NOD2 has also been detected in 
epithelial and vascular endothelial cells [59, 221]. Moreover, an ex vivo analysis 
of the pathway activation after pathogen stimulation should be performed.  
Following on from the previously presented results, we could also suggest that it 
was not only the HEK293 cell line that leads to the lack of NF-κB activity of 
p.E383K NOD2, but may be also the properties of this mutation itself. Since 
p.R334W NOD2 was shown to enhance the pathway in HEK293 cells, this 
perhaps suggests some differences in the behaviour of both mutants. This aspect 
could be worth analyzed in future. 
 
1.2 Cytokines profile 
We further investigated whether the presence of p.E383K mutation in NOD2 
would upregulate the pro-inflammatory cytokines production both in vitro and ex 
vivo. 
In vitro analysis on transfected cells evaluated only the production of IL8, since 
HEK293 cells secretes a limited set of inflammatory cytokines. The basal level of 
IL8 produced by p.E383K mutated cells were significantly lower than in wild-type 
cells. Stimulation with MDP leaded also to a less IL8 level in p.E383K compared 
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to wild-type. Observing these results, we can suppose that the lack of increase of 
pro-inflammatory cytokines in p.E383K NOD2 cells could be linked to the failed 
activation of the NF-κB pathway in these cells. Results from p.R334W mutated 
cells seemed to support this hypothesis. Even if there was not a significantly 
higher level of IL8 in absence of stimulation, in p.R334W NOD2 transfected cells 
IL8 production were slightly increased after stimulation with MDP compared to 
wild-type. 
Ex vivo data from patients PBMC and serum showed a similar trend for IL1β, IL6, 
IL8,TNFα and IFNγ production compared to healthy controls. 
PBMC and serum from Blau syndrome patients did not show higher basal 
production of pro-inflammatory cytokines, even if the concentration values were 
generally higher in serum samples. LPS or MDP stimulation in PBMC showed a 
similar or lower levels of these cytokines than in healthy controls. Furthermore, 
no synergistic cytokine release was observed in patients compared to controls 
when muramyldipeptide was used in combination with TLR agonist.  
All these observations were unexpected since BS is known to have an 
autoinflammatory nature due to its "gain-of-function" associated mutations. This 
hypothesis predicted that patients with Blau syndrome would spontaneously 
release more cytokines that could be transcriptionally up-regulated by NF-κB 
activity (such as IL1β). However, recent works in literature also observed no 
evidence of excess pro-inflammatory cytokines such as IL1β and TNFα in PBMC 
from Blau syndrome patients compared to healthy controls [222]. In addition to 
this, Son and collegues confirmed ex vivo that BS is not associated with increased 
basal levels of TNFα [223].  
Focusing on IL1β, its responses in PBMCs from subjects with Blau syndrome 
appeared to be slightly attenuated when compared with the responses in PBMCs 
from the control group, in presence or absence of stimulation. This suggests that 
an exaggerated NOD2 response leading to IL1β release is not a direct mechanism 
explaining the pathophysiology of Blau syndrome. IL1β blocking therapy seems 
not to be an eligible treatment for BS. In literature some authors report the use of 
biologic anti-cytokine agents such as infliximab, a TNFα inhibitor and anakinra, 
the IL1 receptor antagonist, but the results are variable, particularly with regard to 
ocular morbidity [53, 224]. 
Levels of the other cytokine measured in PBMC with NOD2 mutations were also 
not elevated. In patients serum we also evaluated the release of IL17, IL12, IL22 
and IL23 at basal condition. The high levels of IL17, IL22 and IL23 in BS 
patients suggested that they might play a significant role of in the pathogenesis of 
the disease. In literature, those cytokines are extensively studied in inflammatory 
conditions. IL17 is known to be an important proinflammatory cytokine 
upregulated in chronic inflammation [225]. IL23 has been shown to be necessary 
for the development and maintenance of certain inflammatory disease [226]. IL22 
has also a function in inflammation mediated by pathogens and recent data 
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suggested that it plays a role in human infection [203]. Their role in Blau 
syndrome could be deeply investigate.  
Our data for IL12 showed that the cytokine concentration significantly decrease in 
patients. This down-regulation of IL12 level could explain or be linked to the low 
level of IFNγ observed in BS patients. Since the interferon is known to be 
involved in granulomas formation and BS presents granulomatous features, IFNγ 
would be expected to be higher in Blau syndrome patients than in controls. 
Further investigations will be necessary to clarify this result. 
2 Evaluation of possible biomarkers in autoinflammatory 
diseases 
Despite major advances in genetics and pathophysiology in autoinflammatory 
diseases, not all patients show the expected clinical features or respond favourably 
to drugs, leading to a high morbidity in these diseases. 
In this context, the use of biomarkers can help improving the identification of 
autoinflammatory diseases and developing personalized or therapeutic strategies. 
Biomarkers are defined by the European Health Commission as “a characteristic 
that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention”. Their strength lies in providing an objective measure to assess 
disease severity, progression, risk, and survival. Identification of such pattern is a 
sizeable problem, but using an integrative approach to analyse a great number of 
possible biomarkers would represent an enormous advance in the diagnosis and/or 
profiling of disease. To enable this, microarray-based systems will be the high-
throughput assays for measuring cytokines or other serum proteins and signalling 
intermediates possibly associated to autoinflammatory diseases.  
 
2.1 Signalling intermediates 
Reverse phase protein microarray (RPPA) is a relatively new, sensitive and high 
throughput functional proteomic technology that offers many potential advantages 
over other current methods used to detect known protein markers such as Western 
blotting assay. The high sensitivity and miniaturized format of lysate microarray 
technology, makes it suitable for of large clinical trials where limited quantities of 
thousands of samples may need to be interrogated for the expression level of a 
defined set of protein markers. In this thesis work , RPPA was the eligible 
technique to study inflammatory signalling pathways in PBMC of different 
autoinflammatory diseases patients. Advantages of RPPA are the ability to 
provide a descriptive picture of the ongoing state of the signalling networks from 
different cellular samples, and also provide information about the post 
translational modifications such as phosphorylations that can not be provided 
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using gene study [227]. The success of RPPA experiments depends mainly on the 
presence of specific primary antibodies. Antibodies were selected for studying 
NF-κB, PI3K/Akt, MAPK, JAK/STAT and inflammasome signalling pathways in 
the different autoinflammatory diseases. 
Since a lot of data have been obtained for each disease, we focused on description 
of the proteins that better characterize each pathway in Behçet disease, Adult 
Onset Still disease, TRAPS, FMF and Blau syndrome. The other 
autoinflammatory syndrome patients (Schnitzel, MKD and NALP12 disease) 
were not statistically analyzed, due to the low number of patients enrolled for each 
disease. 
 
Behçet disease 
NF-κB is an important transcription factor that is necessary for the transcription of 
many genes involved in inflammatory and immune responses. Analysis of 
microarray data on NF-κB pathway for Behçet disease showed higher level of 
phospho NF-κB (active form of NF-κB) and other upstream component of the 
pathway in Behçet patients compared to healthy controls. We also noted that A20 
was upregulated in patients than in controls and this can reflect the effect of the 
higher level of NF-κB in patients. A20 is in fact an ubiquitin-editing enzyme 
expressed as a result of activation of NF-κB, even if it can also has a negative 
feedback on NF-κB activation.  
The role of PI3K/Akt in regulation of inflammatory process is well established, as 
several studies have demonstrated the role of PI3K/Akt in several inflammatory 
diseases such as rheumatoid arthritis, asthma, chronic obstructive 
pulmonarydisease, psoriasis, multiple sclerosis, and atherosclerosis. The results 
obtained from this study indicated higher levels of active Akt, phosphorylated at 
its key sites (Threonine 308 and Serine 473) and PI3K p85 in patients than in 
controls, indicating activation of this pathway. PI3K/Akt activation in turn 
activates the NF-κB pathway. So, the results obtained are consistent with the ones 
described previously.  
MAPK is an important inflammatory signalling pathway that regulates gene 
expression, cell survival, cell proliferation, and apoptosis. The high level of 
phospho ERK1/2 seen in patients PBMC in comparison to controls reflects the 
activation of this MAPK pathway in our cases of Behçet disease. Phospho HSP27 
level was higher in patients than in controls. In literature, it is reported that the 
level Hsp27 phosphorylation correlated also with ERK1/2 activation [228], 
confirming our results. 
The data obtained from STAT3/JAK2/c-Src pathway showed a higher level only 
of phospho STAT1 in patients than in control. No literature to date was found that 
correlate this finding with Behçet disease. However, it is known that STAT1 is a 
target gene of ERK1/2, central protein of the MAPK pathway previously 
described active in Behçet. Further analysis should be performed in order to 
understand better this datum.  
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The level of MyD88 was upregulated in patients than in controls. The 
upregulation of MyD88 may be related to activation of a TLR pathway. Future 
microarray studies should deeply analyze this pathway in Behçet disease. None of 
the components of inflammasome pathway analyzed were detected at a significant 
higher level in our cohort of Behçet disease patients. 
 
Adult Onset Still's disease (AOSD) 
NF-κB is considered to be the master regulator of both innate and adaptive 
immunity. Analysis of microarray data showed increased phospho NF-κB (active 
form) level in patients than in controls. High level of other upstream component 
of the pathway, in particular phospho IKBα, was seen in AOSD patients 
compared to healthy controls. The results also showed that increased IKB Kinase 
(IKK) levels were associated with more active IKBα (phosphorylated form). A20 
was upregulated in patients than in controls and this can reflect the effect of the 
higher level of NF-κB in patients, as previously explain for Behçet patients. The 
net results of investigating NF-κB signalling pathway demonstrated upregulation 
of this pathway in AOSD patients compared to controls. No data are available in 
literature to confirm our findings.  
PI3K/Akt pathway has a role in several complex inflammatory diseases. The 
results obtained from this study indicated higher levels of active Akt, 
phosphorylated at Threonine 308 residue, in patients than in controls. Upstream 
(PI3K p85 and PI3K p100a) and downstream (phospho Bad, phospho GSK-3b 
and phospho c-Raf) activators of Akt were also present at higher level in patients 
than in controls, indicating activation of this pathway. Since PI3K/Akt activation 
in turn activates the NF-κB pathway through phosphorylation of IKBα, the results 
are consistent with the ones described previously. The observation of high level in 
patients of phospho PTEN, known to inhibit PI3K and Akt signalling cascade, 
have to be deeply investigated. We could speculate that Akt pathway, due to the 
high level of most of the compounds, may be activated by alternative way rather 
than via PI3K.  
The upstream regulators of MAPK pathways such as TRAF2 and phospho 
MKK3/MKK6 were studied and found at higher level in patients. TRAF2 signals 
through MAPK induction, primarily through activation of JNK [229]. Level of 
phospho SAPK/JNK are higher in patients than in controls, leading to activation 
of this MAPK pathway. Higher level of MKK7, observed in AOSD patients, was 
also related to SAPK/JNK pathway activation. Phospho ATF2 level were higher 
in patients compared to controls. ATF2 is normally activated in response to 
signals that converge on JNK [230]. 
High level of phospho ERK1/2 was seen in AOSD patients PBMC in comparison 
to controls, underlining the activation of even this MAPK pathway. Higher level 
of phospho MEK1/2, observed in patients, was upstream related to ERK1/2 
MAPK pathway. 
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Concerning JAK/STAT/c-Src pathway in AOSD, we observed a higher level of 
phosho STAT3 and phospho c-Src in patients rather than in controls. The role of 
STAT3 as a mediator of inflammation is well documented in the literature, since 
its activation is promoted by pro-inflammatory agents as IL6 and TNFα, and there 
is a correlation between STAT3 pathway and NF-κB pathway. STAT3 is known 
to be a target of the non-receptor tyrosine kinase c-Src [231], so we can 
hypothesize that STAT3 may be activated by phosphorylation of c-Src in our 
patients. The high level of SOCS3 observed in patients deals with the activation 
of STAT3, since SOCS3 is a target protein of STAT3 signalling.  
Our results showed also higher level of MyD88 in AOSD patients than in 
controls. This finding may be related to the activation of a TLR pathway MyD88-
dependent. In literature, TLR7 MyD88-dependent signaling pathway is described 
to be involved in the pathogenesis of adult-onset Still's disease [232]. To confirm, 
future analysis could focus on this other pathway components.  
The inflammasome pathway related studies presented higher level of caspase1, 
cleaved caspase1, BCL2 and phospho BCL2 in patients compared to controls. The 
activation of caspase1 is the main downstream event in this pathway after 
inflammasome formation and it is responsible for increased IL1β production; 
furthermore, a higher concentration of IL1β was observed in our patients. BCL2 
activation is reported in literature to inhibit NALP1 inflammasome through 
inhibition of caspase1 activation in a concentration-dependent manner [233]. 
Further experiments should be performed in order to evaluate better NALP1 and 
maybe also NALP3 inflammasome related pathway, in order to understand the 
molecular cause of caspase1 activation in our patients. 
 
TNF-receptor associated periodic fever (TRAPS) 
Activation of NF-κB in TRAPS is a controversial issue as some investigators 
demonstrated reduction of the NF-κB signalling pathway upon expression of 
TRAPS-associated mutations, while others showed up-regulation [234, 235]. 
Shedding light on the activation status of NF-κB in TRAPS is an important goal 
in understanding the pathogenesis of the disease. Analysis of microarray data 
showed increased level of NF-κB and phospho NF-κB (active form) in patients 
compared to controls. Higher level of upstream component of the pathway, in 
particular phospho IKBα and IKK complex, was seen in patients rather than in 
controls. Increased IKB Kinase (IKK) levels was associated with more active 
IKBα (phosphorylated form).  
PI3K/Akt pathway has a main role in several inflammatory diseases. The results 
obtained from this study indicated higher levels of active Akt, phosphorylated at 
both the key residues (T308 and S473) in patients compared to controls. Studying 
the upper regulators of Akt (PI3K p85 and p100), the results demonstrated up 
regulation of both proteins in patients in comparison to controls, again indicating 
activation of the PI3K/Akt pathway. Higher level of the phosphorylated 
downstream activator GSK-3β in patients fits with the activation of Akt exposed 
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above. GSK-3β is important in improvement of NF-κB transcriptional activity and 
prevention of apoptosis. Since PI3K/Akt activation in turn activates the NF-κB 
pathway through phosphorylation of IKBα, the reported results are consistent with 
the ones described previously for NF-κB pathway. 
Two main MAPK pathways (ERK1/2 and SAPK/JNK) were up regulated in our 
cohort of TRAPS patients in comparisons to the controls. These results are in 
agreement with a study by Stjernberg-Salmela and colleagues who demonstrated 
low level of phospho P38 MAPK in leukocytes of patients carrying different 
TRAPS associated mutations [236]. Among the upstream stimulators of MAPK, 
TRAF2 was observed upregulated in patients. TRAF2 is known to activate NF-κB 
by interaction with IKK complex [237]. So, overexpression of TRAF2, as in our 
findings, may correlate with higher levels of NF-κB detected under the same 
conditions. The observed higher levels of MKK7 and phospho MEK1/2 in 
patients correlate with the activation of the two MAPK pathway, since their role 
as upstream activators. We also observed higher level of phospho ATF2 in 
patients, a target protein of the SAPK/JNK pathway. To warrant better 
understanding of this complex pathway, further studies on a bigger cohort of 
TRAPS patients have to be performed. 
The expression of phosphorylated Jak2 was higher in patients than in controls. 
Phosphorylated Jak2 is reported to activate phosphorylation of several 
downstream inflammatory signaling pathways and components, such as PI3K 
p85, NF-κB, MAPK and STATs [238]. Our results seem to present a similar 
activation trend, related to the observed activation of inflammatory pathways. 
Activated Jak2 also supports STAT3 phosphorylation. So, the high level of 
phospho Jak2 in patients was associated with the observed high level of STAT3 
and the related high level of SOCS3, target of STAT3. c-Src, an important 
activator of PI3K/Akt and NF-κB pathway mediated by TNF receptor 1 [239], 
was found upregulated in patients rather than in controls.  
Our results showed also higher level of MyD88 in TRAPS patients than in 
controls. This finding may be related to the activation of a TLR pathway MyD88-
dependent. Further investigation have to be performed, since TLR signalling can 
initiate production of ROS, which are known to be elevated in TRAPS patients 
[240]. 
The inflammasome related pathway analysis resulted on higher level of cleaved 
caspase1 and BCL-XL in patients compared to controls. The reason of the 
presence of activated form of caspase1 and its inhibitor in patients should be 
further evaluated.  
 
Familial Mediterranean Fever (FMF) 
Among all NF-κB pathway components studied in FMF patients, only IKKβ 
presented a higher level compared to controls. This could indicate that in our 
cohort of patients NF-κB pathway was not activated, unlike the literature data that 
displayed activation of NF-κB by N-terminal pyrin [241]. One possible 
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explanation of the different result in our cohort fits with the wide heterogeneityof 
FMF patients in analysis, also related to the mutations associated with the disease. 
Concerning the PI3K/Akt pathway, only the upstream activator PI3K p85 was 
shown with higher level in patients than in controls. This could mean that this 
pathway may be truncated at the beginning of the signalling cascade. This 
preliminary finding has to be confirmed. 
Our data on MAPK pathway showed higher level of phospho ERK1/2 and 
phospho SAPK/JNK in patients PBMC in comparison to controls. Finding a high 
level of phospho HSP27, known to be linked to the activation of ERK1/2, 
confirms the activation of ERK1/2 MAPK in our cohort. Related to the 
phosphorylation of SAPK/JNK, we could further study this MAPK signalling 
cascade in FMF evaluating other upstream and downstream regulators of this 
kinases.  
JAK/STAT/c-Src pathway analysis resulted with higher level of phosho c-Src in 
patients rather than in controls. To date, no study in literature presents an 
evaluation of this pathway in FMF. Future analysis should involved this pathway 
in a wider group of FMF patients.  
Our results concerning the inflammasome-related pathway showed a higher level 
of ASC, NALP1 and BCL-XL in patients than in controls. Upregulation of ASC 
at transcriptional level was also observed in a big cohort of FMF patients carrying 
different mutations [242]. Another study focused on the role of inflammasome in 
FMF using animal models. By generating pyrin-mB30·2knock-in mice in a 
background deficient in inflammasome components, Kastner and colleagues 
proved that the disease was dependent on caspase1, ASC and IL1 signalling but 
was independent of NLRP3, NLRC4 and AIM2 [243]. Our findings about ASC 
activation and also IL1β high concentration (presented below) may provide some 
evidences for the ASC-dependent NLRP3-independent inflammasome causing 
FMF, as reported in Kastner work. Further investigating in our cohort of patients 
may be helpful to elucidate inflammasome and FMF relation. The higher level of 
both NALP1 and its inhibitor BCL-XL in patients need to be better inquired, since 
it was the first time they were evaluated in FMF patients. 
 
Blau syndrome 
In addition to NF-κB pathway, we have also evaluated other signalling pathway in 
Blau syndrome patients. 
The results obtained from PI3K/Akt pathway study indicated higher levels of Akt 
phosphorylated at serine 473 in patients than in controls. This finding is consistent 
with the activation of the pathway. Moreover, an upstream regulator of Akt 
activation, PI3Kp85 were found with higher level in patients. Downstream Akt 
activators, phospho BAD and phospho GSK-3b, were higher in Blau patients than 
in controls. BAD is also a pro-apoptotic signalling molecule but when it is 
phosphorylated it loses this function. In literature a recent study on wild-type 
NOD2 presented that the PI3K/Akt pathway negatively regulates Nod2-mediated 
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NF-κB pathway [244]. Our data on patients carrying mutation p.E383K showed 
instead a positive correlation between these two pathways. Future analysis could 
deeply investigate this aspect.  
P38 MAPK pathway seems to be activated in Blau syndrome, due to the presence 
of higher level of phospho P38 in patients than in controls. The level of phospho 
HSP27 as a down regulator of phospho P38 MAPK was also observed higher in 
patients than in controls. HSP27 is known to be related to NF-ΚB activation, 
enhancing the proteolysis of phosphorylated IKBα [245].  
Analyzing the JAK/STAT/c-Src pathway, the only protein at higher level in 
patients was phospho STAT1. The biological activity of STAT1 correlated with 
pro-inflammatory and antiproliferative responses. In literature, we did not find to 
date any studies correlating the disease or NOD2 protein to this protein activated. 
Further investigation may be helpful to explain our result. Furthermore, none of 
the components of inflammasome pathway analyzed were detected at a significant 
higher level in our cohort of Blau syndrome patients. 
 
Looking at the heatmaps for the different signalling pathways, it is clear that all 
patient groups have raised the levels of signalling molecules compared to the 
control group. Moreover, the heatmaps (Fig. 45, 50, 56, 62 and 68) suggest that 
the patterns of the signalling compounds may relate also to individual patients. 
For example, in the TRAPS cohort, patient 39 has raised levels of signalling 
molecules across virtually all pathways, whereas patient 22 has relatively low 
levels across all pahways. Similar comparisons can be made in the other disease 
cohorts. In Behçet group, patient 7 presented a higher level of signalling 
molecules across all pathways, whereas both patients 27 and 28 showed relatively 
low levels across all pathways. In AOSD patient 13 the expression level of all 
signalling molecules evaluated raised up; for patients 19, 20 and 29, it was quite 
the contrary. In the FMF cohort, patient 6 has raised levels of all signalling 
molecules across the studied pathways, whereas patients 21 and 31 presented low 
levels.  
A possible explanation of this patient-related pattern for signalling pathways may 
lie in the peculiar characteristics of each subject, such as treatment type, disease 
activity or possible mutations. 
Concerning the TRAPS group, higher levels of all signalling molecules observed 
in patient 39 could be associated with the rare mutation p.D12E carried by this 
subject and found in few other cases in literature. This mutation is reported to be 
linked with complex symptoms [246], that may be related to the pathway 
activation observed in this work. We need more information about disease activity 
to confirm this hypotesis for patient 39. Lower levels of all signalling pathways 
compounds were observed in patient 22, similar to ones showed by healthy 
controls. This subject presents some polymorphisms in TNFRSF1A gene and no 
therapy. In this case, it would be useful to know the symptom presented by this 
patients, to infer if the clinical diagnosis was correct at the light of these results. 
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Regarding the Behçet group, there is not enough information about the patient 7 
to discriminate which one could be associated to the increased levels of all the 
pathways components. Then, we also observed low levels in patients 27 and 28, 
whose only peculiarity compared to other Behçet patients is belonging to the same 
family. Concerning the Still's group, the higher levels in all pathways observed in 
patient 13 could be related to the absence of treatment at the time. Further 
information about the disease characteristic needs to be collected, in order to 
understand whether the absence of therapy correlates with higher disease activity. 
In patients 19, 20 and 29, the observed lower levels of molecules in all pathways 
may be related to the treatment. These patients are female subjects treated with 
kineret (anti IL1ra), proven to be effective in a number of autoinflammatory 
diseases. Also in this case, additional information about disease activity could 
confirm the results. For the FMF group, there is not enough information about the 
patient 6 to discriminate which one could be associated to the increased levels of 
all the pathways components. The absence of treatment could maybe be related to 
these results, but activity disease information should be obtained to justify the 
hypothesis. Patients 21 and 31, instead, presented lower levels of compounds 
across all pathways. Since there are no clearly peculiar characteristics among the 
features collected for these patients, further information has to be gathered in 
order to understand if there are any clinical characteristics that may be linked to 
the results.  
It is clear that more information about disease activity, age of onset and other 
clinical features needs to be collected in future for all autoinflammatory patients 
involved in this studies, to understand better to what extent patients characteristics 
might be related with differences in signalling pathway activation. 
 
2.2 Cytokine profile 
Antibody microarray is a high throughput and sensitive technique, used in this 
work to study the cytokines and chemokines mainly presented in sera samples 
obtained from different autoinflammatory disease affected patients. Amplification 
was the main task for using this technique with serum samples. Due to the low 
abundance of some cytokines, an amplification method that balances signal to 
background had to be provided. Even though Genisphere Ultra Amp are 3DNA 
dendrimers customized with a variety of labels to increase the sensitivity, the 
simple Tyramide amplification provides a higher sensitivity with a lower 
background. A possible explanation deals with a longest application time and an 
increased number of steps the Genisphere technique required. This maybe 
increases the possibility of aspecific binding, leading to a higher background 
compared to Tyramide amplification.  
There are also high correlations between antibody microarray and ELISA, 
indicating that this microarray technique can potentially be used as a diagnostic 
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tool for quantification of specific antigen in clinical samples, especially if the 
sample amounts are limiting [70].  
Cytokines represent a group of important signalling molecules whose primary 
function dwells in immunomodulation of both innate and acquired immunity. The 
finely tuned network of cytokine signalling has been a subject of many 
investigations studies on autoinflammatory diseases. In particular, the pro-
inflammatory cytokines (IL1β, IL6, TNFα, IFNγ) are targeted for therapeutic 
intervention because of their role in promoting or sustaining harmful 
inflammation. Spreading the range of investigated cytokines to also IL8, IL12, 
IL17, IL22 and IL23, we would analyse the cytokinic profile of the different 
autoinflammatory diseases studied in this thesis. 
 
Behçet disease 
It is doubtless that cytokines play some crucial roles in the initiation and 
perpetuation of this disease. We showed a statistically higher level of IL8, IL17 
and IL22, along with a lower level of IL12. The upregulation of IL17 was already 
documented in literature [247], as well as the relation between IL8 and Behçet 
disease . IL8 was reported at higher level in active stage of BD in a number of 
studies thus far; Gür-Toy G et al. reported that the association of IL8 level with 
disease activity was better than that of acute phase ESR and CRP [186]. The 
extremely high level of IL22 may points to a possible role of this lymphokine in 
the pathogenesis of this disease, as suggested also by Cai and colleagues [248]. 
All the other evaluated cytokines have not statistically different levels from 
healthy controls. These results move away from literature, that described elevated 
levels of IL1β, IL6, IL12, TNFα [179]. Even IFNγ was highly expressed and 
considered an important mediator involved in the development of Behçet [249]. A 
possible explanation of these different results should be found in the small cohort 
of patients in analysis. The patients presented clinical and genetic differences and 
the most of them were under treatment at the time of the analysis. The therapy 
may have affected the cytokines' profile in those patients.  
 
Adult Onset Still disease (AOSD) 
The antibody microarray data showed higher level of all the cytokines and 
markers studied in patients compared to healthy controls. This is the first time to 
our knowledge that IL17, IL12, IL22 and IL23 are evaluated in AOSD patients. 
The elevated levels point to a possible role in the pathogenesis of this complex 
disease. In literature, elevated levels of proinflammatory cytokines such as IL1β, 
IL6, IL17, IL8, IL18, and TNFα were previously described in untreated AOSD 
patients, often in association with disease activity and/or distinct clinical 
phenotypes and serological features [36, 250]. Since half of our patients 
underwent to IL1β blocking treatment, our finding of elevated levels of 
proinflammatory cytokines (IL1β in primis) appear strange. To understand the 
data, we need further information, concerning how long patients were on therapy 
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and if the dosage is sufficient to give amelioration in their conditions. In fact, 
since disease severity varies significantly among affected individuals and, even, 
within the same individual, patients require continuous and aggressive 
immunomodulatory treatment. 
 
TNF-receptor associated periodic fever (TRAPS) 
The antibody microarray data were a mean of all data obtained from all TRAPS 
patients carrying different mutations. Interesting would be the analysis at 
cytokines levels for each mutation, if the cohort of patients had been more 
consistent. To a better analysis of the disease, future studies with a bigger cohort 
of patients will be performed. 
The data showed higher level of IL8, IL17, IL22, IL23, IFNγ and TNFα in 
patients compared to healthy controls. IL1β level was not increased, due to the 
fact that most of the patients are currently under IL1β blocking treatment 
(canakinumab or anakinra). IL8 and TNFα increased levels were also presented in 
literature for a mutation implied in TRAPS [251].  
The extremely high level of IL22 may points to a possible role of this cytokine in 
the systemic inflammation in the joints, skin and muscles, as suggested also by 
Nakamura and colleagues [252]. In literature, the role of IFNγ, IL17 and IL23 has 
not been investigated yet. Their upregulation may be correlated with the disease. 
 
Familial Mediterranean Fever (FMF) 
The antibody microarray data showed higher levels of IL1β, IL6, IL8, IL17, IL22 
and IL23 in patients compared to healthy controls. Most of the patients were 
under colchicine treatment. Haznedaroglu et al reported that IL17 levels were 
significantly higher in regularly treated FMF patients compared with healthy 
controls, as shown by our data [253]. Levels of IFNγ were higher in patients than 
in controls, as presented in literature by Köklü and colleagues. Moreover, they 
reported that colchicine did not affect circulating IFNγ levels [254]. Concerning 
IL6 and IL23, a study by Pamuk et al did not show any increase in the level of 
these cytokines in treated patients compared to controls, unlike our data [255]. 
The incredibly high level of IL22 may play a significant role in the pathogenesis 
of FMF, but there is no data in literature to confirm this finding. Then, it would be 
interesting to evaluate the cytokines secretion pre- and post- febrile attack, to 
assess any changes in the cytokinic profile. 
 
Summarizing, in Behçet disease only IL8, IL17 and IL22 are significantly raised, 
whereas in AOSD all the measured cytokines are significantly heightened. Most 
cytokines are raised in TRAPS or FMF, although not all significantly. For 
example, IL12 is slightly increased in FMF, even if not at significant level; 
instead, it is clearly not raised in TRAPS. Thus, we could argue that the cytokines 
analyzed in this work could help to distinguish the autoinflammatory diseases in 
term of number of cytokines raised, as follow: Behçet<TRAPS<FMF<AOSD. 
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This hypothesis needs to be sustained and validated by further studies including 
bigger samples size and different autoinflammatory diseases, such as CAPS and 
MKD. So, if confirmed, the evaluation of the number of raised cytokines could be 
a new way to stratify autoinflammatory diseases patients, maybe in borderline 
cases.  
Some considerations can be made observing the cytokine profile graphs across all 
the studied diseases (Fig. 73, 74, 75 and 76). The only cytokines significantly 
raised in all four autoinflammatory disorders (Behçet, TRAPS, FMF and AOSD) 
are IL8, IL17 and IL22. IL23 could be added at this list, even if it is not 
statistically significant in Behçet disease. What is particularly striking is the 
upregulation of IL17/22/23. This would clearly suggest an important role for 
Th17 or Th17-like cells in autoinflammatory diseases, since Th17 cells, which are 
directly involved in and mediate chronic inflammation, are characterized by the 
production IL17 and IL22 as well as the recruitment of neutrophils and other 
inflammatory cells. IL23, which promotes Th17 cell development as well as IL17 
and IL22, plays essential roles in various inflammatory diseases [256]. Targeting 
Th17 cells and their related cytokines (IL17/22/23) may be an effective 
therapeutic approach for autoinflammatory diseases in future. 
A linkage between Th17 cells and autoinflammatory diseases is discussed in 
literature on studies about cryopyrin-associated periodic syndromes, familial 
Mediterranean fever, Behçet and Adult onset Still's diseases. In gene-targeted 
mice expressing CAPS mutations, the inflammasome hyperactivation resulted 
from excess IL1β production potentiates Th17-dominant immune responses [257]. 
Ovadia and colleagues suggest the presence of a heightened Th17 response in 
FMF, related with frequent attacks and FMF genotype [258]. Upregulation of 
Th17 shows a correlation with Behçet [247] and Still's disease [225] progression. 
A better understanding of the involvement and possible pathogenic role of Th17 
cells in our group of autoinflammatory diseases requires, however, further 
investigation and a bigger cohort of patients. 
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CONCLUSIONS 
In conclusion, this is the first time that the mutation p.E383K in CARD15/NOD2 
associated with Blau syndrome has been functionally evaluated.  
According to our ex vivo and in vitro studies on cytokines levels, it seems that 
there is not a primary mediation of IL1β and other pro-inflammatory cytokines in 
Blau syndrome patients carrying p.E383K, with the exception of IL17, IL22 and 
IL23. The role of these Th17-related cytokines has to be deeply investigated. 
Concerning our in vitro and ex vivo data on NF-κB pathway, the reported 
contrasting results may indicate that this pathway activation should be regulated 
not only by NOD2 in carriers of p.E383K mutation. Further experiments need to 
be done in order to clarify these results, using different in vitro models. 
From the microarray studies on a wide range of autoinflammatory diseases, we 
can firstly conclude that both techniques (reverse phase protein array and antibody 
microarray) are valuable in studying signalling pathways, cytokines and other 
inflammatory markers. Moreover, they are sensitive and accurate in quantification 
of different regulatory proteins. 
When compared with healthy controls, the results led to the identification of 
raised levels of many of the tested signalling pathway components including NF-
κB, PI3K/Akt, MAPK, Jak2/STAT3/c-Src and inflammasome, and also of Th17-
related cytokines IL17/22/23. We acknowledge some limitations in these studies: 
(1) small samples size and (2) few information on disease activity and clinical 
parameters. However, this thesis work is the starting point for further biomarkers 
evaluation in autoinflammatory diseases, beginning from Th17 cells and their 
related cytokines. Analysis of the significant molecules from signalling pathways 
with biostatistical models will be required to generate specific diagnostic 
algorithms and to identify valuable biomarkers to be used as targets for specific 
therapeutic intervention.  
 
  
 146 
  
References 
147 
REFERENCES 
1- Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror 
autoinflammaticus: the molecular pathophysiology of autoinflammatory 
disease (*). Annu Rev Immunol. 2009;27:621-68 
2- McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade 
BW, Centola M, et al. Germline mutations in the extracellular domains of 
the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited 
autoinflammatory syndromes. Cell 1999;97(1):133-44 
3- Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory 
disease reloaded: a clinical perspective. Cell. 2010 Mar 19;140(6):784-90. 
4- McGonagle D, McDermott MF. A proposed classification of the 
immunological diseases. PLoS Med. 2006;3(8):e297 
5- Dinarello CA. Blocking interleukin-1β in acute and chronic 
autoinflammatory diseases. J Intern Med. 2011;269(1):16-28 
6- Grateau G, Hentgen V, Stojanovic KS, Jéru I, Amselem S, Steichen O. How 
should we approach classification of autoinflammatory diseases? Nat Rev 
Rheumatol. 2013 Oct;9(10):624-9 
7- Cantarini L, Rigante D, Brizi MG, Sebastiani GD, Lucherini OM, Galeazzi 
M et al. The laboratory approach in the diagnosis of systemic 
autoinflammatory diseases. Reumatismo 2011; 63(2):101–10 
8- The International FMF Consortium. Ancient missense mutations in a new 
member of the RoRet gene family are likely to cause familial Mediterranean 
fever. Cell 1997;90:797–807 
9- French FMF Consortium. A candidate gene for familial Mediterranean 
fever. Nat Genet. 1997;17(1):25-31 
10- Drenth JP. Mutations in the gene encoding mevalonate kinase cause hyper-
IgD and periodic fever syndrome. Nature Genet. 1999;22:178 
11- Houten SM, Kuis W, Duran M, de Koning TJ, van Royen-Kerkhof A, 
Romeijn GJ, et al. Mutations in MVK, encoding mevalonate kinase, cause 
hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet. 
1999;22(2):175-7 
12- Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. 
Mutation of a new gene encoding a putative pyrin-like protein causes 
familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat 
Genet. 2001;29(3):301-5 
13- Aksentijevich I, D Putnam C, Remmers EF, Mueller JL, Le J, Kolodner RD, 
et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations 
in North American patients and a new cryopyrin model. Arthritis Rheum. 
2007;56: 1273–85 
 148 
14- Jéru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-
Port-Lis M, et al. Mutations in NALP12 cause hereditary periodic fever 
syndromes. Proc Natl Acad Sci U S A. 2008;105(5):1614-9 
15- Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, 
Häfner R, et al. CARD15 mutations in Blau syndrome. Nature Genet. 
2001;29:19–20 
16- Punzi L, Gava A, Galozzi P, Sfriso P. Miscellaneous non-inflammatory 
musculoskeletal conditions. Blau syndrome. Best Pract Res Clin Rheumatol. 
2011;25(5):703-14 
17- de Koning HD, Bodar EJ, van der Meer JW, Simon A; Schnitzler Syndrome 
Study Group Schnitzler syndrome: beyond the case reports: review and 
follow-up of 94 patients with an emphasis on prognosis and treatment. 
Semin Arthritis Rheum. 2007;37(3):137-48 
18- Rossi-Semerano L, Koné-Paut I. Is Still's Disease an Autoinflammatory 
Syndrome? Int J Inflam. 2012;2012:480373 
19- Koné-Paut I, Sanchez E, Le Quellec A, Manna R, Touitou I. 
Autoinflammatory gene mutations in Behçet's disease. Ann Rheum Dis. 
2007;66(6):832-4 
20- Cantarini L, Vitale A, Lucherini OM, Muscari I, Magnotti F, Brizi G, et al. 
Childhood versus adulthood-onset autoinflammatory disorders: myths and 
truths intertwined.Reumatismo. 2013;65(2):55-62 
21- Aksentijevich I and Kastner DL. Genetics of monogenic autoinflammatory 
diseases: past successes, future challenges. Nat Rev Rheumatol. 
2011;7:469-78 
22- Kastner DL. Familial Mediterranean fever: the genetics of inflammation. 
Hosp Pract 1998;33:131–349–40, 43–46 passim 
23- Akarsu AN, Saatci U, Ozen S, Bakkaloglu A, Besbas N, Sarfarazi M. 
Genetic linkage study of familial Mediterranean fever (FMF) to 16p13.3 
and evidence for genetic heterogeneity in the Turkish population. J Med 
Genet. 1997;34(7):573-8 
24- Gershoni-Baruch R, Broza Y, Brik R. Prevalence and significance of 
mutations in the familial Mediterranean fever gene in Henoch-Schönlein 
purpura. J Pediatr. 2003;143(5):658-61 
25- Yu JW, Wu J, Zhang Z, Datta P, Ibrahimi I, Taniguchi S, et al. Cryopyrin 
and pyrin activate caspase-1, but not NF-κB, via ASC oligomerization. Cell 
Death Differ. 2006;13:236–49 
26- Ter Haar N, Lachmann H, Özen S, Woo P, Uziel Y, Modesto C, et al. 
Treatment of autoinflammatory diseases: results from the Eurofever 
Registry and a literature review. Ann Rheum Dis. 2013;72(5):678-85 
27- Kuijk LM, Beekman JM, Koster J, Waterham HR, Frenkel J, Coffer PJ. 
HMG-CoA reductase inhibition induces IL-1β release through 
Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 2008;112:3563–73 
References 
149 
28- Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM, 
et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging 
concepts of an autoinflammatory disorder. Medicine 2002;81, 349–68 
29- Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, et al. The 
tumor-necrosis-factor receptorassociated periodic syndrome: new mutations 
in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence 
for further genetic heterogeneity of periodic fevers. Am J Hum Genet 
2001;69:301–14 
30- Stojanov S, McDermott MF. The tumour necrosis factor receptor-associated 
periodic syndrome: current concepts. Expert Rev Mol Med. 2005;7(22):1-18 
31- Todd I, Radford PM, Daffa N, Bainbridge SE, Powell RJ, Tighe PJ. Mutant 
tumor necrosis factor receptor associated with tumor necrosis factor 
receptor-associated periodic syndrome is altered antigenically and is 
retained within patients' leukocytes. Arthritis Rheum. 2007;56(8):2765-73 
32- Nedjai B, Hitman GA, Church LD, Minden K, Whiteford ML, McKee S, et 
al. Differential cytokine secretion results from p65 and c-Rel NF-κB subunit 
signaling in periperal blood mononuclear cells of TNF receptor-associated 
periodic syndrome patients. Cell Immunol. 2011;268(2):55-9 
33- Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, et al. The 
NLR gene family: a standard nomenclature. Immunity 2008;28(3):285-7 
34- Strowig T, Henao-Mejia J, Elinav E and Flavell R. Inflammasomes in health 
and disease. Nature 2012;481:278–86 
35- Ryan JG, de Koning HD, Beck LA, Booty MG, Kastner DL, Simon A. IL-1 
blockade in Schnitzler syndrome: ex vivo findings correlate with clinical 
remission. J Allergy Clin Immunol 2008;121:260–2 
36- Chen DY, Lan JL, Lin FJ and Hsieh TY. Proinflammatory cytokine profiles 
in sera and pathological tissues of patients with active untreated adult onset 
still's disease. J Rheumatol 2004;31(11):2189–98 
37- Efthimiou P, Moorthy LN, Mavragani CP, Skokos D and Fautrel B. Adult 
Onset Still's Disease and Autoinflammation. Int J Inflam. 
2012;2012:964751 
38- Touitou I, Magne X, Molinari N, Navarro A, Quellec AL, Picco P et al. 
MEFV mutations in Behçet's disease. Hum Mutat. 2000;16(3):271-2 
39- Atagundunz P, Ergun T, Direskeneli H. MEFV mutations are increased in 
Behçet's disease (BD) and are associated with vascular involvement. Clin 
Exp Rheumatol 2003;21(Suppl 30):S35–S37 
40- Amoura Z, Dodé C, Hue S, Caillat-Zucman S, Bahram S, Delpech M et al. 
Association of the R92Q TNFRSF1A mutation and extracranial deep vein 
thrombosis in patients with Behçet's disease. Arthritis Rheum. 
2005;52(2):608-11 
41- Blau EB. Familial granulomatous arthritis, iritis, and rash. J Pediatr. 
1985;107(5):689-93. 
 150 
42- Tromp G, Kuivaniemi H, Raphael S, Ala-Kokko L, Christiano A, Considine 
E et al. Genetic linkage of familial granulomatous inflammatory arthritis, 
skin rash, and uveitis to chromosome 16. Am J Hum Genet 1996;59:1097–
107 
43- Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, 
Nagai S et al. Early-onset sarcoidosis and CARD15 mutations with 
constitutive nuclear factor kappa B activation: common genetic etiology 
with Blau syndrome. Blood 2005;105:1195-7 
44- Rosé CD, Doyle TM, McIlvain-Simpson G, Coffman JE, Rosenbaum JT, 
Davey MP et al. Blau syndrome mutation of CARD15/NOD2 in sporadic 
early onset granulomatousarthritis. J Rheumatol 2005;32:373-5 
45- Milman N, Ursin K, Rødevand E, Nielsen FC, Hansen TV. A novel 
mutation in the NOD2 gene associated with Blau syndrome: a Norwegian 
family with four affectedmembers. Scand J Rheumatol 2009;38:190-7 
46- Gattorno M, Federici S, Pelagatti MA, Caorsi R, Brisca G, Malattia C et al. 
Diagnosis and management of autoinflammatory diseases in childhood. J 
Clin Immunol 2008;28:S73–83 
47- Masel G, Halbert A. Blau syndrome presenting with ichthyosis. Australas J 
Dermatol 2005;46:29-32 
48- Alonso D, Elgart GW, Schachner LA. Blau syndrome: a new kindred. J Am 
Acad Dermatol 2003;49:299-302 
49- Manouvrier-Hanu S, Puech B, Piette F, Boute-Benejean O, Desbonnet A, 
Duquesnoy B, et al. Blau syndrome of granulomatous arthritis, iritis, and 
skin rash: a new family and review of the literature. Am J Med Genet 
1998;76:217-21 
50- Kurokawa T, Kikuchi T, Ohta K, Imai H, Yoshimura N. Ocular 
manifestations in Blau syndrome associated with a CARD15/Nod2 
mutation. Ophthalmology 2003;110:2040-4 
51- Saini SK, Rose CD. Liver involvement in familial granulomatous arthritis 
(Blau syndrome). J Rheumatol 1996;23:396-9 
52- Ting SS, Ziegler J, Fischer E. Familial granulomatous arthritis (Blau 
syndrome) with granulomatous renal lesions. J Pediatr 1998;133:450-2 
53- Milman N, Andersen CB, Hansen A, van Overeem Hansen T, Nielsen FC, 
Fledelius H, et al. Favourable effect of TNF-alpha inhibitor (infliximab) on 
Blau syndrome in monozygotic twins with a de novo CARD15 mutation. 
APMIS 2006;114:912-9 
54- Rosé CD, Aróstegui JI, Martin TM, Espada G, Scalzi L, Yagüe J, et al. 
NOD2-associated pediatric granulomatous arthritis, an expanding 
phenotype: study of an international registry and a national cohort in Spain. 
Arthritis Rheum 2009;60: 1797-803 
55- Kanazawa N, Matsushima S, Kambe N, Tachibana T, Nagai S, Miyachi Y. 
Presence of a sporadic case of systemic granulomatosis syndrome with a 
CARD15 mutation. J Invest Dermatol 2004;122:851-2 
References 
151 
56- van Duist MM, Albrecht M, Podswiadek M, Giachino D, Lengauer T, Punzi 
L, et al. A new CARD15 mutation in Blau syndrome. Eur J Hum Genet. 
2005;13(6):742-7 
57- Albrecht M, Lengauer T, Schreiber S. Disease-associated variants in 
PYPAF1 and NOD2 result in similar alterations of conserved sequence. 
Bioinformatics 2003;19:2171-5 
58- Tada H, Aiba S, Shibata K, Ohteki T, Takada H. Synergistic effect of Nod1 
and Nod2 agonists with toll-like receptor agonists on human dendritic cells 
to generate interleukin-12 and T helper type 1 cells. Infect Immun 
2005;73:7967-76 
59- Ogura Y, Lala S, Xin W, Smith E, Dowds TA, Chen FF, et al. Expression of 
NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 2003;52:1591-7 
60- Barnich N, Aguirre JE, Reinecker HC, Xavier R, Podolsky DK. Membrane 
recruitmentof NOD2 in intestinal epithelial cells is essential for nuclear 
factor-{kappa}B activation in muramyl dipeptide recognition. J Cell Biol 
2005;170:21-6 
61- Strober W, Murray PJ, Kitani A, Watanabe T. Signaling pathways and 
molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006;6:9–20 
62- Chen G, Shaw MH, Kim YG, Nuñez G. NOD-like receptors: role in innate 
immunityand inflammatory disease. Annu Rev Pathol 2009;4:365-98 
63- Zurek B, Proell M, Wagner RN, Schwarzenbacher R, Kufer TA. Mutational 
analysisof human NOD1 and NOD2 NACHT domains reveals different 
modes of activation.Innate Immun 2012;18:100-11 
64- Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, et al. Host 
recognitionof bacterial muramyl dipeptide mediated through NOD2. 
Implications forCrohn's disease. J Biol Chem 2003;278:5509-12. 
65- Ferwerda G, Girardin SE, Kullberg BJ, Le Bourhis L, de Jong DJ, 
Langenberg DM, et al. NOD2 and toll-like receptors are nonredundant 
recognition systems of Mycobacterium tuberculosis. PLoS Pathog 
2005;1:279-85 
66- Divangahi M, Mostowy S, Coulombe F, Kozak R, Guillot L, Veyrier F, et 
al. NOD2-deficient mice have impaired resistance to Mycobacterium 
tuberculosis infection through defective innate and adaptive immunity. J 
Immunol 2008;181:7157-65 
67- Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, et al. 
Activation of innate immune antiviral responses by Nod2. Nat Immunol 
2009;10:1073-80 
68- Travassos LH, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhães 
JG, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the 
plasma membrane at the site of bacterial entry. Nat Immunol 2010;11:55-62 
69- Rodríguez-Pérez N, Aguinaga-Barrilero A, Gorroño-Echebarría MB, Pérez-
Blas M, Martín-Villa JM. Blau syndrome-related CARD15/NOD2 
 152 
mutations are not linked to idiopathic uveitis in Spanish patients. Dis 
Markers 2009;27:1-5 
70- Tighe P, Negm O, Todd I, Fairclough L. Utility, reliability and 
reproducibility of immunoassay multiplex kits. Methods 2013;61(1):23-9 
71- MacBeath G, Schreiber SL. Printing proteins as microarrays for 
highthroughput function determination. Science 2000;289(5485):1760-3 
72- Spurrier B, Honkanen P, Holway A, Kumamoto K, Terashima M, 
Takenoshita S, et al. Protein and lysate array technologies in cancer 
research. Biotechnol Adv 2008;26(4):361-9 
73- Ekins RP. Ligand assays: from electrophoresis to miniaturized microarrays. 
Clin Chem 1998;44(9):2015–30 
74- Mendoza LG, McQuary P, Mongan A, Gangadharan R, Brignac S, Eggers 
M. High-throughput microarray-based enzyme-linked immunosorbent assay 
(ELISA). Biotechniques 1999;27(4)778–80, 782–6,788 
75- Paweletz CP, Liotta LA, Petricoin EF, 3rd. New technologies for biomarker 
analysis of prostate cancer progression: Laser capture microdissection and 
tissue proteomics. Urology 2001;57(4 Suppl 1):160-3 
76- Sreekumar A, Nyati MK, Varambally S, Barrette TR, Ghosh D, Lawrence 
TS, et al. Profiling of cancer cells using protein microarrays: discovery of 
novel radiation-regulated proteins. Cancer Res 2001;61(20):7585-93 
77- Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton 
S, et al. Tissue microarrays for high-throughput molecular profiling of 
tumor specimens. Nat Med 1998;4(7):844-7 
78- Lal SP, Christopherson RI, dos Remedios CG. Antibody arrays: an 
embryonic but rapidly growing technology. Drug Discov Today 2002;7(18 
Suppl):S143-9 
79- Chang TW. Binding of cells to matrixes of distinct antibodies coated on 
solid surface. J Immunol Methods 1983;65(1–2):217–23 
80- Kusnezow W, Banzon V, Schröder C, Schaal R, Hoheisel JD, Rüffer S, et 
al. Antibody microarray-based profiling of complex specimens: systematic 
evaluation of labeling strategies. Proteomics 2007;7(11):1786–99 
81- Varnum SM, Woodbury RL, Zangar RC. A protein microarray ELISA for 
screening biological fluids. Methods Mol Biol 2004;264:161-72 
82- Haab BB, Dunham MJ and Brown PO. Protein microarrays for highly 
parallel detection and quantitation of specific proteins and antibodies in 
complex solutions. Genome Biol. 2001;2(2):RESEARCH0004 
83- Huang RP, Huang R, Fan Y, Lin Y. Simultaneous detection of multiple 
cytokines from conditioned media and patient’s sera by an antibody-based 
protein array system. Anal Biochem 2001;294(1):55-62 
84- Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, et al. Use 
of reverse phase protein microarrays and reference standard development 
for molecular network analysis of metastatic ovarian carcinoma. Mol Cell 
Proteomics 2005;4(4):346-55 
References 
153 
85- Ekins RP. Multi-analyte immunoassay. J Pharm Biomed Anal 
1989;7(2):155-68 
86- Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, et al. 
Protein microarrays: meeting analytical challenges for clinical applications. 
Cancer Cell 2003;3(4):317-25 
87- Espina V, Woodhouse EC, Wulfkuhle J, Asmussen HD, Petricoin EF 3rd, 
Liotta LA. Protein microarray detection strategies: focus on direct detection 
technologies. J Immunol Methods 2004;290(1-2):121-33 
88- Celis JE, Gromov P. Proteomics in translational cancer research: toward an 
integrated approach. Cancer Cell 2003;3(1):9-15 
89- Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 
2001;411(6835):355-65 
90- Angenendt P, Glökler J, Murphy D, Lehrach H, Cahill DJ. Toward 
optimized antibody microarrays: a comparison of current microarray 
support materials. Anal Biochem. 2002;309(2):253-60. 
91- Zhu H, Bilgin M, Bangham R, Hall D, Casamayor A, Bertone P, et al. 
Global analysis of protein activities using proteome chips. Science 2001; 
293(5537):2101-5 
92- Espina V, Mehta AI, Winters ME, Calvert V, Wulfkuhle J, Petricoin EF 3rd, 
et al. Protein microarrays: molecular profiling technologies for clinical 
specimens. Proteomics 2003;3(11):2091-100 
93- Ambroz KL, Zhang Y, Schutz-Geschwender A, Olive DM. Blocking and 
detection chemistries affect antibody performance on reverse phase protein 
arrays. Proteomics 2008;8(12):2379-83 
94- Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter 
deposition, a novel method of signal amplification. Application to 
immunoassays. J Immunol Methods 1989;125(1-2):279-85 
95- Bobrow MN, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a 
novel method of signal amplification. II. Application to membrane 
immunoassays. J Immunol Methods 1991;137(1):103-12 
96- Mora JR, Zielinski TL, Nelson BP, Getts RC. Protein detection enhanced by 
3DNA dendrimer signal amplification. Biotechniques 2008;44(6):815-8 
97- Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie 
JW, et al. Reverse phase protein microarrays which capture disease 
progression show activation ofpro-survival pathways at the cancer invasion 
front. Oncogene 2001;20(16):1981-9 
98- Charboneau L, Tory H, Chen T, Winters M, Petricoin EF 3rd, LiottaLA, et 
al. Utility of reverse phase protein arrays: applicationsto signalling 
pathways and human body arrays. Brief Funct Genomic Proteomic 
2002;1(3):305-15 
99- Ekins R, Chu F, Biggart E. Fluorescence spectroscopy and its application to 
a new generation of high sensitivity, multi-microspot, multianalyte, 
immunoassay. Clin Chim Acta 1990;194(1):91-114 
 154 
100- Dupuy L, Gauthier C, Durand G, Musnier A, Heitzler D, Herledan A, et al. 
A highly sensitive near-infrared fluorescent detection method to analyze 
signalling pathways by reverse-phase protein array. Proteomics 
2009;9(24):5446-54 
101- Savic S, Dickie LJ, Wittmann M, McDermott MF. Autoinflammatory 
syndromes and cellular responses to stress: pathophysiology, diagnosis and 
new treatment perspectives. Best Pract Res Clin Rheumatol 2012;26(4):505-
33 
102- Heymann MC, Rösen-Wolff A. Contribution of the inflammasomes to 
autoinflammatory diseases and recent mouse models as research tools. Clin 
Immunol 2013;147(3):175-84 
103- Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role 
in innate and adaptive immunity. Trends Immunol 2004;25(6):280-8 
104- Mercurio F, Manning AM. Multiple signals converging on NFkappaB. Curr 
Opin Cell Biol 1999;11(2):226-32 
105- Beg AA, Baldwin AS Jr. The I kappa B proteins: multifunctional regulators 
of Rel/NF-kappa B transcription factors. Genes Dev 1993;7(11):2064-70 
106- Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control 
of NF-[kappa]B activity. Annu Rev Immunol 2000;18:621-63 
107- Häcker H, Karin M. Regulation and function of IKK and IKK-related 
kinases. Sci STKE. 2006;2006(357):re13 
108- Bonizzi G, Bebien M, Otero DC, Johnson-Vroom KE, Cao Y, Vu D, et al. 
Activation of IKKalpha target genes depends on recognition of specific 
kappaB binding sites by RelB:p52 dimers. Embo J 2004;23(21):4202-10 
109- Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 
2004;18(18):2195-224 
110- Tanabe T, Chamaillard M, Ogura Y, Zhu L, Qiu S, Masumoto J, et al. 
Regulatory regions and critical residues of NOD2 involved in muramyl 
dipeptide recognition. EMBO J 2004;23:1587–97 
111- Barnich N, Hisamatsu T, Aguirre JE, Xavier R, Reinecker HC, Podolsky 
DK. GRIM-19 interacts with nucleotide oligomerization domain 2 and 
serves as downstream effector of anti-bacterial function in intestinal 
epithelial cells. J Biol Chem 2005;280:19021–6 
112- Magalhaes JG, Lee J, Geddes K, Rubino S, Philpott DJ, Girardin SE. 
Essential role of Rip2 in the modulation of innate and adaptive immunity 
triggered by Nod1 and NOD2 ligands. Eur J Immunol 2011;41:1445–55 
113- Kobayashi K, Inohara N, Hernandez LD, Galan JE, Nunez G, Janeway CA, 
et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate 
and adaptive immune systems. Nature 2002;416:194–9 
114- Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 
through disruption of ubiquitin enzyme complexes. Science 
2010;327(5969):1135-9 
References 
155 
115- Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. 
Cellular function of phosphoinositide 3-kinases: implications 
fordevelopment, homeostasis, and cancer. Annu Rev Cell Dev Biol 
2001;17:615-75 
116- Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway 
in human cancer. Nat Rev Cancer 2002;2(7):489-501 
117- Coughlin SR, Escobedo JA, Williams LT. Role of phosphatidylinositol 
kinase in PDGF receptor signal transduction. Science 1989;243(4895):1191-
4 
118- Yu J, Wjasow C, Backer JM. Regulation of the p85/p110alpha 
phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and 
cterminal SH2 domains. J Biol Chem 1998;273(46):30199-203 
119- Kapeller R, Cantley LC. Phosphatidylinositol 3-kinase. Bioessays 
1994;16(8):565-76 
120- Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator 
ofoncogenic signaling. Cancer Treat Res 2003;115:145-67 
121- Li J, Yen C, Liaw D, Bose S, Wang SI, Puc J, et al. PTEN, a putative 
protein tyrosinephosphatase gene mutated in human brain, breast, and 
prostatecancer. Science 1997;275(5308):1943-7 
122- Sable CL, Filippa N, Hemmings B, Van Obberghen E. cAMPstimulates 
protein kinase B in a Wortmannin-insensitive manner. FEBS Lett 
1997;409(2):253-7 
123- Konishi H, Tanaka M, Takemura Y, Matsuzaki H, Ono Y, Kikkawa U, et al. 
Activation of protein kinase C by tyrosinephosphorylation in response to 
H2O2. Proc Natl Acad Sci U S A 1997;94(21):11233-7 
124- Liao Y and Hung MC. Physiological regulation of Akt activity and stability. 
Am J Transl Res 2010;2(1):19–42 
125- Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-
kappaB activation by tumour necrosis factor requires the Aktserine-
threonine kinase. Nature 1999;401(6748):82-5 
126- Pastorino JG, Tafani M, Farber JL. Tumor necrosis factor induces 
phosphorylation and translocation of BAD through a phosphatidyl inositide-
3-OH kinase-dependent pathway. J Biol Chem 1999;274(27):19411-6 
127- Foster JG, Blunt MD, Carter E, Ward SG. Inhibition of PI3K signaling 
spurs new therapeutic opportunities in inflammatory/autoimmune diseases 
and ematological malignancies. Pharmacol Rev 2012;64(4):1027-54 
128- Patel RK, Mohan C. PI3K/AKT signaling and systemic autoimmunity. 
Immunol Res 2005;31(1):47-55 
129- Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, 
Bolon B, et al. Function of PI3Kgamma inthymocyte development, T cell 
activation, and neutrophil migration. Science 2000;287(5455):1040-6 
 156 
130- Di Lorenzo A, Fernandez-Hernando C, Cirino G, Sessa WC. Akt1 iscritical 
foracute inflammation and histamine-mediated vascular leakage. Proc Natl 
Acad Sci U S A 2009;106(34):14552-7 
131- Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinasesignal 
transduction pathways activated by stress and inflammation. Physiol Rev 
2001;81(2):807-69 
132- Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase 
cascades. Adv Cancer Res 1998;74:49-139 
133- Freed E, Symons M, Macdonald SG, McCormick F, Ruggieri R. Binding of 
14-3-3 proteins to the protein kinase Raf and effects on itsactivation. 
Science 1994;265(5179):1713-6 
134- Hallberg B, Rayter SI, Downward J. Interaction of Ras and Raf in 
intactmammalian cells upon extracellular stimulation. J Biol Chem 
1994;269(6):3913-6 
135- Khokhlatchev AV, Canagarajah B, Wilsbacher J, Robinson M, Atkinson M, 
Goldsmith E, et al. Phosphorylation of the MAPkinase ERK2 promotes its 
homodimerization and nuclear translocation. Cell 1998;93(4):605-15 
136- Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein 
kinase: conservation of a three-kinase module from yeast to human. Physiol 
Rev 1999;79(1):143-80 
137- Chen RH, Abate C, Blenis J. Phosphorylation of the c-Fostransrepression 
domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 
kinase. Proc Natl Acad Sci U S A 1993;90(23):10952-6 
138- Han J, Lee JD, Tobias PS, Ulevitch RJ. Endotoxin induces rapidprotein 
tyrosine phosphorylation in 70Z/3 cells expressing CD14. J Biol Chem 
1993;268(33):25009-14 
139- Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, et al. Pro-
inflammatory cytokines and environmental stress cause p38 mitogen-
activated protein kinase activation by dual phosphorylation on tyrosine and 
threonine. J Biol Chem 1995;270(13):7420-6 
140- Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, et 
al. Essential function for the kinaseTAK1 in innate and adaptive immune 
responses. Nat Immunol 2005;6(11):1087-95 
141- Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen- and stressactivated 
protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, 
and may mediate activation of CREB. EMBO J 1998;17(15):4426-41 
142- Juretic N, Santibanez JF, Hurtado C, Martinez J. ERK 1,2 and p38 pathways 
are involved in the proliferative stimuli mediated by urokinase in 
osteoblastic SaOS-2 cell line. J Cell Biochem 2001;83(1):92-8 
143- Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin 
and hyperosmolarity in mammalian cells. Science 1994;265(5173):808-11 
References 
157 
144- Kyriakis JM, Avruch J. pp54 microtubule-associated protein 2 kinase. A 
novel serine/threonine protein kinase regulated by phosphorylation and 
stimulated by poly-L-lysine. J Biol Chem 1990;265(28):17355-63 
145- Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin 
Genet Dev 2002;12(1):14-21 
146- Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev 
Immunol 1998;16:293-322 
147- Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling 
through the JAK/STAT pathway, recent advances and future challenges. 
Gene 2002;285(1-2):1-24 
148- Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001;2(6):467-75 
149- Ihle J. Pathways in cytokine regulation of hematopoiesis. Ann N Y Acad Sci 
2001;938:129-30 
150- Yi T, Mui AL, Krystal G, Ihle JN. Hematopoietic cell phosphatase 
associates with the interleukin-3 (IL-3) receptor beta chain and 
downregulates IL-3-induced tyrosine phosphorylation and mitogenesis. Mol 
Cell Biol 1993;13(12):7577-86 
151- Chen XP, Losman JA, Rothman P. SOCS proteins, regulators of 
intracellular signaling. Immunity 2000;13(3):287-90 
152- Lee C, Piazza F, Brutsaert S, Valens J, Strehlow I, Jarosinski M, et al. 
Characterization of the Stat5 protease. J Biol Chem 1999;274(38):26767-75 
153- Somani AK, Bignon JS, Mills GB, Siminovitch KA, Branch DR. Src kinase 
activity is regulated by the SHP-1 protein-tyrosine phosphatase. J Biol 
Chem 1997;272(34):21113-9 
154- Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform 
triggering activation of inflammatory caspases and processing of proIL-
beta. Mol Cell 2002;10:417–26 
155- Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the 
body. Annu Rev Immunol 2009;27:229–65 
156- Kovarova M, Hesker PR, Jania L, Nguyen M, Snouwaert JN, Xiang Z, et al. 
NLRP1-dependent pyroptosis leads to acute lung injury and morbidity in 
mice. J Immunol 2012;189:2006-16 
157- Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, et 
al. The AIM2 inflammasome is essential for host defense against cytosolic 
bacteria and DNA viruses. Nat Immunol 2010;11:395-402 
158- Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated 
uric acid crystals activate the NALP3 inflammasome. Nature 
2006;440:237–41 
159- Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et 
al. The NALP3 inflammasome is involved in the innate immune response to 
amyloid-beta. Nat Immunol 2008;9:857-65 
160- Jiang Y, Wang M, Huang K, Zhang Z, Shao N, Zhang Y, et al., Oxidized 
low-density lipoprotein induces secretion of interleukin-1beta by 
 158 
macrophages via reactive oxygen species-dependent NLRP3inflammasome 
activation. Biochem Biophys Res Commun 2012;25:121-6 
161- Vajjhala PR, Mirams RE, Hill JM. Multiple binding sites on the pyrin 
domain of ASC protein allow self-association and interaction with NLRP3 
protein. J Biol Chem 2012;287:41732–43 
162- Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of 
IL-1 in monogenic autoinflammatory diseases and implications for common 
illnesses. J Allergy Clin Immunol 2009;124:1141-9 
163- Ozkurede VU, Franchi L. Immunology in clinic review series; focus on 
autoinflammatory diseases: role of inflammasomes in autoinflammatory 
syndromes. Clin Exp. Immunol 2012;167:382-90 
164- Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, et 
al., Interleukin-1 receptor antagonist activity of a human interleukin-1 
inhibitor. Nature 1990;343:336-40 
165- Doherty TA, Brydges SD, Hoffman HM. Autoinflammation: translating 
mechanism to therapy. J Leukoc Biol 2011;90:37-47 
166- Tschopp J, Schroder K. NLRP3 inflammasome activation: The convergence 
of multiple signalling pathways on ROS production? Nat Rev Immunol 
2010;10(3):210-5 
167- Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, Sims JE. Four 
new members expand the interleukin-1 superfamily. J Biol Chem 
2000;275:1169–75 
168- Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et 
al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-
related protein ST2 and induces T helper type 2-associated cytokines. 
Immunity 2005;23:479–90. 
169- Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 
1996;87:2095–147 
170- Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 
2005;201:1355–9 
171- Dinarello CA. Immunological and inflammatory functions of the 
interleukin-1 family. Annu Rev Immunol 2009;27:519–50 
172- Hacham M, Argov S, White RM, Segal S, Apte RN. Distinct patterns of IL-
1 alpha and IL-1 beta organ distribution—a possible basis for organ 
mechanisms of innate immunity. Adv Exp Med Biol 2000;479:185–202 
173- Steinman RM. Cytokines amplify the function of accessory cells. Immunol 
Lett 1988;17:197–202 
174- Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. 
NALP3 forms an IL-1beta-processing inflammasome with increased 
activity in Muckle-Wells autoinflammatory disorder. Immunity 
2004;20(3):319-25 
175- Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of 
cytokines and gp130. Blood 1995;86:1243–54 
References 
159 
176- Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy 
KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a 
lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 
2005;6:1123–32 
177- Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. 
Reciprocal developmental pathways for the generation of pathogenic 
effector TH17 and regulatory T cells. Nature 2006;441:235–8 
178- Ovadia A, Livneh A, Feld O, Ben-Zvi I, Kukuy E, Kivity S, et al. T helper 
17 polarization in familial Mediterranean fever. Genes Immun 
2013;14(4):212-6 
179- Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behcet's disease. 
Autoimmun Rev 2012;11(10):699-704 
180- Kownatzki E, Kapp A, Uhrich S. Novel neutrophil chemotactic factor 
derived from human peripheral blood mononuclear leucocytes. Clin Exp 
Immunol 1986;64:214-22 
181- Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic 
cytokines: CXC and CC chemokines. Adv Immunol 1994;55:97-179 
182- Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et 
al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 
1992;258:1798-1801 
183- Hillyer P, Mordelet E, Flynn G, Male D. Chemokines, chemokine receptors 
and adhesion molecules on different human endothelia: discriminating the 
tissue-specific functions that affect leucocyte migration. Clin Exp Immunol 
2003;134:431-41 
184- Elliott CL, Allport VC, Loudon JA, Wu GD, Bennett PR. Nuclear factor-
kappa B is essential for up-regulation of interleukin-8 expression in human 
amnion and cervical epithelial cells. Mol Hum Reprod 2001;7(8):787-90 
185- Brennan FM, Zachariae CO, Chantry D, Larsen CG, Turner M, Maini RN, 
et al. Detection of interleukin 8 biological activity in synovial fluids from 
patients with rheumatoid arthritis and production of interleukin 8 mRNA by 
isolated synovial cells. Eur J Immunol 1990;20:2141-4 
186- Grimm MC, Elsbury SK, Pavli P, Doe WF. Interleukin 8: cells of origin in 
inflammatory bowel disease. Gut 1996;38:90-8 
187- Gür-Toy G, Lenk N, Yalcin B. Serum interleukin-8 as a serologic marker of 
activity in Behçet's disease. Int J Dermatol 2005;44:657–60 
188- Aggarwal BB, Aiyer RA, Pennica D, Gray PW, Goeddel DV. Human 
tumour necrosis factors: structure and receptor interactions. Ciba Found 
Symp 1987;131:39-51 
189- Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et 
al. A metalloproteinase disintegrin that releases tumour-necrosis factor-
alpha from cells. Nature 1997;385(6618):729-33 
190- Beutler B, Cerami A. The biology of cachectin/TNF--a primary mediator of 
the host response. Annu Rev Immunol 1989;7:625-55 
 160 
191- Endres R, Luz A, Schulze H, Neubauer H, Futterer A, Holland SM, et al. 
Listeriosis in p47(phox-/-) and TRp55-/- mice: protection despite absence of 
ROI and susceptibility despite presence of RNI. Immunity 1997;7(3):419-
32. 
192- Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et 
al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of 
action and clinical management. Lancet Infect Dis 2003;3(3):148-55 
193- Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis 
factor/tumour necrosis factor receptor superfamily: players, rules and the 
games. Immunology 2005;115(1):1-20 
194- Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, et al. 
Cutting edge: cross-talk between cells of the innate immune system: NKT 
cells rapidly activate NK cells. J Immunol 1999;163:4647–50 
195- Frucht DM, Fukao T, Bogdan C, Schindler H, O’Shea JJ, Koyasu S. IFN-
gamma production by antigen-presenting cells: mechanisms emerge. Trends 
Immunol 2001;22:556–60 
196- Munder M, Mallo M, Eichmann K, Modolell M. Direct stimulation of 
macrophages by IL-12 and IL-18 — a bridge built on solid ground. 
Immunol Lett 2001;75:159–60 
197- Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an 
overview of signals, mechanisms and functions. J Leukoc Biol 
2004;75(2):163-89  
198- Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. 
The interleukin-12/interleukin-12-receptor system: role in normal and 
pathologic immune responses. Annu Rev Immunol 1998;16:495-521 
199- Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A 
large-scale genetic association study confirms IL-12B and leads to the 
identification of IL-23R as psoriasis-risk genes. Am J Hum Genet 
2007;80(2):273–90 
200- Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ et al. 
A genome-wide association study identifies IL23R as an inflammatory 
bowel disease gene. Science 2006;314(5804):1461–3 
201- Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-
23 promotes a distinct CD4 T cell activation state characterized by the 
production of interleukin-17. J Biol Chem 2003;278:1910-4 
202- Chen DY, Chen YM, Lan JL, Lin CC, Chen HH, Hsieh CW. Potential role 
of Th17 cells in the pathogenesis of adult-onset Still's disease. 
Rheumatology (Oxford) 2010;49(12):2305-12 
203- Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol 
2011;23(3):159-63 
204- Punzi L, Furlan A, Podswiadek M, Gava A, Valente M, De Marchi M, et al. 
Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one 
family and a literature review. Autoimmun Rev 2009;8(3):228-32. 
References 
161 
205- Sfriso P, Caso F, Tognon S, Galozzi P, Gava A, PunziL. Blau syndrome, 
clinical and genetic aspects. Autoimmun Rev 2012;12(1):44-51 
206- Xiao W, Oefner PJ. Denaturing high-performance liquid chromatography: A 
review. Hum Mutat 2001;17(6):439-74 
207- Ogawa C, Liu YJ, Kobayashi KS. Muramyl dipeptide and its derivatives: 
peptide adjuvant in immunological disorders and cancer therapy. Curr 
Bioact Compd 2011;7(3):180-197 
208- Engler MJ and Richardson CC (1982) In: The Enzymes, Boyer PD, ed., 
Academic Press, New York, NY 
209- Thomas P, Smart TG. HEK293 cell line: a vehicle for the expression of 
recombinant proteins. J Pharmacol Toxicol Methods 2005;51(3):187-200 
210- Janeway CAJ, Medzhitov R. Innate immune recognition. Annu Rev 
Immunol 2002;20,197–216 
211- Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteinsfrom 
polyacrylamide gels to nitrocellulose sheets: procedure and some 
applications. Proc Natl Acad Sci USA 1979;76(9):4350-4 
212- Mannsperger HA, Gade S, Henjes F, Beissbarth T, Korf U. RPPanalyzer: 
Analysis of reverse-phase protein array data. Bioinformatics 
2010;26(17):2202-3 
213- R Development Core Team (2011), R: A Language and Environment for 
Statistical Computing. Vienna, Austria: the R Foundation for Statistical 
Computing. ISBN: 3-900051-07-0.  
214- Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A, et 
al. A comparison of background correction methods for two-colour 
microarrays. Bioinformatics 2007;23(20):2700-7 
215- Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A 
frameshift mutation in NOD2 associated with susceptibility to Crohn’s 
disease. Nature 2001;411:603-6 
216- Milhavet F, Cuisset L, Hoffman HM, Slim R, El-Shanti H, Aksentijevich I, 
et al. The infevers autoinflammatory mutation online registry: update with 
new genes and functions. Human Mutation 2008;29:803–8 
217- Chamaillard M, Philpott D, Girardin SE, Zouali H, Lesage S, Chareyre F, et 
al. Gene-environment interaction modulated by allelic heterogeneity in 
inflammatory diseases. Proc Natl Acad Sci U S A 2003;100:3455–60 
218- Kim YG, Park JH, Shaw MH, Franchi L, Inohara N, Nunez G. The 
cytosolic sensors Nod1 and Nod2 are critical for bacterial recognition and 
host difense after exposure to Toll-like receptor ligands. Immunity 
2008;28:246-57 
219- Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a 
Nod1/Apaf-1family member that is restricted to monocytes and activates 
NF-kappaB. J Biol Chem 2001;276:4812-8 
 162 
220- Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. 
Establishment and characterization of a human acute monocytic leukemia 
cell line (THP-1). Int J Cancer 1980;26(2):171–6 
221- Davey MP, Martin TM, Planck SR, Lee J, Zamora D, RosenbaumJT. 
Human endothelial cells express NOD2/CARD15 and increase IL-6 
secretion in response to muramyl dipeptide. Microvasc Res 2006;71:103–7 
222- Martin TM, Zhang Z, Kurz P, Rosé CD, Chen H, Lu H, et al. The NOD2 
defect in Blau syndrome does not result in excess interleukin-1 activity. 
Arthritis Rheum 2009;60(2):611-8  
223- Son S, Lee J, Woo CW, Kim I, Kye Y, Lee K, et al. Altered cytokine 
profiles of mononuclear cells after stimulation in a patient with Blau 
syndrome. Rheumatol Int 2010;30(8):1121-4 
224- Aróstegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno 
P, et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical 
diversity, novel and recurrent mutations, and evidence of clinical 
improvement with interleukin-1 blockade in a Spanish cohort. Arthritis 
Rheum 2007;56(11):3805-13 
225- Waite JC, Skokos D. Th17 response and inflammatory autoimmune 
diseases. Int J Inflam 2012;2012:819467 
226- Chi W, Zhu X, Yang P, Liu X, Lin X, Zhou H, et al. Upregulated IL-23 and 
IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 
2008;49(7):3058-64 
227- Espina V, Liotta LA, Petricoin EF 3rd. Reverse-phase protein microarrays 
for theranostics and patient tailored therapy. Methods Mol Biol 
2009;520:89-105 
228- Hirano S, Rees RS, Gilmont RR. MAP kinase pathways involving hsp27 
regulate fibroblast-mediated wound contraction. J Surg Res 2002;102(2):77-
84 
229- Au PYB, Yeh WC. Physiological Roles and Mechanisms of Signaling by 
TRAF2 and TRAF5. In: Madame Curie Bioscience Database [Internet]. 
Austin (TX): Landes Bioscience; 2000 
230- Gupta S, Campbell D, Dérijard B, Davis RJ. Transcription factor ATF2 
regulation by the JNK signal transduction pathway. Science 
1995;267(5196):389–93 
231- Silva CM. Role of STATs as downstream signal transducers in Src family 
kinase-mediated tumorigenesis. Oncogene 2004;23(48):8017–23 
232- Chen DY, Lin CC, Chen YM, Lan JL, Hung WT, Chen HH, et 
al.Involvement of TLR7 MyD88-dependent signaling pathway in the 
pathogenesis of adult-onset Still's disease. Arthritis Res Ther 
2013;15(2):R39 
233- Faustin B, Chen Y, Zhai D, Le Negrate G, Lartigue L, Satterthwait A, et al. 
Mechanism of Bcl-2 and Bcl-XL inhibition of NLRP1 inflammasome: Loop 
References 
163 
domain-dependent suppression of ATP binding and oligomerization. PNAS 
2009;106(10):3935-40 
234- Siebert S, Fielding CA, Williams BD, Brennan P. Mutation of the 
extracellular domain of tumour necrosis factor receptor 1 causes reduced 
NF-kappaB activation due to decreased surface expression. FEBS Lett 
2005; 579(23):5193-8 
235- Yousaf N, Gould DJ, Aganna E, Hammond L, Mirakian RM, Turner MD, et 
al. Tumor necrosis factor receptor I from patients with tumor necrosis factor 
receptor-associated periodic syndrome interacts with wild-type tumor 
necrosis factor receptor I and induces ligand-independent NF-kappaB 
activation. Arthritis Rheum 2005;52(9):2906-16 
236- Stjernberg-Salmela S, Ranki A, Karenko L, Siitonen S, Mustonen H, 
Puolakkainen P, et al. Low TNF-induced NF-kappaB and p38 
phosphorylation levels in leucocytes in tumour necrosis factor receptor-
associated periodic syndrome. Rheumatology (Oxford) 2010;49(2):382-90 
237- Devin A, Lin Y, Yamaoka S, Li Z, Karin M, Liu Z. The alpha and beta 
subunits of IkappaB kinase (IKK) mediate TRAF2-dependent IKK 
recruitment to tumor necrosis factor (TNF) receptor 1 in response to TNF. 
Mol Cell Biol 2001;21(12):3986-94  
238- Tao W, Wen F, Zhang H, Liu G. The signal transduction mediated by 
erythropoietin and proinflammatory cytokines in the JAK/STAT pathway in 
the children with cerebral palsy. Brain Dev 2009;31(3):200-7 
239- Pincheira R, Castro AF, Ozes ON, Idumalla PS, Donner DB. Type 1 TNF 
receptor forms a complex with and uses Jak2 and c-Src to selectively 
engage signaling pathways that regulate transcription factor activity. J 
Immunol 2008;181(2):1288-98 
240- Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY et al. 
Mitochondrial reactive oxygen species promote production of 
proinflammatory cytokines and are elevated in TNFR1-associated periodic 
syndrome (TRAPS). J Exp Med 2011;208:519–33 
241- Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, et al. The 
familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and 
activates NF-kappaB through its N-terminal fragment. Blood 
2008;112(5):1794-803  
242- Nalbantoglu S, Tanyolac B, Berdeli A. Apoptosis-associated speck-like 
protein containing a CARD (ASC) expression profiles in familial 
Mediterranean fever (FMF) patients with different MEFV mutation patterns. 
Scand J Rheumatol 2013;42(2):159-62 
243- Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, et al. Gain-of-
function Pyrin mutations induce NLRP3 protein-independent interleukin-1β 
activation and severe autoinflammation in mice. Immunity 2011;34(5):755-
68 
 164 
244- Zhao L, Lee JY, Hwang DH. The phosphatidylinositol 3-kinase/Akt 
pathway negatively regulates Nod2-mediated NF-kappaB pathway. 
Biochem Pharmacol 2008;75(7):1515-25 
245- Guo K, Kang NX, Li Y, Sun L, Gan L, Cui FJ, et al. Regulation of HSP27 
on NF-kappaB pathway activation may beinvolved in metastatic 
hepatocellular carcinoma cells apoptosis. BMC Cancer 2009;9:100 
246- Havla J, Lohse P, Gerdes LA, Hohlfeld R, Kümpfel T. Symptoms related to 
tumor necrosis factor receptor 1-associated periodic syndrome, multiple 
sclerosis, and severe rheumatoid arthritis in patients carrying the TNF 
receptor superfamily 1A D12E/p.Asp41Glu mutation. J Rheumatol 
2013;40(3):261-4 
247- Na SY, Park MJ, Park S, Lee ES. Up-regulation of Th17 and related 
cytokines in Behçet's disease corresponding to disease activity. Clin Exp 
Rheumatol 2013;31(3 Suppl 77):32-40 
248- Cai T, Wang Q, Zhou Q, Wang C, Hou S, Qi J, et al. Increased expression 
of IL-22 is associated with disease activity in Behçet's disease. PLoS One 
2013;8(3):e59009. 
249- Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. 
Cytokine profile in Behçet ’s disease: relationship with disease activity. 
Scand J Rheumatol 2002;31(4):205–10 
250- Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, et al., Serum 
cytokine profiles in patients with adult onset Still’s disease, J Rheumatol 
2003;30(11):2422-7 
251- Nowlan ML, Drewe E, Bulsara H, Esposito N, Robins RA,Tighe PJ, et al. 
Systemic cytokinelevels and the effects of etanercept in TNF receptor-
associated periodic syndrome (TRAPS) involving a C33Y mutation in 
TNFRSF1A. Rheumatology 2006;45:31–7 
252- Nakamura M, Tokura Y. A novel missense mutation in tumour necrosis 
factor receptor superfamily 1A (TNFRSF1A) gene found in tumour necrosis 
factor receptor-associated periodic syndrome (TRAPS) with high serum 
interleukin (IL)-22. Eur J Dermatol 2010;20(4):508-9 
253- Haznedaroglu S, Ozturk MA, Sancak B, Goker B, Onat AM, Bukan N et al. 
Serum interleukin 17 and interleukin 18 levels in familial Mediterranean 
fever. Clin Exp Rheumatol 2005;23(4 Suppl 38):S77–S80 
254- Köklü S, Oztürk MA, Balci M, Yüksel O, Ertenli I, Kiraz S. Interferon-
gamma levels in familial Mediterranean fever. Joint Bone Spine 
2005;72(1):38-40 
255- Pamuk BO, Sari I, Selcuk S, Gokce G, Kozaci DL. Evaluation of circulating 
endothelial biomarkers in familial Mediterranean fever. Rheumatol Int 
2013;33(8):1967-72 
256- Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K, et al. 
Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in 
inflammatory diseases. Clin Dev Immunol 2013;2013:968549 
References 
165 
257- Meng G, Zhang F, Fuss I, Kitani A, Strober W. A mutation in the Nlrp3 
gene causing inflammasome hyperactivation potentiates Th17 cell-dominant 
immune responses. Immunity 2009;30(6):860-74 
258- Ovadia A, Livneh A, Feld O, Ben-Zvi I, Kukuy E, Kivity S, et al. T helper 
17 polarization in familial Mediterranean fever. Genes Immun 
2013;14(4):212-6 
 
  
 166 
 
  
 167 
AKNOLEDGEMENT 
I am deeply grateful to my supervisor Professor Leonardo Punzi, for providing me 
with the support and opportunity to do research also abroad leading to this PhD 
thesis, educating me in all aspects of rheumatism sciences. 
I wish to express my gratitude to Professor Ian Todd, Dr Paddy Tighe and Dr 
Lucy Fairclough for your continuous support throughout the beautiful period I 
have spent in your labs and your suggestions and precious help in my work. 
I want to acknowledge also Professor Sibilia, for his important reviewing 
suggestions. 
I really want to thank Dr Alessandra Gava for her coordination at the beginning of 
my PhD and her very precious help and support in everything. Grazie Ale della 
tua amicizia! 
I wish to thank also Dr Ola Negm for her precious help and her teaching on 
microarray analysis. Ola, thanks so much! 
My gratitude also to Eliana Greco, Daniela Basso and all the people working at 
Biologia Molecolare. Grazie per avermi accolta e avermi dato la possibilità di 
lavorare con voi. 
My heartfelt thanks to prof. Rampazzo Alessandra, Marzia, Martina, Emanuela 
and Alessandra for the possibility to start my thesis works in their lab. Grazie 
mille dell'aiuto e della vostra amicizia. 
I want to thank also all my colleagues in Padua and Nottingham University. 
Thanks guys for all your support and our beautiful moments together. Grazie a 
tutta la stanza 63 del Palafellin, Anna Nick Francy Elena Lauro Paola siete i 
migliori..un grazie a tutti gli specializzandi, strutturati e segretarie della 
Reumatologia padovana per avermi fatto sentire parte di questo grande gruppo. 
Financial support from the Fondazione Aldo Gini for my period abroad was 
greatly appreciated. 
Last but not least, my most heart-full gratitude goes to my family. Grazie mamma 
per il tuo sostegno e la tua sollecitudine, specie in quest'ultimo periodo. Grazie 
anche a te papà per tutto quello che hai fatto per me, per avermi sempre 
supportato e aver creduto in me. Grazie anche a mia sorella e ai miei nipotini per 
aver capito quando era il momento di lasciarmi lavorare. Grazie anche a te 
Antonio per essermi sempre stato vicino, anche nei momenti no di questo periodo 
di dottorato: sei un tesoro. Questa tesi è anche merito tuo! 
